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Abstract 
Extended spectrum beta-lactamase (ESBL) producing bacteria are the cause of widespread 
infections worldwide, in both hospital and community settings. The presence of ESBLs prevent 
treatment of the infection with many β-lactam antibiotics. Highly mobile genetic element 
such as plasmids carrying ESBL genes often also harbour resistance genes to other classes of 
antimicrobials. To date, susceptibility generally remains high to the carbapenem antibiotics 
and to the polymyxin colistin and the glycylcycline tigecycline. However rigorous antibiotic 
stewardship programmes on national and international level will be crucial in maintaining the 
status of these drugs. This study provides epidemiological and molecular information 
regarding ESBL-producing bacteria both-in- patients and out-patients at the Saudi Aramco 
Dhahran Health Center, an acute care facility in the Eastern Province of Saudi Arabia, over 
four years.  
Two sampling cohorts (2010-2011 and 2012-2013 gave a total of 385 ESBL-producing isolates 
dominated by Enterobacteriaceae, mainly from urine cultures, followed by blood cultures. 
Most patients were from the out-patient setting. The majority of strains were Escherichia coli, 
followed by K. pneumoniae. Other isolates included members of Enterobacter, Citrobacter, 
Morganella, Serratia and Proteus families. K. pneumoniae became relatively more common 
in 2012 compared to 2010. Overall, female gender was identified as a risk factor for ESBL 
infection. Older age (>60 years) was also a risk factor, particularly for males.  
Susceptibility of infections to nine β-lactams was tested, namely ampicillin/sulbactam, 
ceftazidime, ceftriaxone, cefazolin, cefepime, cefoxitin and the carbapenems imipenem, 
meropenem, and ertapenem. There were high levels of resistance in both 2010 and 2012 for 
ampicillin/sulbactam, cefazolin, ceftriaxone and ceftazidime. While high percentages of both 
E. coli and K. pneumoniae were sensitive to cefoxitin in both 2010 and 2012, both E. cloacae 
and E. aerogenes isolates were uniformly resistant to this drug. For cefepime, sensitivity fell 
sharply in 2012, attributable to equivalent drops among E. coli and K. pneumoniae. There was 
consistently high sensitivity in 2010 and 2012 to the carbapenems. 
Seven non--lactam antibiotics were tested, namely nitrofurantoin, amikacin, ciprofloxacin, 
trimethoprim/sulfamethoxazole, gentamicin, colistin and tigecycline. There was 100% 
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sensitivity to colistin and tigecycline in both years. For ciprofloxacin, 
trimethoprim/sulfamethoxazole and gentamicin, there was low sensitivity in 2010 and 2012. 
For the aminoglycoside antibiotic amikacin, 98.4% of isolates were sensitive in 2010; this had 
fallen significantly to 69.3% in 2012, attributable to decreased sensitivity of E. coli isolates. 
ESBL-positive E. coli were relatively sensitive to nitrofurantoin, but the other bacterial species 
had low sensitivity. Overall, these results suggest a worrying trend for reduced sensitivity to 
a range of antibiotics of different classes.  
Multiplex PCR for the resistance determinants SHV, TEM and CTX-M showed that the CTX-M 
determinant was most prevalent, either alone or in combination with TEM and/or SHV, in all 
study years. Prevalence rose from 49.2% of isolates in 2010, to 84.7% in 2012. While the 
second most common genotype in 2010 was TEM-only, this had fallen to 5.4% in 2012, 
reflecting drops in both E. coli and most strikingly K. pneumoniae isolates. CTX-M in 
combination with other resistance determinants became more prevalent in 2012. This was 
particularly apparent for K. pneumoniae. Microarray MDR analysis on a sample set of 159 
isolates in 2012 revealed that the most prevalent CTX-M subtype, was type 15 (61.6%), 
consistent with worldwide experience, followed by CTX-M9 (8.2%). MDR analysis revealed 
that OXA-48 was present in three out of the 159 isolates, while there was no expression of 
KPC or NDM. The three OXA-48 isolates were, however, sensitive to the carbapenems. In fact, 
there was uniformly high sensitivity to the carbapenems and to colistin and tigecycline. There 
was relatively high prevalence of sensitivity to cefoxitin among CTX-M-expressing isolates. 
Amikacin also emerged as a possible choice for infections expressing CTX-M type 15 in 
combination with TEM and/or SHV, for CTX-M-9 isolates, and for SHV-only isolates. 
Nitrofurantoin could also be cautiously considered for isolates expressing CTX-M-1 type 15- 
only or CTX-M-9, and for CTX-M-1 type 15 in combination with TEM isolates, but not with CTX-
M –type 15+TEM+SHV isolates. There was 90.9% prevalence of gentamicin sensitivity for CTX-
M-9 isolates.  
Genotyping of E. coli and K. pneumoniae isolates by ERIC-PCR and by PFGE identified groups 
with a potentially clonal origin, with the PFGE technique having the greater discriminatory 
power. 
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1 Introduction 
1.1 Antibiotic resistance 
1.1.1 Overview of antibiotic resistance 
The history of the development of antibiotics, including -lactam antibiotics, is paralleled by 
development of antibiotic resistance mechanisms in bacteria (Figure 1.1) (Davies & Davies, 
2010; Iredell, Brown & Tagg, 2015). Selective pressures, exacerbated by over-prescription of 
antibiotics, have inevitably led to evolution of antibiotic resistance mechanisms. Resistance 
determinants are both chromosomal and extra-chromosomal, and can be mobilised via 
conjugation, transduction or transformation. Exchange of mobile resistance elements, most 
commonly by plasmid transmission, between different bacterial species has contributed to 
the worldwide spread of antibiotic resistant bacteria (Davies & Davies, 2010). Both Gram-
positive and Gram-negative bacteria have evolved multiple mechanisms of antibiotic 
resistance (Iredell et al., 2015). In this review, we are mainly concerned with Gram-negative 
bacteria, in particular the Enterobacteriaceae, including Escherichia, Klebsiella, Citrobacter, 
Salmonella, Proteus, Enterobacter and Serratia genera, which are particularly associated with 
-lactamase-mediated antibiotic resistance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Timeline of bacterial and antibiotic resistance evolution 
Taken from Iredell, Brown & Tagg, 2015 
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1.1.2 Mechanisms of antibiotic resistance in Gram-negative bacteria 
Mechanisms of antibiotic resistance are summarised in Figure 1.2. They include modification 
of the target molecule, such as the penicillin-binding proteins (PBPs), the main -lactam 
antibiotic targets and essential enzymes in the cross-linking of glycan strands to each other 
and to the bacterial cell wall in bacterial peptidoglycan (PG) synthesis (Sauvage et al., 2008; 
Sauvage & Terrak, 2016; van Heijenoort, 2011). Other mechanisms include modification of 
bacterial membrane permeability, for example porin modification (Iredell et al., 2015; Kojima 
& Nikaido, 2013; Sato & Nakae, 1991). Excretion of antibiotic via efflux pumps, for example 
resistance-nodulation-division (RND) transporters, is another mechanism (Li et al., 2015; Lim 
& Nikaido, 2010; Nagano & Nikaido, 2009). For -lactam antibiotics, enzyme-mediated 
hydrolytic degradation of the antibiotic by lactamases is the main mechanism of antibiotic 
resistance employed by Enterobacteriaceae and many other Gram-negative bacteria, via -
lactamases such as the AmpC, TEM, SHV, CTX-M and OXA enzyme families, including ESBLs, 
as discussed below (Iredell, Brown & Tagg, 2015; Xia et al., 2016).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Summary of mechanisms of antibiotic resistance in Gram negative bacteria 
Taken from Peleg & Hooper, 2010 
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1.2 -lactam antibiotics and -lactamase inhibitors 
1.2.1 lactam overview 
The first -lactam to be discovered was penicillin (Fleming, 1980). -lactams have in common 
the cyclic amide -lactam ring (Figure 1.3) (Fisher, Meroueh & Mobshery, 2005). They also 
have a fused bicyclic ring structure and are classified into groups according to the chemical 
structure of this ring, namely penicillins, cephalosporins, carbapenems, cephamycins and 
monobactams (no ring) (Lewis, 2013; Livermore & Woodford, 2006). The -lactam ring 
structure makes the -lactams susceptible to hydrolysis, a feature that is enhanced by the 
fused ring structure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Structures of major -lactam antibiotics 
Taken from Konaklieva, 2014 
 
The general mechanism of action of -lactams is prevention of bacterial wall synthesis, via 
interference with peptide bond formation between bacterial peptidoglycan (PG) forming 
molecules. The -lactams achieve this interference at the penicillin-binding proteins (PBPs) 
stage of PG synthesis (Fisher, Meroueh & Mobshery, 2005; Waxman, Yocum & Strominger, 
1980). -lactams are an analogue of the PG D-alanyl-D-alanine terminal residues (Silvaggi et 
al., 2004; Waxman, Yocum & Strominger, 1980). This structural similarity allows them to 
irreversibly bind to the Ser403 residue of the PBP active site, blocking the final 
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transpeptidation step of PG synthesis and disrupting the bacterial cell wall (Fisher, Meroueh 
& Mobshery, 2005; Silvaggi et al., 2004; Waxman, Yocum & Strominger, 1980).  
1.2.1 Emergence of resistance to -lactams: -lactamases 
Even before penicillin came into clinical use, the AmpC β-lactamase had been discovered 
(Abraham & Chain, 1940; Jacoby, 2009). Emergence of bacterial resistance to penicillin and 
other antibiotics developed through the 1940s and 1950s (Figure 1.1) (Bellamy & Klimek, 
1948; Frère, Sauvage & Kerff, 2015; Ghuysen, 1991; Livermore & Woodford, 2006; Lubsen, 
1950). By the 1970’s, infections such as penicillin-resistant Streptococcus pneumoniae and 
Neisseria gonorrhoea, became common (Appelbaum et al., 1977; Centers for Disease Control, 
1974; Jacobs et al., 1978; Workowski et al., 2008) 
Efforts were made to overcome -lactamase-mediated are resulted, for example, in the 
discovery of  inhibitor clavulanic acid in the mid-1970s (Figure 1.1) (Brown et al., 1976; Drawz 
& Bonomo, 2010), followed by other synthetic inhibitors, i.e. the penicillanic acid sulfones 
sulbactam and tazobactam (Drawz & Bonomo, 2010; English et al., 1978; Fisher et al., 1980) 
(Figure 1.4). They can be used in combination with -lactams to give conjugates such as 
augmentin, a combination of clavulanic acid and amoxicillin (Drawz et al., 2014; Lewis, 2013; 
Weber, Tolkoff-Rubin, & Rubin, 1984). However, they share a -lactam backbone, and over 
time -lactamases have evolved that can combat their effects (Drawz & Bonomo, 2010; Drawz 
et al., 2014). New non--lactam -lactamase inhibitors are in development, such as avibactam 
(NXL104) (Azap et al., 2010; Drawz et al., 2014; Lucasti et al., 2013; Vazquez et al., 2012).  
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Figure 1.4: Structures of lactamase inhibitors. a: Structures of clavulanate, sulbactam and tazobactam; b: 
acylation step employed in inhibition of class A β-lactamases by β-lactamase inhibitors, illustrated for 
clavulanic acid. 
Taken from Drawz et al., 2013 
 
New -lactam antibiotics, such as ampicillin and second generation cephalosporins including 
cefmetazole and cefoxitin, were also developed. However, over-prescription again 
contributed to the rise of novel -lactamase variants. The early 1980s saw the introduction of 
third generation cephalosporins such as ceftriaxone, ceftazidime and cefotaxime (Figure 1.1). 
However, selective pressure quickly led to evolution of extended spectrum lactamases 
(ESBLs) that could target them (Bush & Jacoby, 2010; Knothe et al., 1983; Livermore & 
Woodford, 2006; Philippon et al., 1989). These could be transferred on plasmids by 
conjugation, for example from K. pneumoniae and Serratia marcescens to E. coli K-12, Proteus 
or Salmonella recipients (Knothe et al., 1983; Philippon et al., 1989). In Gram-negative 
bacteria, chromosomal β-lactamase expression is normally inducible, while plasmid-mediated 
-lactamases are usually expressed constitutively (Cantón et al., 2012). Resistance has also 
arisen to fourth generation cephalosporins such as cefepime, and fifth generation drugs such 
as ceftaroline. Highly mobile plasmids carrying -lactamase enzyme and ESBL genes often also 
harbour resistance genes to several other unrelated classes of antimicrobials, including 
aminoglycosides and trimethoprim/sulfamethoxazole (Livermore & Woodford, 2006; 
Paterson and Bonomo, 2005)  
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1.3 Classification of β-lactamases 
There are currently two classification schemes for -lactamases. The Ambler scheme is a 
molecular classification scheme that groups the -lactamases according to sequence 
homology (Ambler, 1980; Hall & Barlow, 2005). The Bush-Jacoby-Medeiros scheme groups 
them functionally, according to antibiotic-resistance profiles (Bush, Jacoby & Medeiros, 1995; 
Bush & Jacoby, 2010). This is usually considered more clinically meaningful. 
According to the Ambler classification scheme, -lactamases are divided into four molecular 
classes A, B, C and D based on sequence homology, (Ambler, 1980; Ambler et al., 1991; Hall 
& Barlow, 2005). Groups A, C and D comprise different groups of active-site serine -
lactamases, and group B comprises the metallo--lactamases (MBLs), which have a different 
evolutionary origin and use at least one zinc active site (Hall & Barlow, 2005). Group B was 
subsequently sub-divided into sub-groups B1, B2 and B3 (Galleni et al., 2001). Further 
modifications in 2005, saw re-classification of the B1 and B2 subgroups as MB (comprising 
MB1 and MB2) and the B3 group as ME (Hall & Barlow, 2005). Renaming the serine active 
site--lactamase groups as SA, SC and SD was also suggested. They maintained that such a 
modification would facilitate accommodation of newly discovered -lactamase groups within 
the scheme, as well as allowing easy recognition of sub-classes (Hall & Barlow, 2005).  
The -lactamases are classified functionally according to the Bush-Jacoby-Medeiros scheme 
into four main groups (1-4), which are in turn divided into multiple sub-groups reflecting their 
substrate and inhibitor profiles (Bush, Jacoby & Medeiros, 1995). The Bush-Jacoby-Medeiros 
scheme was updated in 2010 to include many new subgroups, in recognition of the major 
expansion of the -lactamase family in the intervening period (Bush & Jacoby, 2010).  
Group 1 of the original Bush-Jacoby-Medeiros scheme included the chromosomal and 
plasmid-carried AmpC -lactamases from Gram-negative bacteria (Ambler Group C) (Bush, 
Jacoby & Medeiros, 1995). Their preferred substrates are cephalosporins; they are not well-
inhibited by clavulanic acid (Bush, Jacoby & Medeiros, 1995; Paterson & Bonomo, 2005).  
Group 2 of the original Bush-Jacoby-Medeiros scheme contained eight subgroups, 2a, 2b, 2be, 
2br, 2c, 2d, 2e and 2f (Bush, Jacoby & Medeiros, 1995). The members of these subgroups are 
distributed between Groups A and D of the Ambler scheme (Bush, Jacoby & Medeiros, 1995). 
8 
 
 
 
Sub-group 2b enzymes included TEM-1, the first-discovered plasmid-mediated -lactamase 
(Sections 1.4, 1.5 and 1.6.2), its derivative TEM-2 and SHV-1 (Sections 1.4, 1.5 and 1.6.3) 
(Bush, Jacoby & Medeiros, 1995). Subgroup 2be included ESBLs derived from mutations of 
TEM-1 and SHV-1 (Sections 1.6.2 and 1.6.3) (Bush, Jacoby & Medeiros, 1995). CTX-M enzymes 
also fell in this group, due to their ability to confer resistance to cefotaxime. Sub-group 2d 
contained enzymes conferring resistance both to penicillins but strikingly also to oxacillin, 
such as the enzymes OXA-1 to OXA-11, (Group D in the Ambler scheme) (Sections 1.5 and 
1.6.5) (Bush, Jacoby & Medeiros, 1995).  
Group 3 of the original Bush-Jacoby-Medeiros scheme contained enzymes that conferred 
resistance to most -lactams, including carbapenems, but not monobactams (Ambler Group 
B) (Bush, Jacoby & Medeiros, 1995; Bush & Jacoby, 2010). Examples included L1 from 
Xanthomonas maltophilia and CcrA from Bacteroides fragilis (Bush, Jacoby & Medeiros, 
1995). Finally, Group 4 contained incompletely-characterised penicillin-resistance conferring 
enzymes, including the penicillinase from P. cepia (Bush, Jacoby & Medeiros, 1995). 
By 2009, more than 890 unique protein sequences had been identified, prompting Bush and 
Medeiros to update and expand the original scheme (Bush, Jacoby & Medeiros, 1995; Bush & 
Jacoby, 2010). Again, enzymes were grouped functionally according to resistance to -
lactamase inhibitors such as clavulanic acid, sulbactam and tazobactam and the ability to 
hydrolyze different -lactam classes (Bush, Jacoby & Medeiros, 1995; Bush & Jacoby, 2010). 
Group 1 gained a subgroup 1e, which contained Group 1 enzymes conferring increased 
hydrolysis of ceftazidime and other oxyimino--lactams, termed ‘extended spectrum AmpC 
-lactamases’ (ESAC) including GC1 and CMY-1-50 (See Section 1.6.6) (Bush & Jacoby, 2010). 
Four new sub-groups were added to Group 2, 2ber, 2ce, 2de and 2df (Bush & Jacoby, 2010). 
Sub-group 2ber contains ESBL enzymes that confer resistance to both extended-spectrum 
cephalosporins and to -lactamase inhibitors (Bush & Jacoby, 2010; Robin et al., 2007; Sirot 
et al., 1997). These enzymes have also been termed complex mutant TEM (CMT). Sub-group 
2ce was added to Group 2c and contains enzymes with the ability to hydrolyze both 
carbenicillin and the fourth-generation cephalosporins cefepime and cefpirome, such as the 
RTG-4 (Bush & Jacoby, 2010; Potron et al., 2009). The new sub-group 2de contains enzymes 
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which can hydrolyze cloxacillin or oxacillin, like the original sub-group 2d enzymes, but also 
to hydrolyze oxyimino--lactams (Bush & Jacoby, 2010). The sub-group is dominated by OXA-
10 derivatives (See Section 1.6.5) (Evans & Amyes, 2015). The new sub-group 2df contains the 
carbapenem-hydrolyzing OXA enzymes such as the OXA-23, OXA-52 and OXA-58 groups 
(Section 1.6.5) (Bush & Jacoby, 2010; Donald et al., 2000; Evans & Amyes, 2015; Scaife et al., 
1995). Finally, the original Group 3 MBLs of the Bush-Jacoby-Medeiros scheme was sub-
divided into sub-groups 3a and 3b (Bush & Jacoby, 2010). Sub-group 3a included carbapenems 
but not monobactams (Bush & Jacoby, 2010). Sub-group 3b comprises the smaller group of 
MBLs that preferentially hydrolyze carbapenems (Group B2 of the Ambler scheme) (Bush & 
Jacoby, 2010).  
In a classification system proposed in 2009, Giske et al. suggested expansion of the definition 
of ESBL to include other clinically important acquired β-lactamases with activity against 
extended-spectrum cephalosporins and/or carbapenems (Giske et al., 2009). While the 
simplified classification proposed risked subtle differences between -lactamases being 
missed, the scheme was not proposed to replace the existing schemes but to complement 
them in a healthcare context (Giske et al., 2009). In the meantime, the Ambler and Bush-
Jacoby-Medeiros remain in common usage. Table 1.1 shows an overview of the classification 
of -lactamases. Over 1000 -lactamases have now been identified (Bush, Palzkill & Jacoby, 
2015; Malloy & Campos, 2011). 
1.4 Historical overview of -Lactamase enzymes 
The first penicillin-destroying bacterial enzyme to be identified was the AmpC β-lactamase, in 
E. coli in 1940 (Abraham & Chain, 1940; Jacoby, 2009; Jaurin & Grundström, 1981).  
The first plasmid-mediated -lactamase was identified in Greece in the 1960s within E. coli 
K12, and was designated TEM-1 because it was identified in the blood culture of a patient 
named Temoniera (Datta & Kontomichalou, 1965) (Figure 1.1). Its plasmid-mediated status 
facilitated the rapid spread of TEM-1 within a few years to other bacterial species worldwide. 
A number of organisms express TEM-1 resistance, including many Enterobacteriaceae family 
members, as well as Haemophilus influenzae, N. gonorrhoeae and P. aeruginosa (Bradford, 
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2001). TEM-2 was the first mutation-derived derivative of TEM-1 to be identified (Barthélémy 
et al., 1985) but retained the same substrate profile. While TEM-1 and TEM-2 are not ESBLs, 
multiple modified variants have been identified, most of which are ESBLs with diverse 
phenotypes (Bush & Jacoby, 2010; Salverda et al., 2010) 
In 1972 SHV-1 -lactamase was identified and named because of its sulphydryl variable active 
site (Pitton, 1972). In K. pneumoniae SHV-1 is usually chromosomal, but it is usually plasmid 
mediated in E.coli (Bradford, 2001). A numbers of SHV-1 genetic variants have emerged that 
confer ESBL status (Ambler et al., 1991; Bush, Palzkill & Jacoby, 2015; Drawz, & Bonomo, 2010; 
Sulton et al., 2005; Totir et al., 2006; Winkler et al., 2015). 
The OXA enzymes hydrolyze the oxazolylpenicillins, oxacillin or cloxacillin, at a greater than 
50% higher rate than benzylpenicillin (Bush & Jacoby, 2010; Paterson & Bonomo, 2005). 
OXA-1, OXA-2 and OXA-3 were identified as three distinct oxacillinases (Dale et al., 1985; 
Evans & Amyes, 2015; Ouellette et al., 1987; Sykes & Matthews, 1976). OXA- 1 and OXA-2 
shared active site homology and were carried on a Tn21-derived transposon (Dale et al., 1985; 
Evans & Amyes, 2015; Ouellette et al., 1987). OXA enzymes predominantly occur in P. 
aeruginosa, however they are also found in many other Gram-negative bacteria, including E. 
coli (Livermore, 1995). The OXA-10 enzyme (originally designated PSE-2) has given rise to 
several OXA-10 ESBL variants (Couture, Lachapelle, & Levesque, 1992; Evans & Amyes, 2015; 
Hall et al., 1993; Medeiros et al., 1982). 
Thus, many clinically important ESBLs have arisen from mutation of TEM-1, SHV-1 and OXA-
10. However, the CTX-M type of ESBLs are a separate lineage of ESBLs, arising from plasmid 
acquisition of chromosomal -lactamase genes from Kluyvera species (Cantón et al., 2012). 
 
 
 
 
 
 
 
11 
 
 
 
 
Table 1.1: Bush-Jacoby-Medeiros functional and Ambler molecular lactamase classification schemes 
 
  
Bush-Jacoby 
Group 2009 
Bush-Jacoby 
Medeiros 
Group 1995 
Ambler 
Class 
Distinctive 
Substrate(s) 
Inhibited by 
 
CA/TZB  EDTA 
Defining Characteristics Representative 
Enzyme(s) 
1 1 C Cephalosporins  No           No  Greater Hydrolysis of 
cephalosporins than 
benzylpenicillin; hydrolyses 
cephamycins 
E.coli AmpC, P99, 
ACT-1, CMY-2, FOX-
1, MIR-1 
1e NI C Cephalosporins  No           No Increased hydrolysis of 
ceftazidime and often 
other oxyimino-β-lactams 
GC1, CMY-37 
2a 2a A Penicillins Yes           No Greater hydrolysis of 
benzylpenicillin than 
cephalosporins 
PC1 
2b 2b A Penicillins, early 
cephalosporins 
Yes           No Similar hydrolysis of 
benzylpenicillin and 
cephalosporins 
TEM-1, TEM-2, SHV-
1 
2be 2be A Extended 
spectrum 
cephalosporins, 
monobactams 
Yes           No Increased hydrolysis of 
oxyimino-β-lactams 
(ceftoaxime, ceftazidime, 
ceftriaxone, cefepime, 
aztreonam)  
TEM-3, SHV-2, CTX-
M-15, PER-1, VEB-1 
2br 2br A Penicillins No           No Resistance to clavulanic 
acid, sulbactam and 
tazobactam 
TEM-30, SHV-10 
2ber NI A Extended 
spectrum 
cephalosporins, 
monobactams 
No           No Increased hydrolysis of 
oxyimino-β-lactams 
combined with resistance 
to clavulanic acid, 
sulbactam and tazobactam 
TEM-50 
2c 2c A Carbenicillin Yes           No Increased hydrolysis of 
carbenicillin 
PSE-1, CARB-3 
2ce NI A Carbenicillin, 
cefepime 
Yes           No Increased hydrolysis of 
carbenicillin, cefepime and 
cefpirome 
RTG-4 
2d 2d D Cloxacillin Variable   No            Increased hydrolysis of 
cloxacillin or oxacillin 
OXA-1, OXA-10 
2de NI D Extended 
spectrum 
cephalosporins 
Variable   No            Hydrolyses cloxacillin or 
oxacillin and oxyimino-β-
lactams 
OXA-11, OXA-15 
2df NI D Carbapenems Variable   No            Hydrolyses cloxacillin or 
oxacillin and carbapenems 
OXA-23, OXA-48 
2e 2e A Extended 
spectrum 
cephalosporins 
Yes           No Hydrolyses cephalosporins.  
Inhibited by clavulanic acid 
but not aztreonam 
CepA 
2f 2f A Carbapenems Variable   No            Increased hydrolysis of 
carbapenems, oxyimino-β-
lactams, cephamycins 
KPC-2, IMI-1, SME-1 
3a 3 B Carbapenems No            Yes Braod-spectrum hydrolysis 
including carbapenems but 
not monobactams 
IMP-1, VIM-1, CcrA, 
IND-1 
3b 3 B Carbapenems No            Yes Preferential hydrolysis of 
carbapenems 
CphA, Sfh-1 
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1.5 Emergence of ESBLs 
The formal definition of ESBLs are -lactamases conferring bacterial resistance to an extended 
range of -lactam antibiotics, including penicillins, first-, second- and third-generation 
cephalosporins and aztreonam, but not carbapenems or cephamycins (Paterson & Bonomo, 
2005). While some are sensitive to -lactamase inhibitors such as clavulanic acid, others are 
not (Bush & Jacoby, 2010; Paterson & Bonomo, 2005).  
SHV-2, a natural point mutation mutant of SHV-1, was the first reported plasmid-encoded 
ESBL, in Germany in 1985, isolated from K. pneumoniae (Ambler et al., 1991; Kliebe et al., 
1985). SHV-2 had the ability to hydrolyze broad-spectrum cephalosporins, as well as 
penicillins and monobactams (Kliebe et al., 1985). A number of other SHV-1 genetic variants 
with ESBL properties have since emerged (Ambler et al., 1991; Bush, Palzkill & Jacoby, 2015; 
Drawz, & Bonomo, 2010; Sulton et al., 2005; Totir et al., 2006; Winkler et al., 2015). 
Following the identification of SHV-2, ESBLs derived by mutation of blaTEM-1 and blaTEM-2 genes 
were soon identified in K. pneumoniae, E. coli and Citrobacter freundii in France and Germany 
(Sougakoff et al., 1988). These plasmid-mediated ESBL variants were designated TEM-3 to 
TEM-7 (Sougakoff et al., 1988). Since then, more than 170 modified TEM-1 variants have been 
identified, most of which are ESBLs (Salverda et al., 2010).  
Throughout the 1980s and 1990s, TEM and SHV-derived ESBLs dominated, often associated 
with hospital-centred outbreaks and with K. pneumoniae, and less often E. coli and other 
Enterobacteriaceae (Bradford, 2001; Paterson & Bonomo, 2005). The CTX-M ESBL group, 
which is not related to TEM and SHV, rose in prominence during the early 2000s due to a 
major increase in the CTX-M evolution rate and in its geographic spread (Cantón et al., 2012).  
CTX-M-1 was first reported in E. coli and CTX-M-2 in Salmonella typhimurium, in Germany and 
Argentina respectively, in the early 1990s (Bauernfeind, Schweighart, & Grimm, 1990; 
Bauernfeind et al., 1992). The name CTX-M was derived from the relatively high resistance to 
cefotaxime compared to ceftazidime. Reports from France and Japan quickly followed 
(Barthélémy et al., 1992; Bernard et al., 1992; Cantón et al., 2012; Ishii et al., 1995). Over 160 
variants of CTX-M enzymes have been detected in many different species of 
Enterobacteriaceae, as well as non- Enterobacteriaceae (Bush, Palzkill & Jacoby, 2015; Cantón 
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et al., 2012). Currently in Europe, ESBLs are most often observed in E. coli and cause 
community-acquired rather than nosocomial infections (Coque et al., 2008).  
OXA-11, an OXA-10 variant, was the first OXA enzyme-derived ESBL, identified in Turkey in 
1991 (Hall et al., 1993). Since then, several OXA-10-derived ESBLs have been identified, 
including OXA-13, OXA-14, OXA-16, OXA-17, OXA-19 and OXA-28 (Evans & Amyes, 2015). 
Some other OXA-derivatives such as OXA-23 and OXA-48 may be of importance in the rise of 
carbapenem resistance (Bush & Jacoby, 2010; Evans & Amyes, 2015).  
1.6 ESBL types 
1.6.1 ESBL overview 
ESBL-related infections have contributed majorly to the worldwide problem of antibiotic 
resistance (Cantón et al., 2012; Davies & Davies, 2010; Salverda et al., 2010; Winkler et al., 
2015). These ESBLs are considered in more detail in the following sections. 
1.6.2 TEM ESBLs 
The more than 170 modified TEM-1 and TEM-2 derivatives currently in circulation have 
phenotypes that include resistance to second and third generation cephalosporins and 
monobactams, and/or to -lactamase inhibitors (Table 1.1) (Bush & Jacoby, 2010; Salverda et 
al., 2010). Most differ from TEM-1 or TEM-2 by between one to five amino acid substitutions 
around the active site (Salverda et al., 2010). Among the substitutions with known impact on 
the resistance phenotype are E104K, R146C, R164H, RI64S, A237T, G238S and E240K (Ambler 
et al., 1991; Salverda et al., 2010). Examples in Group 2be are TEM-3, TEM-10, TEM-24 and 
TEM-26 (AitMhand et al., 2002; Arpin et al., 2003 and 2009; Brun-Buisson et al., 1987; Bush 
& Jacoby, 2010; Chanal et al., 1989; Duarte et al., 2002; Galas et al., 2007; Machado et al., 
2007; Marchandin et al., 1999; Naumovski et al., 1992; Novais et al., 2010; Palzkill et al., 1995; 
Philippon et al., 1989; Quinn et al., 1989; Rasmussen et al., 1994; Rodriguez-Villalobos et al., 
2011; Schiappa et al., 1996; Sougakoff et al., 1988; Stapleton et al., 1999; Urban et al., 1994; 
Yano et al., 2013). Other TEM variants, for example TEM-30 and TEM-31, are in Group 2br 
and have amino acid substitutions that confer resistance to one or more of clavulanic acid, 
sulbactam and/or tazobactam (Bush & Jacoby, 2010; Bradford, 2001; Cantón et al., 2008; 
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Lemozy et al., 1995; Salverda et al., 2010; Zhou et al., 1994), They are generally due to 
substitutions of TEM-1 or TEM-2 amino acid residues 69, 130, 165, 244, 275 or 276 (Ambler 
positions). TEM-50 and TEM-158 are in Group 2ber, combining resistance to extended 
spectrum cephalosporins with resistance to clavulanic acid, sulbactam and/or tazobactam 
(Alibi et al., 2015; Bush & Jacoby, 2010; Robin et al., 2007; Sirot et al., 1997). 
1.6.3 SHV ESBLs 
SHV-2 (Group 2be) arose from SHV-1 by G238S subsitution (Ambler et al., 1991; Kliebe et al., 
1985), which conferred the ability to hydrolyze broad-spectrum cephalosporins, penicillins 
and monobactams (Kliebe et al., 1985). Its plasmid-mediated status has facilitated its spread 
among different species, particularly Enterobacteriaceae, worldwide (Mulvey et al., 2004; 
Paterson et al., 2003; Toth et al., 2005). Other SHV-1 variants with ESBL properties are most 
often due to mutations at the Ambler positions G238 or E240, and are also in Group 2be (Bush 
& Jacoby, 2010; Bush, Palzkill & Jacoby, 2015). Among the most prevalent are SHV-5 and SHV-
12 (Gutmann et al., 1989; Nüesch-Inderbinen et al., 1997; Newire et al., 2013; Perilli et al., 
2011; Silva-Sanchez et al., 2011; Tawfik et al., 2011). Like TEM-1 and TEM-2, SHV-1 has also 
been subject to amino acid substitutions that confer -lactamase inhibitor resistance, usually 
at the Ambler M69, S130, K234 or N276 positions, for example SHV-49 and SHV-72 (Group 
2br) (Ambler et al., 1991; Bush & Jacoby, 2010; Bush, Palzkill & Jacoby, 2015; Drawz, & 
Bonomo, 2010; Dubois et al., 2004; Empel et al., 2008; Mendonça et al., 2008; Sulton et al., 
2005; Totir et al., 2006; Winkler et al., 2015). These, and equivalent TEM variants, are a threat 
to therapies that combine -lactam antibiotics with -lactamase inhibitors (Drawz, & 
Bonomo, 2010; Winkler et al., 2015).  
1.6.4 CTX-M 
The increasing predominance of CTX-M ESBLs led to the coining of the term ‘CTX-M pandemic’ 
(Baraniak et al., 2013; Cantón & Coque, 2006; Coque et al., 2008). Some CTX-M β-lactamases 
are also associated with co-expression of plasmid-mediated quinolone resistance (PMQR) 
determinants (Robicsek et al., 2006). CTX-M is associated with both nosocomial and 
15 
 
 
 
community-acquired infections, mainly in E. coli (Cantón & Coque, 2006; Coque et al., 2008; 
Cantón et al., 2012).  
The acquisition of -lactamase genes from Kluyvera species chromosomes has occurred on at 
least nine independent occasions, giving several clusters of CTX-M, namely CTX-M-1 (three 
clusters), CTX-M-2 (two clusters), CTX-M-9 (two clusters), CTX-M-8 (one cluster) and CTX-M-
25 (one cluster) (Cantón et al., 2012). This has been facilitated by genetic mobilization units, 
such as insertion sequences, and then incorporation into structures such as integrons and 
transposons (Cantón et al., 2012). Selective pressures resulted in diversification within the 
clusters, to give a variety of CTX-M ESBLs by gene mutation and amino acid substitutions 
(Cantón et al., 2012). The increasing dominance of CTX-M ESBLs has probably been further 
fuelled by co-resistance to other antibiotic types (Cantón et al., 2012; Cantón & Ruiz-
Garbajosa, 2011; Morosini et al., 2006). To date, approximately 168 CTX-M variants have been 
described (Bush, Palzkill & Jacoby, 2015).  
Among the most epidemiologically important CTX-M enzymes are CTX-M-3, CTX-M-9, CTX-M-
14 and CTX-M-15 (Baraniak et al., 2013; Cantón et al., 2012). CTX-M-3 belongs to a CTX-M-1 
cluster, which also includes CTX-M-10 (Arpin et al., 2009; Baraniak et al., 2002; De Champs et 
al., 2000; Gniadkowski et al., 1998; Livermore et al., 2007; Ma et al., 2005; Yan et al., 2000), 
and CTX-M-15, which differs from CTX-M-3 at only one position (D240G) (Cantón et al., 2012). 
CTX-M-15 is the most prevalent ESBL carried by E. coli and contributing to UTIs and 
bacteraemia (Johnson et al., 2010; Woodford, Turton & Livermore, 2011). It is carried, for 
example, by the internationally disseminated E. coli clone, B2, O25:H4-ST131 (Alghoribi et al., 
2015; Johnson et al., 2010; Peirano, Costello, & Pitout, 2010; Woodford, Turton & Livermore, 
2011). CTX-M-15 has become one of the most widely disseminated ESBLs worldwide, both in 
hospital and community settings (Ahmed et al., 2014; Barguigua et al., 2013;  Baraniak et al., 
2013; Cantón et al., 2012; Castanheira et al., 2010; Coque et al., 2008; Ferjani et al., 2015; 
Hara et al., 2015; Johnson et al., 2010; Lewis et al., 2007; Machado et al., 2007; Nogueira et 
al., 2015; Peirano, Costello, & Pitout, 2010; Rafaï et al., 2015; Rodriguez-Villalobos et al., 2011; 
Seki et al., 2013; Sherchan et al., 2015; Yezli et al., 2015; Zamani et al., 2015; Zhang et al., 
2015; Zhong et al., 2015). CTX-M-9 cluster enzymes are also widely disseminated (Cantón et 
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al., 2012; Chanawong et al., 2002; Coque et al., 2008; Jean & Hsueh, 2011; Sabaté et al., 2000; 
Saladin et al., 2002). CTX-M-14 is a variant of CTX-M-9, differing by a single A231V substitution 
(Ma et al., 2002).  
1.6.5 OXA ESBLs 
The OXA-11 ESBL variant of OXA-10, identified in a strain of P. aeruginosa from a patient 
Turkey in 1991 (Hall et al., 1993), differed from OXA-10 by two amino acid substitutions, 
N143S and G157D, and conferred resistance to ceftazidime (Hall et al., 1993). Since then, 
several OXA-10-derived ESBLs have been identified, all of which have been found in P. 
aeruginosa (Evans & Amyes, 2015). They vary from OXA-10 by up to nine amino acid 
substitutions. The G157D in OXA-11 is conserved in four of the other OXA-10 ESBLs (Danel et 
al., 2001). OXA-10 and its variants have been identified worldwide (Al-Agamy et al., 2012; 
Farshadzadeh et al., 2014; Hansen et al., 2014; Vatcheva-Dobrevska et al., 2013). OXA-2 is 
another OXA -lactamase for which ESBL variants including OXA-15 (D150G substitution; 
Danel et al., 1997) and OXA-32 (L169I substitution; Poirel et al., 2002) have been found.  
There have been few reports of OXA-10, OXA-2 and their derived ESBLs in species outside P. 
aeruginosa (Evans & Amyes, 2015), however in an A. baumannii laboratory strain, they 
acquire ESBL characteristics and confer carbapenem-resistance (Antunes et al., 2014). There 
have been scattered reports of OXA-2 in S. typhimurium, M. morganii, K. pneumoniae and E. 
coli (Bush, Palzkill & Jacoby, 2015; Empel et al., 2007; Libisch et al., 2008; Power et al., 2005; 
Sanschagrin, Couture, & Levesque, 1995; Vignoli et al., 2005), indicating the possibilities for 
cross-over to other strains.  
Some OXA-derivatives are of importance in the rise of carbapenem resistance (Bush & Jacoby, 
2010; Evans & Amyes, 2015). The OXA carbapenemases can be divided into the subgroups 
OXA-23, OXA-24/40, OXA-48, OXA-51 and OXA-58  and have been observed in multiple 
bacterial species worldwide (Alyamani et al., 2015; Bou, Oliver & Martínez-Beltrán, 2000; 
Brown et al., 2005; Brown, Young & Amyes, 2004; Cakirlar, Ciftci & Gonullu, 2014; Carrër et 
al., 2010; Castanheira et al., 2011; Cuzon et al., 2011; D’Arezzo et al., 2009 and 2011; Donald 
et al., 2000; Evans & Amyes, 2015; Héritier et al., 2005; Kaitany et al., 2013; Kamolvit et al., 
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2015; Kalpoe et al., 2011; Moquet et al., 2011 Poirel et al., 2010; Scaife et al., 1995; Shrestha 
et al., 2015; Smith et al., 2013; Tsiatsiou et al., 2015).  
1.6.6 AmpC and Extended-spectrum AmpC (ESAC) ESBLs 
AmpC -lactamase itself is not defined as an ESBL, but is of clinical importance (Jacoby, 2009). 
Structurally, it has been proposed to be the archetypal -lactamase (Burman et al., 1973; 
Jaurin & Grundström, 1981). It differs in structure from TEM and the penicillinases, but like 
them it has serine at its active site (Jaurin & Grundström, 1981). AmpC β-lactamases are 
chromosomally encoded by many Enterobacteriaceae and a few other organisms (Jacoby, 
2009). However, plasmid-acquired AmpC genes such as CMY-8, CMY-9 and CMY-19 have 
facilitated its expression in bacteria which lack or only poorly express the blaAmpC gene, 
including E. coli, K. pneumoniae and P. mirabilis (Doi et al., 2002; Jacoby, 2009; Wachino et 
al., 2006; Yan et al., 2000). AmpC enzyme expression is inducible, and mutation can lead to 
high expression, conferring extended resistance to broad-spectrum cephalosporins (Jacoby, 
2009). Extended-spectrum AmpC (ESAC) ESBLs have been identified with increased resistance 
against cefoxitin or oxyiminocephalosporins and imipenem (Lee, Jeong & Park, 2003; 
Rodríguez-Martínez, Poirel, & Nordmann, 2009). ESACs have now been reported in multiple 
Enterobacteriaceae from human isolates (Ahmed & Shimamoto, 2008; Barnaud et al., 2001; 
Crichlow et al., 1999; Hidri et al., 2005; Mammeri et al., 2004; Matsumura et al., 1998), and 
other bacterial types including P. aeruginosa and A. baumannii (Rodríguez-Martínez et al, 
2009 and 2010). E. coli clones expressing ESACs predominantly belong to Clonal Complex (CC) 
23 (Crémet et al., 2010). ESACs have been identified in E. coli isolates from cattle, a possible 
emerging contributor to extended-spectrum cephalosporin resistance in animals (Haenni et 
al., 2014a).  
1.6.7 Other ESBLs 
Beyond the main ESBL groupings, there are a number of rarer ESBL families. The Pseudomonas 
Extended Resistance (PER) -lactamase family, for example PER-1 (Group 2be) is associated 
with resistance to extended-spectrum cephalosporins (Bush & Jacoby, 2010; Nordmann et al., 
1993; Paterson & Bonomo, 2005; Vahaboglu et al., 1997). Integron-borne PER-1 has also been 
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recently identified in nosocomial isolates of Gram-negative bacteria including E. coli and K. 
pneumoniae in India (Maurya et al., 2015).  
Another ESBL family is the Vietnamese extended-spectrum –lactamase (VEB). VEB-1 was 
first identified in an E. coli isolate taken from a Vietnamese child in France (Poirel et al., 1999) 
and was subsequently isolated in Vietnam in nosocomial isolates of K. pneumoniae, E. cloacae 
and P. aeruginosa (Girlich et al., 2001). They have since been identified in other countries 
(Naas et al., 2008). 
Other rare ESBLs include SFO-1, BES-1, BEL-1, TLA-1, TLA-2 and GES-1 (Naas et al., 2008). 
While these are often associated with resistance in Pseudomonas aeruginosa, some have 
been isolated from Enterobacteriaceae (Naas et al., 2008).  
1.6.8 Mobile genetic elements and ESBL and AmpC transmission 
Transmission of ESBL and AmpC has been facilitated by carriage on genetic mobilization units, 
such as plamids, insertion sequences, integrons and transposons (Cantón et al., 2012). Genes 
encoding CTX-M variants, for example, were transferred from Kluyvera species, often in 
transposons or as cassettes in integrons, such as carriage of blaCTX-M-2 on a complex class 1 
integron, In35, on plasmid pMAR-12 (Arduino et al., 2002). In35 contains orf513, which is an 
example of a CR (common region) element, mobile elements with IS91-like features which 
support unique gene rearrangements (Toleman et al., 2006). Orf513 is often found associated 
with antibiotic-resistance genes such as CTX-M subtypes, usually associated with complex 
class I integrons (Poirel et al., 2008; Toleman et al., 2006). CTX-M genes are also often flanked 
by ISEcp1-like insertion sequence elements (Poirel et al., 2008; Toleman et al., 2006). TEM 
and SHV genes are not found in integrons to date, but are carried on plasmids and 
transposons (Poirel et al., 2008). IS26 elements appear to be important in blaSHV acquisition 
(Poirel et al., 2008). The IS26 element is also often found flanking blaCTX-M-15, for example in 
the pandemic B2-O25b-ST131 clone (Burke et al., 2016; Dolejska et al., 2011). 
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1.7 Epidemiology 
1.7.1 ESBL epidemiology overview 
Since the early 2000s, the CTX-M ESBL group, has taken over from TEM- and SHV-derived 
ESBLs as the most common ESBL type in Enterobacteriaceae, both in hospital and community-
acquired infections (Cantón et al., 2012). However, relative prevalence of different ESBL types 
varies between countries. ESBL-carrying infections can be transferred between hospitals, 
within hospitals and between the community and care facilities (Baraniak et al., 2013; Burke 
et al., 2012; Cantón & Coque, 2006; Coque et al., 2008; Stuart et al., 2011; Valenza et al., 
2014).  
1.7.2 Europe 
Extended-spectrum -lactam antibiotics were first used clinically in Western Europe, 
precipitating the rise and spread of ESBL-organisms in Europe, followed closely by Asia and 
the United States (Bradford, 2001). In a 2007 study of hospital infections in 266 centres in 
Asia, North America, Latin America and Europe, the rate of ESBL infections was lower in 
European hospitals than in other areas (Reinert et al., 2007). Greece and Poland were the 
European countries with the highest ESBL prevalence in Enterobacteriaceae. Since then, ESBLs 
have been detected in clinical isolates in several of those apparently ESBL-free countries, and 
CTX-M type enzymes, especially the CTX-M-15 subtype, have emerged as the dominant type 
in Enterobacteriaceae throughout Europe, including Austria (Huemer et al., 2011), Denmark 
(Hansen et al., 2012), Sweden (Brolund et al., 2014), Norway (Naseer et al., 2009), Finland 
(Nyberg et al., 2007), Ireland (Burke et al., 2012; Morris et al., 2009), the United Kingdom 
(Horner et al., 2013, 2014; Wickramasinghe et al., 2012), France (Arnaud et al., 2015; Galas et 
al., 2008 Nicolas-Chanoine et al., 2012; Ruppe et al., 2012; Woerther et al., 2013), and 
Germany (Valenza et al., 2014). In many cases, CTX-M-15 expression is associated with the 
sequence type (ST) ST131, a virulent, fluroquinolone-resistant E. coli strain belonging to the 
B2 phylogenetic group (Coque, Baquero, & Canton, 2008). In Spain, by contrast, there is 
higher prevalence of CTX-M-9 and CTX-M-14, perhaps due to different migration patterns 
(Miró et al., 2005; Rodríguez-Baño et al., 2008; Woerther et al., 2013). In Poland, a high rate 
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of ESBL-carriage was observed in nosocomial enterobacterial isolates from hospitals, with 
CTX-M-3 the dominant type (Empel et al., 2008). Figure 1.5 shows the increase in third 
generation cephalosporin-resistant E.coli in Europe between 2001 and 2014. 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Third generation Cephalosporin-resistant E.coli in Europe: ECDC 
1.7.3 North America: United States and Canada 
In the United States, between 2000 and 2002 isolates were predominantly SHV enzyme-
expressing, with no CTX-M-only isolates; by 2003 CTX-M ESBLs represented 60% of all ESBL-
positive isolates, 89% in 2005 and 70% in 2006 (Lewis et al., 2007; Smith Moland et al., 2003). 
This coincided with E. coli becoming the most common CTX-M-positive pathogen (Lewis et al., 
2007). The majority of samples were urinary samples, usually from outpatients, suggesting a 
community source. The most common CTX-M was CTX-M-15, (Lewis et al., 2007). OXA-1/OXA-
30 was commonly associated with CTX-M-15, similarly to Canada (Lewis et al., 2007; Pitout et 
al., 2007). The SENTRY Antimicrobial Surveillance Program showed that in 195 
Enterobacteriaceae bacteraemia isolates from 26 United States hospitals in 20 states, 43.6% 
expressed CTX-M genes, most commonly CTX-M-15, the most prevalent -lactamase gene 
(Castanheira et al., 2013). 
From the SENTRY and Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) 
surveillance programs of 2007, ST131 was identified as the probable cause of most important 
multi-drug resistant E. coli infections in the United States (Johnson et al., 2010). 
In Canada, emergence of CTX-M was already evident by 2000, especially CTX-M-14 and CTX-
M-15, although SHV enzymes were most prevalent (Mulvey et al., 2004). In a study in the 
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Calgary Health Region of Canada, most ESBL-positive E. coli isolates expressed CTX-M 
enzymes, with CTX-M-14 the most common, followed by CTX-M-15 (Pitout et al., 2007). The 
majority of the isolates originated in the community. Data collected between 2007 and 2011 
in the CANWARD national surveillance study (Denisuik et al., 2013) revealed that the 
proportions of both ESBL-producing E. coli and K. pneumoniae increased over this time, as did 
AmpC-producing E. coli (Denisuik et al., 2013). The predominating ESBL genotype in both E. 
coli and K. pneumoniae was CTX-M-15. The ESBL-producing E. coli had a significant association 
with the ST131 clone, and multiple antibiotics resistance (Denisuik et al., 2013).  
1.7.4 South America 
South America has one of the highest ESBL prevalence levels worldwide (Jones et al., 2013; 
Villegas et al., 2008; Winokur et al., 2001). JMI Laboratories-administered Latin American 
(LATAM) surveillance programs data from eleven countries in 2011 showed that ESBL-
phenotype rates were high in both E. coli (37.3%) and in Klebsiella species (52.4%) (Jones et 
al., 2013). Carbapenem-resistant Enterobacteriaceae (CRE) were also identified in several 
countries (Jones et al., 2013). There is variation between and within countries. In Brazil, the 
CTX-M phenotype is becoming dominant in Enterobacteriaceae (Seki et al., 2013). In one 
study from tertiary care hospitals in the State of Rio de Janeiro, the dominant phenotype was 
CTX-M-15 (Seki et al., 2013). However, in another study from a hospital in southern Brazil, it 
was CTX-M-2 (Nogueira et al., 2015). This highlights how ESBL molecular epidemiology can 
vary within countries. Community-acquired ESBLs are now becoming of concern throughout 
South America (Pallecchi et al., 2004; Valenzuela de Silva et al., 2006; Villegas et al., 2008).  
1.7.5 Australia 
In Australia, ESBLs have been associated with outbreaks in hospitals and nursing homes, and 
the community (Denholm et al., 2009; Eisen et al., 2005; Osthoff et al., 2015; Stokes et al., 
2015; Stuart et al., 2011). In a study on community-acquired UTIs/ bacteriuria in Melbourne, 
risk factors for ESBL-Gram-negative bacteria were identified as length of admission prior to a 
positive sample, antibiotic treatment in the previous six weeks, overseas travel, especially to 
Asia, and residency in a nursing home (Osthoff et al., 2015). ESBL-Gram –negative bacterial 
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infections were associated with more severe illness requiring longer hospital stays and with 
more frequent ICU admission (Osthoff et al., 2015). A study in residential aged care facilities 
in the Melbourne area showed overall incidence of ESBL carriage of 12% (Stuart et al., 2011). 
CTX-M enzymes are again the predominant ESBLs in Australia (Zong et al., 2008). In both E. 
coli and K. pneumoniae isolates in health facilities in the Sydney area, CTX-M-15 was the 
dominant enzyme (Zong et al., 2008). In three residential aged care facilities in the Melbourne 
area, however, CTX-M-9 predominated (Stuart et al., 2011). This again underscores how 
molecular epidemiology of ESBL can vary within a country.  
1.7.6 Africa 
Epidemiological information on ESBL occurrence in Africa is scarce (Sonda et al., 2016). The 
majority of studies focus on hospitals, rather than on community-acquired infections, and 
most have been carried out in South Africa (Tansarli et al., 2013). There is a need for better 
clinical microbiology services to coordinate surveillance and provide informed guidance for 
appropriate local treatment options, and for national and regional policies (Mshana et al., 
2013b). Recent meta-analysis suggests that there is heterogeneity between east African 
countries for ESBL prevalence, but that it is generally high (Sonda et al., 2016). The most 
frequently identified enzymes are CTM-X, SHV, TEM and OXA types. Hospital-based studies in 
Tanzania and the Central African Republic suggest 50-65% ESBL prevalence, with dominance 
of the CTX-M-15 type (Mshana et al., 2013a; Ndugulile et al., 2005; Rafaï et al., 2015), while a 
study in a small private hospital in Sierra Leone suggested ESBLs arose in the community 
rather than the hospital environment (Leski et al., 2016). Data from South Africa on E. coli 
urinary isolates show that susceptibility to -lactam antibiotics fell significantly between 2007 
to 2011 (Bamford et al., 2012). In a study on K. pneumoniae isolates from five regions of South 
Africa between 2010 and 2012, 68.3% of the isolates expressed ESBLs, although most were 
susceptible to carbapenems (Perovic et al., 2014). In paediatric bloodstream infection (BSI) 
samples in Tanzania, antimicrobial resistance was associated with increased mortality 
(Blomberg et al., 2007), but not in South Africa, possibly due to use of carbapenems in in 
South African hospitals (Dramowski et al., 2015). 
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1.7.7 Asia  
High ESBL-prevalence is accepted to be a major public health issue throughout Asia, although 
prevalence and dominant subtypes vary between countries (Jean & Hsueh, 2011). In a study 
of Enterobacteriaceae isolates from a variety of patient samples between 2007 and 2009 at a 
tertiary care centre in India, 45.8% of isolates were ESBL-positive (Kaur and Aggarwal, 2013); 
CTX-M genes dominated in both E. coli and K. pneumoniae isolates. In Korea, 97.9% of ESBL-
producing E. coli isolates collected from a secondary care, community hospital between 2008 
and 2009 were positive for CTX-M genes, mainly CTX-M-14 and/or CTX-M-15 (Park et al., 
2012). ST131 was overall the most predominant in both hospital and community isolates and 
was significantly associated with CTX-M-15 and multi-drug resistance. Recently, clonal 
dissemination of CTX-M-15–producing S. enterica serotype Virchow has become evident in 
South Korea (Kim et al., 2016). Elsewhere in Asia, the emergence of E. coli ST131 expressing 
CTX-M-15 has confirmed its importance as a worldwide pandemic clone, including in In Japan 
(Yano et al., 2013) and Nepal (Sherchan et al., 2015). The importance of the ST131 clone in 
community-acquired samples was demonstrated in a study undertaken between 2013 and 
2014 on stool specimens in Hunan Province in China (Zhong et al., 2015). CTX-M-1-type genes 
were also recently shown to be the dominant ESBL types in E. coli and K. pneumoniae in both 
hospital and community-acquired isolates in Iran (Zamani et al., 2015). Thus it is imperative 
to carry out studies to distinguish between community- and nosocomial- acquired ESBLs in 
both healthy and unhealthy individuals worldwide, to further understand the epidemiology 
and make targeted interventions, including in Saudi Arabia. 
1.7.8 Saudi Arabia and the Middle East 
As in other parts of the world, prevalence of ESBL-mediated antibiotic resistance has been 
growing in Saudi Arabia and other parts of the Middle East (Coque et al., 2008; Jean & Hsueh, 
2011; Zowawi et al., 2013). While more common genes including CTX-M-15, SHV-12 and OXA-
48 have been identified in nosocomial and community isolates, other less commonly 
identified genes such as PER-7, GES-11 and PME-1 have also been observed (Carrër et al., 
2010; Coque et al., 2008; Jean & Hsueh, 2011; Newire et al., 2013; Zamani et al., 2015; Zowawi 
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et al., 2013). In Saudi Arabia in particular, studies on ESBL-mediated antibiotic resistance have 
been performed in a range of settings, including hospital wards and ICUs, as well as in the 
community (Zowawi et al., 2013). ESBLs have been detected in clinical isolates in 
Enterobacteriaceae, P. aeruginosa and Acinetobacter (Al-Agamy et al., 2012; Alyamani et al., 
2015; Bindayna et al., 2010; Somily et al., 2014; Zowawi et al., 2013).  
Most recent trends in Saudi Arabia point to emerging dominance of CTX-M genes in 
Enterobacteriaceae, especially CTX-M-15, in particular in the community setting, although 
SHV genes remain prevalent (Al-Agamy et al., 2009, 2014; Al-Qahtani et al., 2014; Bindayna 
et al., 2010; Tawfiq et al., 2011, 2012). One study undertaken in two Riyadh hospitals in 2007 
on 400 K pneumoniae samples revealed ESBL prevalence of 55%, mainly SHV enzymes, and 
represented the first report of CTX-M in clinical isolates in Saudi Arabia (Al-Agamy et al., 
2009). Later studies undertaken on 430 K. pneumoniae isolates in the Al-Qassim area showed 
lower ESBL prevalence (Tawfiq et al., 2011). 89.1% of isolates were positive for SHV, 
predominantly SHV-12, 70.9% for TEM genes and 36.4% for CTX-M, predominantly CTX-M-15 
(Tawfiq et al., 2011). All the CTX-M genes but none of the SHV genes were transferable 
(Tawfiq et al., 2011). More recent studies from a tertiary hospital in Riyadh on both K. 
pneumoniae (Al-Qahtani et al., 2014) and E. coli (Al-Agamy et al., 2014) highlight the trend of 
increased CTX-M. In the K. pneumoniae study, prevalence of ESBL-positive isolates among 98 
K. pneumoniae isolates was 37.75% (Al-Qahtani et al., 2014). Of these, 91.9% were positive 
for blaSHV genes, mainly SHV-12. CTX-M genes prevalence was 86.5%, with CTX-M-15 
dominant (Al-Qahtani et al., 2014). In 152 E. coli isolates, ESBL expression had overall 
prevalence of 20.39% (Al-Agamy et al., 2014). 30 of 31 isolates were positive for CTX-M-15, 
mainly on the ST131 clone (Al-Agamy et al., 2014).  
Identity of genes from P. aeroginosa isolates in Saudi Arabia differs from those typically found 
in Enterobacteriaceae. In one study on P. aeruginosa isolates in 2010 in Riyadh, prevalence of 
ESBL and MBLs in extended-spectrum cephalosporin (ESC)-non-susceptible isolates was high 
(69.44% and 42.85% respectively). The most commonly expressed ESBL genes were for VEB-
1 and OXA-10, while the most common MBL gene was for the carbapenemase GES. The gene 
for VIM-1, another acquired MBL, was found in 100% of MBL-producing isolates. OXA-10 was 
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often co-expressed with VEB, GES and/or VIM. In another study on P. aeruginosa isolates 
taken in the Armed Forces Hospital in Riyadh, 23 isolates were confirmed to be ESBL-positive 
(prevalence 11.5%) (Al-Agamy et al., 2012). blaVEB was the dominant gene, with blaGES gene 
also expressed, often together with blaOXA-10-like genes (Al-Agamy et al., 2012). VEB, as well as 
PER, has also been identified as the least rare of the ESBL enzymes in P. aeruginosa in other 
countries, in contrast to Enterobacteriaceae (Al-Agamy et al., 2012). A worrying development 
is further emergence of -lactamase genes conferring resistance to carbapenems, in species 
beyond P. aeruginosa, for example blaOXA-51 in ICU-isolates of A. baumannii in Makkah in Saudi 
Arabia, blaOXA-23-like and blaNDM-1 in carbapenem-resistant A. calcoaceticus-baumannii complex 
isolates from patients in the Eastern region of Saudi Arabia and of blaOXA-48, blaNDM, and blaVIM 
in K. pneumoniae isolates with decreased carbapenem sensitivity in Riyadh (Alyamani et al., 
2015; El-Mahdy et al., 2016; Shibl et al., 2013).  
In other countries in the Middle East, the familiar pattern of CTX-M-15 dominance can also 
be detected, for example in the United Arab Emirates (UAE) (Alfaresi et al., 2011; Rotimi et 
al., 2008; Sonnevend et al., 2006) and Kuwait (Al Hashem et al., 2011; Ensor et al., 2009; 
Rotimi et al., 2008. CTX-M-15-producing K. pneumoniae was associated with an outbreak that 
caused 24.1% mortality among fourteen patients between August and September, 2008 in 
the ICU of a Kuwaiti teaching hospital (Al Sweih et al., 2011).  
As in Saudi Arabia, Kuwait, UAE and Oman have experienced increased carbapenem-
resistance in Enterobacteriaceae (Sonnevend et al., 2015). blaNDM-1 was the most prevalent 
carbapenemase gene (46.5%) (Sonnevend et al., 2015). Most NDM, OXA-48-like and VIM 
positive strains were isolated from samples from patients without documented foreign travel 
or healthcare abroad, suggesting predominance of autochthonous infections. These countries 
may act as reservoirs from which these carbapenem-resistant strains could be globally 
disseminated (Sonnevend et al., 2015). This underscores the imperative for improved 
surveillance of carbapenem resistant Enterobacteriaceae in the Arabian Peninsula and the 
Middle East in general (Jamal, Albert, & Rotimi, 2016). As in Saudi Arabia, carbapenem 
resistance is also evident in other bacterial species in countries in the Middle East, in 
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particular P. aeruginosa and Acinetobacter (Jamal et al., 2009; Meric et al., 2008; Sonnevend 
et al., 2013; Zowawi et al., 2013).  
Thus, in Saudi Arabia, and the rest of the Middle East, there are important emerging trends. 
These notably include increasing dominance of CTX-M ESBL genes, especially CTX-M-15 in 
Enterobacteriaceae, in particular in E. coli, often carried on the ST131 clone, and present in 
both hospital and community-acquired infections. There is also increasing prevalence of ESBLs 
in different bacterial species such as P. aeruginosa, often characterised by OXA-10 co-
expression with VEB, GES and/or VIM, and increasing carbapenem resistance in both 
Enterobacteriaceae and other bacterial species, associated with expression of genes such as 
blaOXA-51, blaOXA-23-like and blaNDM-1, blaOXA-48, and blaVIM. The potential sources of these diverse 
drug-resistant bacteria are considered in the next section. 
1.8 Potential sources of infection 
1.8.1 Animals 
1.8.1.1 Pets/companion animals 
Potential sources of vectors for dissemination of ESBLs are zoonotic spread from 
pets/companion animals or farm animals, contaminated food, or water pollution (Woerther 
et al. 2013). The first report of an ESBL in an animal was an E. coli isolate from a laboratory 
dog in Japan in 1988 (Matsumoto et al., 1988). Rise of ESBLs in companion animals/pets and 
farm animals has been facilitated by veterinary use of expanded-spectrum cephalosporins. 
Transmission of CTX-M, SHV and TEM ESBLs from pets/companion animals to humans has 
been suggested in many countries (Costa et al., 2004; Trott, 2013; Woerther et al. 2013). CTX-
M-15 has been identified as the dominant ESBL in studies on Klebsiella and E. coli isolates 
from dogs, cats and horses in studies from Europe and the United States (Donati et al., 2014). 
The ST101 clone was most prevalent and the blaCTX-M-15 gene was the most common (Donati 
et al., 2014; Ewers et al., 2014; O’Keefe et al., 2010). Emergence of E. coli O25-ST131 strains 
expressing CTX-M-15 ESBL in animals has been identified as a major cause for concern (Trott, 
2013). A study on unrelated healthy dogs in Paris showed unexpected predominance of blaCTX-
M-1/IncI1/ST3 (Haenni et al., 2014b). Thus healthy dogs are a possible reservoir for CTX-M-1 
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dissemination to humans; in Paris, prevalence of CTX-M-1 was recently found to equal that of 
CTX-M-15 in healthy human subjects (Nicolas-Chanoine et al., 2012). Genetic characterisation 
on E. coli isolates from both sick and healthy pets in China between 2007 and 2008 showed 
40.4% ESBL prevalence, with CTX-M types on mobile genetic elements dominating (Sun et al., 
2010). The predominant CTX-M types were CTX-M-14 and CTX-M-55, (Sun et al., 2010).  
1.8.1.2 Livestock animals and food chain 
Livestock animals have also been identified as potential reservoirs of ESBLs, for example due 
to use of nontherapeutic antimicrobials (NTAs) in the farming industry (Marshall & Levi, 2011; 
Zowawi et al., 2013). In fact, the practice of using antibiotics for growth promotion in livestock 
has been banned in the European Union since 2006, without any harm to animal health or to 
production (WHO, 2011). The European Food Safety Authority (EFSA) has also identified 
commensal bacteria as a source of antibiotic resistance genes from food animals (EFSA, 2012). 
In a recent study on ESBL-positive E. coli isolates from livestock animals and farmworkers in 
pig and poultry farms in Germany, one of five positive human isolates had an identical MLST 
sequence type (ST) 3891 and CTX-M allele to the cattle faecal sample isolate from the same 
farm, showing zoonotic transfer (Dahms et al., 2015). In two other cases, human-pig and 
human-cattle E. coli isolate pairs from the same farm had the same ESBL genes but a different 
ST, possibly showing horizontal resistance gene transfer (Dahms et al., 2015). A more indirect, 
wider impact via the food chain is also possible (Marshall & Levi, 2011). For example, in a 
study on E. coli isolates from faecal samples and environmental water in a duck farm in China, 
many samples were ESBL-positive, with CTX-M genes predominant (Ma et al., 2012). 
Importantly, the CTX-M genes were carried on transferable plasmids, and there was evidence 
of clonal transmission between duck and water isolates. Evidence of ESBL-positive 
Enterobacteriaceae has also been found in faecal samples of pigs, cattle, chicken and sheep 
in slaughterhouses in Portugal and Switzerland, mainly TEM and CTX-M types (Costa et al., 
2009; Geser, Stephan & Hächler, 2012). In the Swiss study, the most prevalent genes 
identified were CTX-M-1, followed by CTX-M-14 and CTX-M-15 (Geser, Stephan & Hächler, 
2012). SHV and TEM-type -lactamases were also present. While raw bulk tank milk samples 
and minced meat samples were free of ESBLs in the Swiss study (Geser, Stephan & Hächler, 
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2012), in other studies ESBL-positive E. coli has been identified in meat sold in Denmark 
(Jensen et al., 2006) and Tunisia (Jouini et al., 2007), in retail chicken products in Portugal 
(Silva et al., 2012), and in raw milk in Japan (Hammad et al., 2008), among others (Marshall & 
Levi, 2011). Studies from the Netherlands have also suggested ESBL gene and plasmid 
transmission, and E. coli transmission, from poultry to humans via the food chain (Leverstein‐
van Hall et al., 2011). 
1.8.1.3 Wild animals 
Carriage of ESBLs by wild animals is also increasingly recognised as a potential dissemination 
route. Wild animals are vulnerable to environmental exposure to antibiotics or ESBLs which 
have been released into the environment (Cantón et al., 2012; Sousa et al., 2014). For 
example, genotyping studies on gull species in Europe, Canada and Chile suggest that 
common migratory birds are a potentially significant source of ESBL environmental 
dissemination, especially of CTX-M (Stedt et al., 2014, 2015). In other studies on wild animals, 
bacteria expressing ESBL genes carried on mobile genetic elements have been isolated from 
faecal samples in animals in many countries, for example red foxes (Radhouani et al., 2013), 
Iberian lynx (Gonçalves et al., 2012a) and Iberian wolves (Gonçalves et al., 2012b) in Portugal, 
stray dogs in Angola (Albrechtova et a., 2014a), water birds in the Czech Republic and Slovakia 
(Tausova et al., 2012) and in Poland (Literak et al., 2010a) and wild boars in the Czech Republic 
and Slovakia (Literak et al., 2010b).  
1.8.2 Aquatic sources 
The presence of ESBLs has been detected in wastewater from treatment plants in many 
countries, suggesting that treatment processes are inadequate for removal of MDR bacteria. 
Examples include E. coli and Klebsiella ESBL-positive species isolated from wastewater in the 
Czech Republic, predominantly the pandemic B2-O25b-ST131 clone, most of which had an 
IS26 element flanking blaCTX-M-15 (Dolejska et al., 2011) and hospital wastewaters and STP 
wastewater isolates in South East Queensland in Australia (Gündoğdu et al., 2013). In Saudi 
Arabia, while no study has specifically examined ESBLs in wastewater, a recent year-long 
study on the efficiency of the removal of microbial contaminants in a wastewater treatment 
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plant in Jeddah suggested that antibiotic-resistant bacterial isolates were present even in 
chlorinated effluent (Al-Jassim et al., 2015), highlighting the potential risks in re-using treated 
wastewater in agricultural irrigation (Al-Jassim et al., 2015; Hassan et al., 2011). In India the 
blaNDM-1 gene was detected in tap water and seepage water samples (Walsh et al., 2011), the 
Yangtze River in China has been shown to be polluted by ESBL-positive thermotolerant 
coliforms carrying Class 1 integrons (Chen et al., 2010) and the River Thames in London has 
been shown to be contaminated with E. coli of the O25b:H4-ST131 lineage, predominantly 
expressing blaCTX-M-14 (Dhanji et al., 2011). Another potential environmental source of spread 
of ESBL-carrying bacteria in Saudi Arabia is sandstorms, although this has not been definitively 
studied (Zowawi et al., 2013). All these sources contribute to risk of acquiring ESBL-positive 
infections in the community. 
1.9 Risk factors  
Risk factors for infection with ESBLs at an individual level include being seriously ill, prolonged 
hospital stay, prior surgery, prior antibiotic use and presence of in-dwelling medical devices 
(Bradford, 2001; Karanika et al., 2016; Stuart et al., 2011). In hospitals, one of the most serious 
risk factors is sharing a room or ward with other patients with ESBL-producing organisms 
(Livermore, & Paterson, 2006). Over-use of antibiotics in healthcare settings in countries of 
the Arabian Peninsula, due to sub-optimal antibiotic stewardship programs, has been 
associated with increased occurrence of ESBL-positive bacterial infections (Zowawi et al., 
2013). In Saudi Arabia, over-use of antibiotics has been reported in four ICUs, including 
meropenem use (Zowawi et al., 2013). This has contributed to outbreaks of carbapenem-
resistant K. pneumoniae (CRKP) in hospitals in Saudi Arabia (Balkhy et al., 2012). A recent CRKP 
outbreak in a tertiary care hospital in Riyadh was associated with OXA-48 gene carriage (uz 
Zaman et al., 2014). Carbapenems can be the last line of defence against MDR isolates. 
Increases in ESBLs and of MDR generally in the Arab Peninsula has led to prioritisation of 
antimicrobial resistance (AMR) by the Gulf Cooperation Council Center for Infection Control 
(GCC-IC) in the last four years (Balkhy et al., 2016).  
In some cases of community-acquired ESBL infections, the bacterial colonisation may 
originally have occurred nosocomially. For example, in one study on patients with UTIs 
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associated with ESBL-positive isolates, risk factors included past history of hospitalization, 
antibiotic use within the previous three years, indwelling urinary catheters and recurrent 
UTIs, and former experience of an ESBL-positive UTI, and the infections were considered likely 
to have resulted from an original nosocomial infection, then prolonged digestive carriage 
(Arpin et al., 2005). However, as described in section 1.8, there is also risk of infection in the 
community from sources such as contaminated food products, aquatic sources and animals, 
and other infected individuals (Costa et al., 2004; Marshall & Levi, 2011; Trott, 2013; 
Woerther et al. 2013). Regular consumption of meat or chicken were associated with 
community-acquired ESBL colonization faecal samples of non-hospitalized children in a recent 
study in Lebanon (Hijazi et al., 2016). Another recognised risk factor for acquisition of ESBL-
associated disease is international travel, in particular to South and East Asia. For example, 
acquisition of CTX-M-15- associated Enterobacteriaceae infections, in particular E. coli, has 
been associated with travellers returning to European countries such as Spain (Valverde et 
al., 2015), the Netherlands (Paltansing et al., 2013), Germany (Lübbert et al., 2015) and 
Sweden (Östholm-Balkhed et al., 2013), from tropical and sub-tropical regions, with travel to 
South and East Asia and to India associated with particularly high risk. Indeed, developing 
countries with lower economic resources are associated with the highest rates of ESBL-
carriage globally, due to poverty, high population density and poor access to clean drinking 
water, all of which are associated with spread of faecal-oral transmission of infections 
generally (Woerther et al., 2013). In general, hygiene standards are associated with 
prevalence of community-acquired ESBL-positive infections (Koningstein et al., 2015). 
Improvement in decontamination processes can eliminate ESBLs within farms (Schmithausen 
et al., 2015). Within healthcare institutions, hygiene is also vital in control and prevention of 
nosocomial ESBL infections. One recent study on strategies for controlling ESBL-producing 
Enterobacteriaceae transmission in ICUs, for example, showed that improvement in hand 
hygiene is the most effective strategy (Pelat et al., 2015).  
Assessment of the extent and type of ESBL-positive infections and of measures taken to 
counteract them depend on reliable detection methods, as considered in the following 
sections. 
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1.10 Detection of ESBL 
1.10.1 Overview of detection methods 
In terms of patient treatment, time from triage to administration of the appropriate 
antimicrobial treatment are critical mortality determinants (Gaeski et al., 2010; Dellinger et 
al., 2008; Harbarth et al., 2003; Ibrahim et al., 2000; Kumar et al., 2006, 2009; Perez et al., 
2013). Clearly it is imperative that ESBL-detection methods give reliable results in a timely 
manner to rapidly facilitate the most appropriate treatments (Ibrahim et al., 2000).  
Laboratory detection of ESBL-producing bacteria fall into phenotypic and genotype methods. 
In phenotypic methods, non-molecular techniques are used to determine the ability of the 
enzymes to hydrolyse different antimicrobial agents. They are primarily used clinically to 
provide information as to the presence or absence of ESBLs and the range of antimicrobial 
resistance. Examples include the double-disk synergy test, ESBL strip E tests or Liofilchem 
strips, sometimes used in conjunction with automated antimicrobial susceptibility testing 
(AST) systems, such as the VITEK® 2 (bioMérieux) and BD Phoenix (BD Diagnostic Systems) 
systems (Hassan & Abdalhamid, 2014; Kaur et al., 2013; Machen, Drake & Wang, 2014; Mast 
Group, 2016; Sullivan et al., 2015; Vlek, Bonten & Boel, 2012). In genotypic methods, 
molecular techniques are utilised to give information on the gene(s) responsible for ESBL 
production or to give a strain karyotype. Examples are polymerase chain reaction (PCR), 
Pulsed Field Gel Electrophoresis (PFGE), Multilocus sequence typing (MLST) and DNA 
microarray-based techniques (Naas et al., 2010; Pitout & Laupland, 2008; Sullivan et al., 2015 
Stuart et al., 2010).  
1.10.2 Phenotypic methods 
Both the US Clinical and Laboratory Standards Institute (CLSI) and the UK Health Protection 
Agency (HPA) in the United Kingdom have produced standardised guidelines for methods for 
the detection and reporting of ESBL producing organisms, in particular E. coli, Klebsiella 
species, Proteus species and Salmonella species (CLSI, 2014; HPA, 2012). These methods are 
based on the principle that most ESBLs hydrolyse the third generation cephalosporins but are 
inhibited by clavulanic acid (Pitout & Laupland, 2008).  
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The HPA recommends a two-step approach if an ESBL producing organism is suspected (HPA, 
2012). Most guidelines recommend screening isolates based on decreased susceptibility to 
extended-spectrum cephalosporins in primary susceptibility testing and to use one of the 
available tests to confirm ESBL production. While hospital isolates would be primarily 
screened using ceftazidime and cefotaxime or cefpodoxime, community isolates would only 
be screened using cefpodoxime as an indicator, along with the standard antibiotic panel (HPA, 
2012). The second step would involve further confirmatory phenotypic investigation of any 
suspected ESBL producing organism, which include a range of both manual and automated 
methods. One example of a manual phenotypic confirmatory method is the double-disk 
diffusion method for ESBL production in Enterobacteriaceae. It involves measurement of 
growth-inhibitory zones around both cefotaxime (CTX) and ceftazidime (CAZ) disks, with or 
without clavulanate (CA) (CLSI, 2014; HPA, 2012; Mast Group, 2016; Sullivan et al., 2015). This 
is a relatively simple and cost effective method for diagnostic laboratories, but it can be 
complicated by masking of underlying ESBLs by, for example, constitutive plasmid-expressed 
AmpC or KPC carbapenemases, or induction of inducible chromosomal AmpC by clavulanic 
acid. Modifications of the disk diffusion method have been designed to overcome this, such 
as inclusion of cloxacillin, boronic acid compounds, or use of the Tris-EDTA test, also known 
as the AmpC disk test (Black, Moland & Thomson, 2005; Ingram et al., 2011; Mast Group, 
2016; Shevade et al., 2013; Tsakris et al., 2009). Disk diffusion methods that identify AmpC 
and ESBL simultaneously are available (Mast Group, 2016). Alternatively, chromogenic assays 
such as use of the chromogenic cepahalosporin HMRZ-86 in combination with specific AmpC 
and ESBL inhibitors can be used (Mast Group, 2016). One study aimed to evaluate sensitivity 
and specificity of methods for AmpC detection, showed that sensitivity and specificity of the 
methods varied widely, with Tris-EDTA and MAST ID D68C tests emerging as the most 
sensitive and specific (Ingram et al., 2011).  
E-tests and Liofilchem strips work similarly to double-disk diffusion, with minimum inhibitory 
concentration (MIC) in response to -lactam antibiotics expressed in g/ml and resistance 
defined as two double-dilution reduction between clavulanic acid-plus versus clavulanic acid-
minus strips (Sullivan et al., 2015). While reproducibility and accuracy of the E-test strips are 
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generally good, and it is considered less subjective than double-disk diffusion methods, it can 
cause technical difficulties and can be prone to false positives (Brown et al., 2000; Leverstein-
van Hall et al., 2002; Stürenburg et al., 2004).  
A number of different chromogenic culture media products are now available for 
distinguishing between non ESBL and ESBL producing organisms. The basis of these products 
is inclusion of chromogen mixes in the media which are differentially utilised by different 
bacteria, giving characteristic coloured colonies in the presence of antibiotics. Examples 
include ChromID ESBL agar (bioMérieux) CHROMagar products, including CHROMagar ESBL, 
CHROMagar CTX-M and CHROMagar KPC (all CHROMagar, Paris, France), Brillance ESBL agar 
(Thermo Scientific Oxoid Microbiological Products), which has a novel formulation enhancing 
selectivity for selective inhibition of AmpC resistance mechanisms, and cepahalosporin 
HMRZ-86, which is used in the βLacta test (Bio-Rad) (Hanaki et al., 2004; Morosini et al., 2014). 
One study comparing ChromID ESBL agar, to Brillance ESBL agar on presumptive ESBL-
producing Enterobacteriaceae indicated that both chromogenic agars had high sensitivity and 
specificity levels (Huang et al., 2010). Brilliance ESBL agar had a high negative predictive value, 
suggesting its potential excellence for rapidly excluding patients not carrying ESBL-positive 
isolates (Huang et al., 2010). A study on ESBLs in Enterobacteriaceae isolates from patients in 
King Fahad Specialist Hospital in Saudi Arabia indicated high sensitivity and specificity of ESBL 
screening by VITEK® 2, CHROMagar and ESBL-E-strips by comparison to a PCR-based 
molecular method (Hassan & Abdalhamid, 2014).  
While phenotypic methods are an essential element of diagnostics, genotypic methods give 
insight into ESBL subtypes and can facilitate faster turnaround of results. 
1.10.3 Genotypic methods 
1.10.3.1 PCR 
PCR is an essential genotyping method for identification of ESBL genes and subtypes, (Al-
Agamy et al., 2014; Alfaresi et al., 2009; Arpin et al., 2009; Baraniak et al., 2013; Bhattacharjee 
et al., 2007; Brown et al., 2005; Carrër et al., 2010; Castanheira et al., 2013; Chanawong et 
al., 2002; D’Arezzo et al., 2011; Denisuik et al., 2013; Dubois et al., 2008; Empel et al., 2007; 
Galas et al., 2008; Girlich et al., 2001; Hansen et al., 2012; Hassan & Abdalhamid, 2014; Kaur 
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& Aggarwal, 2013; Lewis et al., 2007). While it is expensive relative to many of the available 
phenotypic methods, it is more sensitive and specific (Krishnamurthy et al., 2013; Walker et 
al., 2015). Major advantages include improved throughput and turnaround times, allowing 
for appropriate antibiotic treatment to be expedited (Deccache et al., 2015). Multiplex PCR 
can be efficiently used to detect CTX-M, TEM and SHV genes simultaneously (Kaur & 
Aggarwal, 2013).  
Enterobacterial Repetitive Intergenic Consensus (ERIC) PCR is a bacterial fingerprinting 
method using primers based on ERIC sequences, which are imperfect palindromes of 127 base 
pairs found in intergenic regions within transcribed regions of Enterobacteriaceae genomes. 
Shorter and longer sequences also exist due to internal deletions or insertions, respectively 
and the number of ERIC sequence copies varies among species. ERIC-PCR analysis gives 
multiple band patterns corresponding to unambiguous DNA bacterial ‘fingerprints’, thus 
facilitating determination of phylogeny (Versalovic, Koeuth, & Lupski, 1991). ERIC analysis has 
been used to identify clusters of ESBL-expressing strains in various studies, for example 
clinical isolates gathered in Northern Portugal (Fernandes et al., 2014). 
1.10.3.2 Microarrays 
A major advantage of microarray technology is its capacity to simultaneously detect an almost 
unlimited number of genes in a single run. This has been harnessed in ESBL detection, for 
example in the Check-Points ESBL and ESBL/KPC arrays (Naas et al., 2010; Stuart et al., 2010). 
The Check-Points ESBL array exploits the fact that a number of known substitutions result in 
most known ESBL variants of TEM and SHV (Sections 1.6.2 and 1.6.3) , and probes were 
designed to detect these substitutions, giving coverage of 95% and 77% of TEM and SHV ESBL 
variants respectively (Stuart et al., 2010). Additionally, probes were designed to distinguish 
between CTX-M groups 1, 2, 9 and 8/25 (Stuart et al., 2010). Using PCR and sequencing as a 
reference method, the sensitivity of the ESBL array was 95% and the specificity 100% on a test 
of 212 well-characterised Enterobacteriaceae isolates (Stuart et al., 2010). Advantages 
compared to phenotypic testing include more rapid turnaround time, with results available 
within a single working day, its accuracy for species producing potentially confounding -
lactamases, and provision of information on gene families and single nucleotide 
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polymorphisms (Stuart et al., 2010). Another Check-Points array was designed to further 
identify KPC producers in addition to ESBL producers. When this array was tested on well-
characterised clinical isolates in a French hospital, it was found that it could readily identify 
CTX-M, TEM and SHV ESBLs, as well as the KPC-2 gene and could distinguish between ESBL 
and non-ESBL TEM and SHV derivatives (Naas et al., 2010). Currently, an array is available that 
allows simultaneous detection of clinically prevalent carbapenemase, ESBL and AmpC genes 
in a single test (Check-Points, 2014).  
1.10.3.3 Isoelectric focussing  
Isoelectric focusing (IEF) was at one point considered the gold standard method before PCR 
detection became more widespread (Jouvenot et al., 1987; Matthew et al., 1975). It is used 
to separate molecules (usually proteins) in an immobilised pH gradient polyacrylamide gel 
according to differences in their isoelectric point (pI). Proteins migrate under the influence of 
electric current until the point is reached where the protein is in the pH region matching its 
pI, and it stops. The method can achieve high resolution (Fujita et al., 2015), but is labour 
intensive, expensive, can lack specificity and requires technical expertise (Sharma et al., 
2010). Use of IEF alone for ESBL identification is not now considered effective and is more 
usually combined with other techniques (Arpin et al., 2005; Fernandes et al., 2014; Fujita et 
al., 2015; Sharma et al., 2010). 
1.10.3.4 Pulsed-field gel electrophoresis 
Pulsed-field gel electrophoresis (PFGE) is a technique for separation of large DNA fragments 
in a gel matrix to which an electric field which periodically changes directions in ‘pulses’ is 
applied. It is a widely used macrorestriction pattern analysis genotyping method which can 
scan the whole chromosome for restriction polymorphisms. Bacterial cell walls are lysed and 
the bacterial cells embedded in agarose, before partial digestion of the bacterial DNA with a 
range of restriction endonucleases and separation on the pulsed field gel. It is regularly used 
in ESBL characterisation in order to define PFGE pulsotype and assignment to clonal clusters 
(CC). For example, in a study on CTX-M-producing E. coli strains in Canada, most CTX-M-14 
producers fell into three PFGE clusters, i.e. the closely related 14A and 14AR clusters and the 
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separate 14B cluster, while the remaining isolates were designated 14NR (Pitout et al., 2007). 
This type of information is useful, for example, in identifying patterns and tracing the 
responsible organisms in outbreaks. In this case, it was confirmed that the 14A cluster was 
responsible for outbreaks in 2000, 2001 and 2003. The CTX-M-15 producers could be similarly 
divided into clusters. PFGE was also used to confirm genetic heterogeneity among CTX-M-
producing E. coli in Korean hospital and community isolates, with 75 different types identified 
(Park et al., 2012). In Saudi Arabia, use of PFGE in studies on ESBL-producing E. coli and K. 
pneumoniae isolates from a Riyadh hospital revealed the presence of many diverse 
pulsotypes (Al-Agamy et al., 2014; Al-Qahtani et al., 2014). The major advantage of PFGE is 
that it is highly discriminatory. However it also quite technically complicated, time-consuming 
and has very limited portability and it is difficult to compare, standardize and share 
information between laboratories.  
1.10.3.5 Multilocus sequence typing 
MLST is a highly discriminatory method used in clonal typing of bacteria. Sequences of 
multiple genes (loci), often a series of housekeeping genes, are obtained to give a measure of 
genetic relatedness, and sequence variation is analysed between alleles from many strains 
(Maiden et al., 1998). MLST offers potential advantages over PFGE, including, in some cases, 
higher discriminatory ability (Nemoy et al., 2005), as well as allowing ready comparison of 
data between laboratories (Maiden et al., 1998). In a study comparing PFGE and MLST typing 
of 40 ESBL-positive E. coli isolates from ICU patients, PFGE identified 19 unique pulsotypes, 
while MLST identified 22 unique sequence types (STs) and had higher discriminatory ability 
(Nemoy et al., 2005). MLST is now regularly used as an ESBL identification method in 
genotyping studies, including identification of the dominance of ST131 in E. coli in many 
countries including Saudi Arabia (Al-Agamy et al., 2014; Brolund et al., 2014; Burke et al., 
2012; Denisuik et al., 2013; Horner et al., 2012; Johnson et al., 2010; Naseer et al., 2009; Park 
et al., 2012; Sherchan et al., 2015; Yano et al., 2013). 
All these methods of ESBL identification are vital in determining the causative organism and 
hence informing choice of appropriate treatment. 
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1.11 Treatment 
Treatment of infections caused by ESBL-positive bacteria is complicated by the ineffectiveness 
of commonly used antibiotics including penicillins, cephalosporins and monobactams, and by 
the fact that ESBL-producing strains are often also resistant to other antibiotic types such as 
ciprofloxacin, gentamicin and fluoroquinolone (Sections 1.2, 1.6.4) (Aggarwal et al., 2016; 
Robicsek et al., 2006; Patersen & Bonomo, 2005; Xue et al., 2016). Treatment options are 
needed for both the nosocomial and community settings. This is where information gleaned 
from phenotyping and genotyping is vital. In a study on oral therapy given to community 
patients with UTIs, from whom 100 ESBL-positive E. coli isolates were retrieved, resistance 
rates to ciprofloxacin and trimethoprim-sulfmethoxazole were greater than 70%,while those 
for gentamicin were approximately 21% (Auer et al., 2010). This suggested that these 
antibiotics should not be used in community patients with ESBL-positive UTIs (Auer et al., 
2010). As an alternative, all ESBL-producing strains were tested for resistance to the potential 
alternatives pivmecillinam, fosfomycin, nitrofurantoin and ertapenem using the agar diffusion 
test and the Etest. All emerged as potentially useful agents for ambulatory patients with UTIs 
associated with ESBL-positive E. coli (Auer et al., 2010). Both testing methods showed 97% 
susceptibility of infections to fosfomycin. No resistance was observed to ertapenem. There 
was 94% susceptibility to nitrofurantoin. Results were more variable for pivmecillinam (Auer 
et al., 2010). However, in vitro results suggested high β-lactamase stability for pivmecillinam 
against ESBL-positive E. coli.  
There is also some clinical evidence from case studies that pivmecillinam can be efficacious in 
CTX-M ESBL-associated E. coli infections (Nicolle & Mulvey, 2007). It has been used 
extensively within Nordic countries, but more rarely elsewhere, such as the United States or 
the UK (Dewar, Reed & Koerner, 2014). Based mainly on both in vitro and in vivo evidence 
from Nordic countries, there is increasing recognition of its activity against ESBL-positive 
organisms and its synergistic potential with β-lactamase inhibitors such as clavulanic acid 
(Dewar, Reed & Koerner, 2014; Livermore et al., 2008). Pivmecillinam is also well tolerated 
with relatively few side-effects. It is potentially a useful alternative for treatment of 
uncomplicated UTIs associated with ESBLs. 
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Fosfomycin also emerged as a potential alternative oral treatment option of UTIs associated 
with ESBL-producing E. coli (Auer et al., 2010). A systematic review was carried out of 17 
antimicrobial-susceptibility studies in which fosfomycin was included as a treatment option 
in multi-drug resistant Enterobacteriaceae infections, including ESBLs (Falagas et al., 2010). 
The results suggested that in 11 of the studies, 90% or more of isolates were susceptible to 
fosfomycin, including most ESBL-positive E. coli and K. pneumoniae (Falagas et al., 2010). 
However, more studies are needed to support the initial clinical evidence for potential 
efficacy of fosfomycin for uncomplicated UTIs associated with ESBLs.  
Ertapenem emerged as a potentially very useful agent for treatment of UTI infections 
associated with ESBLs, consistent with previous studies suggesting its use particularly in 
nursing homes and outpatient health care settings (Auer et al., 2010; Paterson & Bonomo, 
2005). Various clinical studies on ESBL isolates, including from UTIs, have suggested its 
effectiveness as an alternative to the more common carbapenems, meropenem and 
imipenem (Alhambra et al., 2004; Mody et al., 2007; Tamayo et al., 2007). Currently 
carbapenems are the treatment of choice in cases of ESBL- associated urosepsis and severe 
sepsis (Pallett & Hand, 2010). However, acquired resistance to carbapenemases is a growing 
concern, for example with the increasing prevalence of OXA carbapenemases (Section 1.6.5) 
(Bush & Jacoby, 2010; Evans & Amyes, 2015; Poirel et al., 2010). International travel has been 
associated with increases in carbapenem resistance, for example travel to the Indian 
subcontinent and spread of the New Delhi metallo-beta-lactamase (NDM) enzyme, often in 
conjunction with ESBL expression (Wei et al., 2015). Thirteen NDM gene variants have 
emerged since it was first documented in India, In the Indian subcontinent (Gottig et al., 2013; 
Nordman et al., 2011a and 2011b; Wei et al., 2015; Yong et al., 2009). It has been detected in 
several other countries due to human factors including travel, food production and 
preparation standards and hygiene/sanitation issues, as well as mobile genetic element 
transfer between unrelated bacterial species (Kus et al., 2011; Wei et al., 2015). While many 
NDM-positive organisms are susceptible to polymyxin (including colistin and polymuxin B) and 
to tigecycline, some have developed colistin-resistance (Arpin et al., 2012). Furthermore 
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efficacy of colistin is uncertain in pulmonary infections, while tigecycline is not very effective 
in systemic infections and may not be useful in UTIs (Uppu et al., 2015; Wei et al., 2015).  
In order to try to reduce the spread of resistance to carbapenems and other antibiotics, 
rigorous application of antibiotic stewardship on a global scale is imperative. For example in 
cases such as asymptomatic bacteriuria in the elderly, antibiotics should be avoided unless 
there are clinical signs of UTI, and use of suppressive or long-term prophylactic antibiotic use 
needs to be addressed (Pallett & Hand, 2010). The World Health Organization (WHO) has 
made antibiotic stewardship recommendations for developing countries (Khan & Nordmann, 
2012; Walsh & Toleman, 2011; Wei et al., 2015).  
As there is a lack of new antibiotics coming to the forefront, rehabilitation and re-purposing 
of ‘old’ options for treating carbapenem-resistant, ESBL-expressing organisms is a possible 
option. For example, use of membrane-active macromolecules was effective in restoring 
susceptibility of NDM-1-expressing E. coli and K. pneumoniae isolates to tetracycline (Uppu et 
al., 2015). Fosfomycin may also be effective in combating NDM-positive and ESBL-positive 
Enterobacteriaceae, although it is usually prescribed for uncomplicated infections, and is only 
absorbed to a limited extent, making it ineffective for pyelonephritis or severe urinary sepsis 
(Auer et al., 2010; Wei et al., 2015). Use of combination drug antibiotic/adjuvant therapy is 
another possible avenue, where adjuvants can include bioactive molecules beyond 
antibiotics. For example, the fungal product aspergillomarasmine A (AMA) rapidly and 
potently inhibits both NDM-1 and VIM-2 and restores meropenem effectiveness against 
Enterobacteriaceae, Acinetobacter and Pseudomonas species (King et al., 2014). Use of 
combination therapy of two antibiotics has also had some success, for example ceftazidime 
plus ceftazidime-avibactam against NDM-positive isolates in mice (MacVane et al., 2014a).  
1.12 Clinical and economic impact of ESBLs 
ESBL producing Enterobacteriaceae are associated with a wide spectrum of disease, ranging 
from asymptomatic colonisation to serious infections, such as UTIs, pneumonia, bacteraemia 
and peritonitis. The spread of ESBLs, has greatly added to the clinical, human and financial 
burdens on healthcare systems worldwide. ESBLs are associated with longer hospital stays, 
more frequent readmissions, more severe illness and increased mortality, inadequate initial 
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treatment and prolonged treatment, and additional nursing care needs (Esteve-Palau et al., 
2015; Garner et al., 2015; Lee t al., 2006; MacVane et al., 2014b; Melzer & Petersen, 2007; 
Ndir et al., 2016; Tumbarello et al., 2010; WHO, 2011, 2014). Treatment of severe ESBL-
associated infections, as explained in section 1.11, is largely dependent on carbapenems, 
which are more expensive and may not be available in resource-poor settings, apart from the 
growing issue of resistance to these drugs (WHO, 2014). The European branch of the World 
Health Organisation (WHO) has estimated that within the 29 countries covered in this region, 
the death of 25,000 individuals annually can be attributed to antibiotic resistant infections, 
usually contracted within a hospital or healthcare setting (WHO, 2011). ESBLs have also been 
consistently associated with increased financial cost of treatment of each patient, in both 
lower and higher income status countries (Conterno et al., 2007; Melzer & Petersen, 2007; 
Ndir et al., 2016; Tumbarello et al., 2010). Such costs are partially associated with longer 
hospital stays. Increased hospital stay is also associated with acquisition of ESBLs in the 
community. For example in a study from Taiwan, patients with ESBLs were significantly more 
likely to be male, to have indwelling urinary catheters and to have been admitted from other 
healthcare facilities. Both hospital length of stay and antibiotic costs, incidence of 
inappropriate antibiotic prescribing and ICU admission rates, were greater for patients with 
ESBL- associated infections (Yang et al., 2010).  
WHO has stressed the importance of cooperative strategies to control the rise of 
antimicrobial resistance (AMR) generally, including cross-sector cooperation in containing 
AMR, strengthening surveillance in healthcare facilities, promotion of strategies for rational 
antibiotic use and increasing surveillance of antibiotic consumption, strengthening infection 
prevention and control activities in healthcare facilities, preventing and controlling antibiotic 
use in animals, supporting and promoting innovative research on development of new 
antibiotics and rehabilitation of existing drugs and improving partnerships with patients 
(WHO, 2011, 2014). The effectiveness of strategies aimed at developing an active surveillance 
culture, including the possibility of targeted screening, implementing contact precautions and 
other infection prevention and control procedures for all colonized or infected patients, and 
rigorously applying antimicrobial stewardship, is supported both by evidence and by expert 
41 
 
 
 
opinion in reduction of nosocomial spread of ESBLs and carbapenem-resistant infections 
(Conterno et al., 2007; Dananché et al., 2015; Domenech de Cellès et al., 2013; Mattner et al., 
2012). 
1.13 Study aims 
1. To investigate, and to analyze the epidemiological status of the Extended Spectrum 
Beta-lactamase (ESBL) Enterobacteriaceae in a tertiary-care hospital in the Eastern Province 
in Saudi Arabia. 
2. Phenotypic detection of ESBL Enterobacteriaceae using VITEK® 2, and MAST ID 
techniques to detect any changes in bacterial organism identities and antibiotic resistance 
between 2010 and 2012. 
3. Molecular detection of the most common ESBL resistance genes in 
Enterobacteriaceae (TEM, SHV, and CTX-M) to detect any changes between 2010 and 2012. 
4. Genotypic characterization of extended-spectrum Beta-lactamase producing (ESBL), 
and carbapenemases in Enterobacteriaceae using MDRCT102 techniques. 
5. Molecular typing of the Extended Spectrum Beta-lactamase (ESBL) 
Enterobacteriaceae using Pulsed-field gel electrophoresis (PFGE), ERIC-PCR.  
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2. Materials and Methods 
2.1 Study site and population 
This study was performed at the Aramco Dhahran Health Center, a 483-bed, acute-care 
hospital in Dhahran, in the Eastern Province of Saudi Arabia. The facility has all major 
specialties and most subspecialties. Saudi Aramco also operates outpatient and emergency 
care clinics in its three surrounding communities, and an 80-bed hospital in Al-Hasa. The 
Aramco Dhahran Health Center serves a patient base of approximately 350,000 employees, 
dependents or annuitants of the Saudi Aramco energy corporation (Saudi Aramco, 2014).   
2.2 Bacterial sampling 
385 Gram-negative Enterobacteriaceae bacterial isolates collected between January 2010 and 
December 2013 which were identified as having resistance to one or more cephalosporins 
were confirmed as being ESBL producers and their species identified using upgraded VITEK® 2 
Systems Software PC5.04 (bioMérieux) The bacterial strains were collected randomly, and 
non-repetitively, with no duplication between patients, whenever ESBL-positive isolates were  
detected. The isolates were recovered from different body sites. Table 2.1 shows the 
distribution of body sites according to gender and out-patient/in-patient status. Most isolates 
(309/385) were from urine cultures, followed by 34 isolates from blood cultures (Table 2.1). 
The majority of ESBL-producers were female, both among in-patients and out-patients (Table 
2.1).  
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Table 2.1: Distribution of body sites for bacterial isolate collection by gender and out-patient/in-patient 
status 
Body Site  In-patients Total Out- patients Total Grand Total 
F M F M 
ABD 4 1 5 2 0 2 7 
BLC 7 9 16 5 13 18 34 
CATH TIP 1 0 1 0 0 0 1 
EYE 0 1 1 0 0 0 1 
NASAL 0 1 1 0 0 0 1 
RESP 2 9 11 
 
1 1 12 
SKIN 3 7 10 1 
 
1 11 
STOOL 0 0 0 1 0 1 1 
UC 57 26 83 173 53 226 309 
WOUND 1 3 4 
 
4 4 8 
Grand Total 75 57 132 182 71 253 385 
 
F: Female; M: Male; ABD: abdominal culture; BLC: blood culture; CATH TIP: catheter tip; EYE: 
eye swab; NASAL: nasal swab; RESP: respiratory culture (upper and lower: expectorated 
sputum and trachial aspirate); SKIN: skin culture swab; STOOL: culture swab; UC: urinary 
culture; WOUND: wound culture swab 
2.3 Phenotypic detection methods 
2.3.1 VITEK® 2 analysis 
The VITEK® 2 (bioMerieux, Inc., USA) automated system was used for identification and 
antimicrobial susceptibility testing (AST) of ESBL- positive Enterobacteriaceae specimens. 
VITEK-2 is accepted as an efficient method of routinely detecting ESBL-positive 
Enterobacteriaceae (Robin et al., 2008; Spanu et al., 2006). Detection of resistant or 
intermediate MIC results for third generation cephalosporins was carried out according to the 
CLSI guidelines. The Gram Negative Identification (GNI) and Gram Negative Susceptibility 
(AST-GN30), card, including the confirmatory ESBL test, were used according to the 
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manufacturer’s instructions. Cards were inoculated from bacterial suspension vials at the 
Smart Carrier Station™ and loaded into the VITEK® 2 automated reader-incubator according 
to the manufacturer’s instructions. Identification and AST cards were inoculated as described 
below and interpreted according to the manufacturer’s instructions using software version 
05.04. Confirmatory ESBL test substrates were included in six wells of the AST-GN30 panel, 
and the interpretation was based on the comparison between the reductions in growth 
caused by one of the cephalosporins. The six wells contained cefotaxime, ceftazidime and 
cefepime respectively at a concentration of 0.5 mg/ml, with or without clavulanic acid (4.0 
mg/ml). Growth in each well was quantitatively assessed by the VITEK® 2 optical scanner and 
results were analyzed when the growth control reached a predominant threshold. The test 
outcome was read as either ESBL positive or ESBL negative. Proportional reduction in growth 
in the wells containing clavulanic acid along with the cephalosporin, compared to those 
containing cephalosporin alone, was considered indicative of ESBL positivity.  
For identification and AST, frozen isolates stored at -800C in skimmed milk were sub-cultured 
twice on 5% sheep blood agar before setting up any Vitek card, then a pure colony from a 
fresh 18 h culture was suspended in 3.0 ml VITEK saline (0.45% w/v), vortexed and the tube 
inverted 2 to 3 times to uniformly suspend the inoculum, and the turbidity adjusted to 
McFarland turbidity of 0.5 to 0.63 (± 0.1) using DensiCHEK. Cards were filled within 15 min for 
both ID (4-6 h) and AST (8-10h) susceptibility cards.  
The AST-GN30 card comprised various β-lactam antibiotics, including cefazolin, ceftriaxone, 
ceftazidime, and cefepime. The results were interpreted by using upgraded VITEK® 2 software 
version 05.04. The susceptibility patterns of the ESBL-producing isolates were interpreted 
against cefoxitin, ampicillin-sulbactam, imipenem, meropenem, ertapenem, amikacin, 
gentamicin, tigecycline, ciprofloxacin, niturofrantoin, colistin, and trimethoprim-
sulphamethoxazol according to 2009 CLSI M100-S19 breakpoint standards. The quality 
control strains used for this study and included in each day's testing were K. pneumonia ATCC 
700603 as positive control, and E. coli ATCC 25922 as negative control. 
Surveillance records were monitored by the infection control department and were reviewed 
to determine antibiograms of resistance rates of Enterobacteriaceae to β-lactam antibiotics 
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and non β-lactam antibiotics. This was to comply with hospital practice, in which on detection 
of MDR, e.g. ESBL or MRSA, the infectious control unit was informed to allow patient, staff 
and visitor safety precautions to be applied, for example isolation, and so that the case could 
be monitored under the hospital stewardship program for in-patients and out-patients. 
2.3.2 Mast ID Discs (AmpC & ESBL Detection) 
As recommended by most guidelines, a two-step approach was adopted to confirm whether 
organisms were ESBL-positive (CLSI, 2014; HPA, 2012). When decreased susceptibility to 
extended-spectrum cephalosporins was confirmed in primary susceptibility testing by VITEK® 
2, phenotypic confirmation of ESBL-producers was determined by use of an AmpC & ESBL disk 
diffusion detection (Mast Group, 2016). This method is routinely used by many clinical 
laboratories and it has been confirmed to be an economical, accurate and straightforward 
test for AmpC and ESBL- positive organisms (Mast Group, 2013, 2016). The D68C AMPC + ESBL 
detection set was used (Mast Group, 2016). This detection set is based on a confirmation of 
AmpC and/or ESBL production in isolates of Enterobacteriaceae by determining 
resistance/susceptibility to cefpodoxime in the presence or absence of ESBL inhibitor and/or 
AmpC inhibitor. Zones of resistance in millimeters around cefpodoxime (A) (10μg), 
cefpodoxime (10μg ) + ESβL inhibitor (B), cefpodoxime (10μg ) + AmpC inhibitor (C), and 
cefpodoxime (10μg ) + ESβL inhibitor + AmpC inhibitor discs (D) were compared to determine 
ESBL and AmpC expression status. The calculations were based on the difference in zone 
diameters, in the presence of the inhibitor of ESBL and/or AmpC, implying ESBL production.  
To carry out the disk diffusion test, four discs were removed from -20˚C freezer and brought 
to room temperature prior to use. Suspensions of bacterial strains were prepared from 
organisms cultured on Mueller-Hinton agar (MHA) plates, supplemented with 5% sheep 
blood. Colonies were suspended in 5 ml of Mueller-Hinton broth (SPML, Saudi Arabia), and 
adjusted to a turbidity of 0.5 McFarland. The organism suspensions were inoculated using 
sterile cotton swabs onto the surface of MHA plates (90 mm diameter). The inoculum was 
allowed to dry, and then the discs were applied to the plates, with four discs A, B, C and D per 
plate. The plates were incubated in an inverted position at 37ºC for 18-24 h. Reading and 
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interpretation of disc diameters were compared according to manufacturer's instructions and 
the CLSI interpretative standards.  
The calculator program from www.mastgrp.com was used to calculate results. Differences 
between zone diameters in mm around the four discs were interpreted as follows:  
ESBL-positive: ZB - ZA and ZD - ZC ≥ 5mm and the differences of each of ZB and ZD and ZA and 
ZC are < 4mm  
AmpC-positive: ZD - ZB and ZC - ZA ≥ 5mm and the differences of each of ZA and ZB and ZC - 
ZD are < 4mm 
ESBL- and AmpC-positive: ZD - ZC ≥ 5mm and the difference of ZA and ZB is < 4mm 
ESBL- and AmpC-negative: All zones differ by ≤ 2mm 
Figure 2.1 shows an example of Mast ID results (Mast Group, 2016).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: D68C AmpC & ESBL Mast Group Detection Set: Representative Results Taken from 
www.mastgrp.com 
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2.4 Molecular characterization of β-lactamase-producing bacteria. 
2.4.1 DNA extraction 
DNA was extracted from preserved clinical isolates for the purposes of carrying out multiplex 
PCR for detection of frequently occurring β-lactamases that can confer resistance to 
extended-spectrum cephalosporins. Frozen preserved isolates stored at -800C in skimmed 
milk were thawed and inoculated on MHA supplemented with 5% sheep blood. After 
overnight incubation at 37°C, pure colonies were suspended in 400 µl of sterilized distilled 
water and turbidity was adjusted to 0.5 McFarland. In 2010, genomic DNA was extracted from 
the suspension using the QIAamp DNA Mini Kit protocols for bacteria (Qiagen) according to 
the manufacturer’s instructions for bacterial suspensions (Qiagen, 2016). Briefly, the 
suspension was centrifuged at room temperature (RT) for 5 min at 5000 x g, then the pellet 
was made up to 180 l with kit buffer ATL. The protocol for ‘DNA purification from tissues’ 
was then followed according to the manufacturer’s instructions (Qiagen, 2016). Briefly, 20 l 
of proteinase K was added and the sample incubated at 56OC for 1 h with occasional vortexing. 
The sample was briefly centrifuged to remove droplets from the lid and then 200 ml of kit 
buffer AL was added, mixed by pulse vortexing for 15 s, and the sample incubated at 70OC for 
10 min. The sample was briefly centrifuged to remove droplets from the lid, then 200 l 
ethanol (96-100%) was added to the sample and mixed by pulse vortexing for 15 s. The sample 
was briefly centrifuged to remove droplets from the lid, then the sample was applied to the 
QIAamp Mini spin column in a 2 ml collection tube. The cap was closed and the sample was 
centrifuged at 6000 x g for 1 min at RT. The QIAamp Mini spin column was placed in a clean 2 
ml collection tube and the tube containing the filtrate was discarded. 500 l kit Buffer AW1 
was added to the spin column, the cap was closed and the sample was centrifuged at 6000 x 
g for 1 min at RT. The QIAamp Mini spin column was placed in a clean 2 ml collection tube 
and the tube containing the filtrate was discarded. 500 l kit Buffer AW1 was added to the 
spin column, the cap was closed and the sample was centrifuged at 20,000 x g for 3 min at 
RT. The QIAamp Mini spin column was placed in a clean 2 ml collection tube and the tube 
containing the filtrate was discarded. The sample was centrifuged for a further 1 min at 
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20,000 x g at RT, the filtrate was discarded, and the spin column was placed in a clean 1.5 ml 
microcentrifuge tube. 200 l kit Buffer AE was added to the column, the sample was 
incubated for 1 min at RT, then centrifuged at 6000 x g for 1 min at RT. The previous step was 
then repeated to increase the yield of DNA. In 2012 the . Figure 2.2 shows a schematic of how 
DNA purification was achieved. Briefly, bacterial suspensions were centrifuged at 1000 x g for 
10 min at RT, and the pellets were resuspended in 180 l kit Bacteria Lysis Buffer and 20 l 
kit Proteinase K, briefly vortexed, then incubated at 65OC for 10 min, then at 95OC for a further 
10 min to diminish the infectiousness of potential pathogenic organisms. Samples were 
cooled to RT, then transferred to  In both time periods, DNA was stored at - 20°C until further 
use. The purity of the isolated  
DNA was checked using NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Scientific). 
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Figure 2.2: MagNA Pure Compact DNA Purification Technology .Taken from Roche Diagnostics: 
http://lifescience.roche.com. 1996-2016 Roche Diagnostics 
2.4.2 Multiplex PCR detection 
Multiplex PCR was carried out using specific primer pairs (Integrated DNA Technologies (IDT), 
Belgium) for amplification of frequently occurring β-lactamases under conditions suggested 
by the enzyme manufacturer. Primer pairs for multiplex PCR specific to betaTEM, betaSHV, and 
betaCTX-M previously used in Monstein et al. (2007) were manufactured; primer sequences, 
melting temperatures (Tm) and expected amplicon product sizes are shown in Table 2.2.  
To confirm that each primer set was giving the expected amplification products, conventional 
PCR reactions were carried out for each primer pair using individual optimised conditions and 
a quality control to detect the expected band; products were subjected to agarose gel 
electrophoresis for verification (Section 2.4.3). 
25µl reactions were achieved by mixing 10µmol/µl (1µl) of each forward and reverse primer 
(Table 2.2), 12.5µl of 2 x HotStarTaq Plus Master Mix (Qiagen) and 6.5µl total bacterial DNA 
extract (isolated as in Section 2.4.1) from one or two bacterial colonies. Negative controls 
were analysed with each set of amplifications; forward and reverse primers and master mix 
were added as described previously, the final volume (25µl) was achieved using molecular 
grade distilled water. 
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The cycling parameters were modified from Monstein et al. (2007) as follows:  
Initial denaturation: 95°C, 5 min  
PCR amplification: 30 cycles: 95°C, 30 s; 54°C, 30 s; 72°C, 120 s  
Final extension: 72°C, 10 min.  
Table 2.2: ESBL primers used in multiplex PCR 
Primer Name Sequence 5’ to 3’ Tm Amplicon Size 
BlaSHV Forward ATGCGTTATATTCGCCTGTG 45 747 
BlaSHV Reverse TGCTTTGTTATTCGGGCCAA 45 747 
BlaTEM Forward TCGCCGCATACACTATTCTCAGAATGA 53 445 
BlaTEM Reverse ACGCTCACCGGCTCCAGATTTAT 52 445 
BlaCTX Forward ATGTGCAGYACCAGTAARGTKATGGC 54 593 
BlaCTX Reverse TGGGTRAARTARGTSACCAGAAYCAGCGG 58 593 
2.4.3 PCR product detection with agarose gel electrophoresis 
To confirm that each primer set was giving the expected amplification products, agarose gel 
electrophoresis was carried out using 10 µl PCR products from individual reactions, mixed 
with 2 µl of loading dye (0.25% bromophenol blue, 0.25% xylene cyanol FF and 15% Ficoll in 
water) and run on a 1.2% agarose gel (Sigma Chemical Co. Type 1-A, USA). A 1 kb DNA ladder 
(Promega, USA.) was used as the molecular size marker. DNA fragments were separated by a 
horizontal electrophoresis cell (Bio-Rad, USA) at 150 V/cm for 45 min in Tris-acetate-EDTA 
(TAE) 1x (40 mM Tris acetate, 1 mM EDTA) buffer. The gels were stained with 0.5 µg/ml 
ethidium bromide (Sigma Chemicals, USA) and photographed under a UV light 
transilluminator (Bio-Rad, USA). 
2.4.4 Microarray (Check-MDR CT102) Method. 
The Check-MDR CT102 DNA microarray (CheckPoints BV, Wageningen, Netherlands) was used 
for detecting the clinically most prevalent carbapenemases and ESBLs in Enterobacteriaceae 
at the Antimicrobial Resistance Research Laboratory, Alfaisal University, Riyadh, Saudi Arabia. 
The Check-MDR CT102 is based on a multiple ligation detection reaction (LDR) methodology 
(Naas et al., 2010). It combines ligation-mediated amplification with detection of amplified 
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products on a microarray to detect ESBL genes blaCTX-M, blaTEM, and blaSHV. It can show which 
carbapenemase and/or ESBL types are present and discriminate between ESBL and non-ESBL 
TEM and SHV variants (Check-Points, 2014). The method employs two probes, a short one 
which has a target-specific sequence and a PCR primer, and a longer one which also has 
another target-specific sequence, a second PCR primer and an intervening ZIP code which is 
complementary to a unique oligonucleotide (cZIP) immobilized on the microarray. When the 
two probes hybridise to a target sequence they become ligated. By this means a collection of 
DNA molecules is gathered and subjected to PCR amplification by the single pair of primers 
(Naas et al., 2010). PCR products detection is achieved by hybridization to a low-density DNA 
microarray, in which a positive hybridization can be detected due to a biotin label on one of 
the PCR primers (Naas et al., 2010). Thus the identification of the -lactamase genes is 
achieved by using a series of probes specific to the individual enzyme genes, resulting in a 
unique microarray hybridization profile by which KPC, CTX-M, TEM, and SHV ESBL variants 
and TEM and SHV non-ESBL variants can be distinguished, along with the five CTX-M groups 
(Naas et al., 2010). 
To carry out the microarray screening in this study, whole-cell DNAs were extracted from 
overnight bacterial cultures using the UltraClean™ Microbial DNA Isolation Kit (Mo Bio 
Laboratories Inc.) according to the manufacturer’s instructions. Check-MDR CT102 microarray 
assays were performed according to the manufacturer’s instructions, using the tubes and 
reagents provided, essentially as previously described (Naas et al., 2010). Briefly, 10 μl of 
purified genomic DNA (5-50 ng/μl) was added to 8 μl of proprietary mix containing ligation 
probes and thermo-stable DNA ligase. The sample was run in a T100 thermal cycler (Bio-Rad) 
for 3 min at 95°C, followed by 24 cycles of 0.5 min at 95°C and 5 min at 65°C, and final 
denaturation at 98°C for 2min. For the DNA amplification step, 30 μl of manufacturer-
provided mix containing PCR primers, deoxynucleoside triphosphates, and thermo-stable 
polymerase was added and the sample was heated for 10 min at 95°C followed by 30 cycles 
of 0.5 min at 95°C, 0.5 min at 55°C, 0.5 min at 72°C, and a final denaturation step of 2 min at 
98°C, using a Verity thermal cycler (Applied Biosystems). The ligation and DNA amplification 
steps were carried out in separate rooms in accordance with the manufacturer’s guidelines. 
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DNA hybridization of the amplified ligation products was carried out in customized array 
tubes (Clondiag) (3 samples per tube). Hybridization was performed using 10 μl of each 
amplified reaction product with 300 μl of preheated hybridization buffer for 30 min at 50°C 
under rotational shaking (400 rpm) in a thermo-mixer (Eppendorf, Hamburg, Germany). 
Unbound DNA was washed away using two 5 min incubation steps with 300μl blocking buffer 
under the same conditions. Then 150μl freshly prepared conjugate solution was added to 
each array tube and incubated for 15 min at 30°C at 400 rpm on the thermo-mixer. Excess 
conjugate was washed away by two 5 min incubation steps using 300 μl detection buffer 
under the same conditions. Finally, 150μl of the staining solution was added and incubated 
for 15 min at room temperature. After 15 min, tubes were inserted in the single-channel 
ATR03 array tube reader, the images were acquired and interpreted with the manufacturer-
provided software. Controls for assessing the success of each critical step in the procedure, 
including ligation specificity and efficiency, PCR amplification, hybridization efficiency, label 
detection and label quality, were inbuilt into the array analysis (Check-Points, 2014; Naas et 
al., 2010). 
2.4.5 Enterobacterial Repetitive Intergenic Consensus (ERIC) PCR.  
One of the most useful tools used in research and diagnostic labs to identify and correlate 
different types of strains is bacterial fingerprinting. Fingerprinting methodology allows 
phylogenetic analysis of bacterial genomes to determine cause of infections between 
different patients and whether they have originated from the same bacteria or whether the 
organism has been genetically modified in any way prior to spreading. ERIC-PCR is based on 
simple PCR using primers based on ERIC sequences. As explained in Section 1.10.3.1, these 
are imperfect palindromes of 127 base pairs in intergenic regions within transcribed regions 
of Enterobacteriaceae genomes. There are also shorter and longer sequences resulting from 
internal deletions or insertions, respectively. The number of ERIC sequence copies varies 
among species. DNA of different strains will give unique multiple band patterns, which 
correspond to unambiguous DNA bacterial ‘fingerprints’ (Versalovic, Koeuth, & Lupski, 1991). 
To perform ERIC-PCR in this study, a fresh BAP (Blood Agar) sub culture was taken from frozen 
isolates stored at -800C in skimmed milk and incubated for 18-24 h to generate pure isolated 
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colonies. The QIAamp DNA Mini Kit (Qiagen) was used for extraction of genomic DNA. A 
loopful of pure isolated colony was suspended in 180 µl ATL buffer, followed by application 
of the DNA extraction from tissue procedure according to the manufacturer’s instructions 
(QIAamp® DNA Mini and Blood Mini Handbook). The concentration of all DNA extracts was 
measured using NanoDrop technology and the ratio of absorbance at 260 nm and 280 nm 
(A260/280) was confirmed to be between 1.8 and 2.2 for all samples. The DNA concentration 
was adjusted to 40 ng/ µl, which was determined to allow good visualization of bands. The 
PCR reaction was carried out on a Bio-Rad thermal cycler, using HotStarTaq Plus DNA 
Polymerase (Qiagen) using 12.5 µl Master Mix (2x), 1.5 µl primer  ERIC1, 1.5 µl primer ERIC2, 
5 µl DNA template (40 ng/ µl), made up to 25 l final reaction volume with deionized, DNase-
free water (ddH2O) (Promega). The sequences of the ERIC primers are shown in Table 2.3. The 
amplification conditions were as follows: 
Initial denaturation: 95°C, 5 min 
PCR amplification: 35 cycles: 92°C, 45 s; 52°C, 1 min; 65°C, 8 min  
Final elongation: 65°C, 16 min  
PCR products were then analyzed by electrophoresis in 1.5% agarose gels using ethidium 
bromide staining, loading dye, and 1 kb ladder, in 1xTAE buffer (all as in Section 2.4.3), at 90 
V for 105 min. Gels were photographed under UV light transilluminator (Bio-Rad, USA). 
 
Table 2.3: ERIC-PCR primer sequences 
Primer Name Sequence 3’ to 5’ 
ERIC 1 CACTTAGGGGTCCTCGAATGTA 
ERIC 2 AAGTAAGTGACTGGGGTGAGCG 
2.4.5.1 Analysis of ERIC-PCR results 
Multiple bands were obtained within each gel and band sizes were calculated in relation to 
the DNA 1 kb size ladder included within each analysis. In order to accurately determine each 
band size, Image J imaging software was used. Gel images were opened within Image J and 
sample lanes were highlighted. A plot of each lane was obtained and peaks relating to each 
band selected. The X values, i.e. the distance each band in the sample lane had migrated, 
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were used to construct a Microsoft Excel spreadsheet in which Rf value was calculated from 
X-value. These were compared to a standard curve in which Rf values for the DNA size ladder 
bands were plotted against log molecular weights and the line of best fit was calculated. 
Molecular weights of all bands within the sample lanes in the gel could then be calculated 
with reference to the standard curve. 
After band size molecular weight calculation, Microsoft Excel was used for construction of a 
presence, absence framework. Band sizes were grouped, allowing a 10% difference within the 
different gel analyses. The presence of a band was scored as ‘1’, and the absence of a band 
was scored as ‘0’. Complete presence, absence frameworks were entered into the software 
programme PAUP for generation of TRE files, which could be opened and manipulated in the 
software programme FigTree to obtain with an unweighted pair group method using 
arithmetic averages (UMPGA) a phylogenetic tree. 
2.4.6 Pulsed-Field Gel Electrophoresis (PFGE) 
Genotyping was performed on E. coli and K. pneumoniae isolates using PFGE, a 
macrorestriction pattern analysis genotyping method which can scan the whole chromosome 
for restriction polymorphisms (Section 1.10.3.4). Briefly, isolates were incubated overnight at 
37°C in 7 mL Mueller Hinton broth. After incubation, 1 mL of bacterial cells was harvested, 
pelleted and washed three times using 1 mL EET (Na2EDTA 100 mM, EGTA 10mM, Tris HCl 1 
M) buffer, before being adjusted to a cell density of 0.5 at 560 nm (Nanodrop 2000). 100 l 
of cell suspension and 100 μL of 1.4% PFGE grade agarose in EET buffer were mixed and 
poured into PFGE plug moulds. The plugs were incubated at 4°C for 30 min to harden, and 1 
mL of lysozyme (5 mg/mL) was then added before incubation at 37°C for 3–4 h. Lysozyme was 
removed from the plugs and 1 mL of deproteinising solution (3 mg/mL proteinase K and 1% 
SDS per plug) was added prior to overnight incubation at 37°C. Next, the plugs were washed 
six times every 30 min with T10E1 (10 mM Tris, 1 mM EDTA) buffer, and then soaked in T10E0.1 
(10 mM Tris, 0.1 mM EDTA) buffer for 30 min. Restriction digestion was performed using 40 
U of XbaI (Fermentas, St. Leon-Rot, Germany) at 37°C. PFGE was performed in a 1% agarose 
gel in a CHEF DR-II system (BioRad, Hercules, CA, USA) with the following conditions: 0.5× 
Tris–Borate EDTA buffer (TBE; 45 mM Tris-borate/1 mM EDTA), 140C, 6 V/cm for 22 h, with 
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switch times ranging from 5 to 40 s. Lambda ladder PFGE marker (BioRad) was used as a 
molecular weight standard.  
2.4.7 Quality control  
When performing screening and phenotypic confirmatory tests, quality control 
recommendations were implemented in that simultaneous testing with a non–ESBL-
producing organism (Escherichia coli ATCC 25922) and an ESBL-producing organism (Klebsiella 
pneumoniae ATCC 700603) were performed (CLSI, 2013). 
2.4.8 Statistical Analysis 
IBM SPSS statistics license 20, Social Science Statistics 
(http://www.socscistatistics.com/Default.aspx) and Microsoft office 2013 software, were 
used to analyze the results were obtained in this study. Statistical tests used included Chi 
squared analysis, Z score and Cohen’s kappa analysis. The microarray objective data analysis 
was carried out with A-Ads software, while PAUP 4.0 software was used to generate the ERIC 
dendrogram, and BioNUmerics Software was used to generate the PFGE dendrogram.  
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3. Phenotyping Results 
3.1 Overview 
A range of phenotypic and genotypic methods are used in modern microbiological diagnostic 
laboratories to determine the MDR expression profiles of bacterial isolates. One of the major 
areas of global concern is the spread of ESBL-expressing Gram-negative bacterial isolates, 
most notably Enterobacteriaceae. In this chapter, results of phenotypic characterization of 
385 ESBL-producing bacterial isolates collected between January 2010 and December 2013 in 
the Saudi Aramco Dhahran Health Center in the Eastern Province of Saudi Arabia are 
presented. They include results of two-step phenotypic characterization by VITEK® 2 and 
AmpC & ESBL disk diffusion detection (Mast Group, 2016).  
The Saudi Aramco Dhahran Health Center joined forces with Johns Hopkins Medicine in 2014 
to establish the Johns Hopkins Aramco Healthcare Company (Saudi Aramco, 2014). The Saudi 
Aramco Dhahran Health Center was chosen as the study site as there has been only limited 
characterization of ESBL infections within the Eastern Province of Saudi Arabia, and in 
particular a lack of any recent genotypic characterization (Bindayna et al., 2010; Khanfar et 
al., 2009; Zowawi et al., 2013). Studies on 6750 Gram-negative organisms isolated from 
clinical samples assessed in the centralized microbiology laboratory in the Eastern Province 
between January 2004 and December 2005 indicated overall ESBL prevalence of 6% (Khanfar 
et al., 2009). Prospective genotypic analysis by multiplex PCR of 100 Enterobacteriaceae 
isolates collected at the Saudi Aramco Dhahran Health Center between April and December 
2006 (E.coli, n=84 and K. pneumoniae, n=16) indicated the dominance of the CTX-M genotype, 
which was present in 71% of samples, either singly or in combination with TEM (Bindayna et 
al., 2010). The blaCTX-M gene was found mainly in urinary isolates (63/71; 88.7%). There were 
high levels of sensitivity to the carbapenem imipenem (100%) and to nitrofurantoin (78%) 
among the samples (Bindayna et al., 2010). The only Ambler class C, AmpC-like -lactamase 
reported to date in Saudi Arabia is encoded by the blaDHA-1 gene, which was first described in 
1997 in an S. enteriditis isolate taken from a stool sample from a lung cancer patient in King 
Fahd Military Medical Complex in Dhahran City (Gaillot et al., 1997) and has since spread 
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(González-Sanz et al., 2009; Ogbolu et al., 2011; Verdet et al., 2006). More recently, the first 
study aimed at characterizing carbapenem resistance in A. baumannii isolates in the Eastern 
Province was carried out at the King Fahad Specialist Hospital in Dammam (Abdalhamid et al., 
2014). Of 141 A. baumannii isolates, 46 (32.6%) isolates were carbapenem-resistant, of which 
43 were positive for metallo -lactamase but negative for blaIMP and blaVIM. 37 of these 46 
strains expressed blaOXA-23 downstream of ISAba1, suggesting that this was the major cause of 
carbapenem-resistance in that Eastern Province sample group.  
The sample of patients in the study in this thesis, as in the study by Bindayna et al. (2010), 
was representative of the study population of approximately 350,000 employees, dependents 
or annuitants of the Saudi Aramco energy corporation, headquartered in Dhahran (Saudi 
Aramco, 2014). The study population is of mainly Asian origin, either Saudis or nationals of 
other Arab or Asian nations. They are a sub-population within the Eastern Province of Saudi 
Arabia, however the large population size and wide geographical spread throughout the 
Eastern Province makes them, in practice, representative of the province as a whole. Patient 
demographic characteristics including age, gender and in-patient versus out-patient status 
were collected and linked to information on body site of the infection and phenotypic and 
genotypic characterization of ESBL-expressing species and determinants, carbapenem 
resistance and resistance to other antibiotics including aminoglycosides and glycylcyclines. In 
this chapter, phenotypic analysis is described for samples collected in 2010 (n=183) and 
characteristics are compared to samples collected in 2012 (n=202), making up the total 
number of 385 patient samples. 
3.2 Patient characteristics 
3.2.1 Patient age group and gender 
A total of 385 bacterial isolates were obtained from clinical samples collected from out-
patients and in-patients attending the Saudi Aramco Dhahran Health Center between January 
2010 and December 2013. Table 3.1 shows the age group and gender breakdown of the 
patients over the whole period. There were more females (257; 66.8% of total) than males 
(128; 33.2% of total) in the whole patient group, suggesting females were more susceptible 
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to ESBL infections. The mean and median ages of the total patient group were 57.9 y and 67 
y respectively. Overall, and within the female and male groups separately, the majority of 
patients were over the age of 60 y, indicating that risk of infection increases with age. There 
was a significantly different age group distribution for females versus males when compared 
by Chi squared analysis (Table 3.2), mainly attributable to differences between the observed 
and expected numbers of patients aged over 80 y; 35/257 (13.6%) of females were aged over 
80 y versus 43/128 (33.6%) of males (Tables 3.1 and 3.2). The Chi-square statistic was 22.3128 
and the p-value was 0.000174. The mean and median age for the female patients was 55.4 y 
and 62 y respectively and for the male patients they were 63.1 y, and 73 y respectively, 
suggesting that older men are at particular risk. 
Table 3.1: Age group distribution by gender (No & %). 
 
Age Groups (y) 
Age Group Distribution by Gender 
  
Females 
N (% of females) 
Males 
N (% of males) 
Total group 
N 
0-19  31 (12.1%) 14 (10.9%) 45 (11.7%) 
20-39  28 (10.9%) 7 (5.5%) 35 (9.1%) 
40-59  60 (23.3%) 23 (18%) 83 (21.6%) 
60-79  103 (40.1%) 41 (32.0%) 144 (37.4%) 
≥80  35 (13.6%) 43 (33.6%) 78 (20.2%) 
Total 257 (100%) 128 (100%) 385 
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Table 3.2: Chi square comparison for age group distribution by gender 
Age group (y) 
Female 
N (expected N) [Chi square] 
Male 
N (expected N) [Chi square] 
Row Totals 
0-19 31 (30.04) [0.03] 14 (14.96) [0.06] 45 
20-39 28 (23.36) [0.92] 7 (11.64) [1.85] 35 
40-59 60 (55.41) [0.38] 23 (27.59) [0.77] 83 
60-79 103 (96.12) [0.49] 41 (47.88) [0.99] 144 
≥80 35 (52.07) [5.59] 43 (25.93) [11.23] 78 
Column Totals 257 128 385 (Grand Total) 
 
3.2.2 Patient age and gender and susceptibility: 2010 and 2012   
The mean and median patient age of the 183 isolates collected in 2010 was 56.8 y and 67 y 
respectively, with ages ranging from 0.017-90 y. The mean and median ages for the 202 
isolates collected in 2012 was 59.0 y and 65 y respectively, with ages ranging from 0.2-102 y. 
Similarly to the total patient group, the gender distribution varied with age group in both 2010 
and 2012 (Figure 3.1A and B). In each year, there were more females than males (124/183 
(67.8%) for 2010; 133/202 (65.8%) for 2012, suggesting that females are more susceptible 
and that there was no change in this trend between 2010 and 2012. Females outnumbered 
males in all age groups from 0-19 up to 60-79, but males outnumbered females in the >80 y 
age groups in both 2010 and 2012 (Figure 3.1A and B). When the mean age for females (54.1 
y) was compared by 2-tail Student’s t-test to the mean age for males (62.5 y) in 2010, the 
female mean age was significantly lower (p=0.040); similarly for 2012 there was a significant 
difference between mean age for females (56.6 y) and males (63.7 y) (p=0.046). The trends 
were very similar in both years. The greater number of female patients in this study is 
consistent with some other studies on ESBL infections, where a distribution of 78% females 
(Lee et al., 2010) or a ratio of 1:16 males to females (Wani et al., 2009) have been reported. 
In both 2010 and 2012, of patients positive for ESBL or AmpC or both by AmpC & ESBL disk 
diffusion detection (Mast Group, 2016), the majority were aged greater than 60 y (51.4% in 
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2010 and 55.7% in 2012) (Figure 3.2). This indicates that susceptibility increases with patient 
age, with patients aged over 60 demonstrating an increased susceptibility, although clearly 
ESBL producing bacteria can cause disease at any age (Figure 3.2). The age distribution was 
similar in both 2010 and 2012 (Figure 3.2). 
The increased susceptibility to ESBL/AmpC infection with age is consistent with observations 
in other studies (Auer et al., 2010; Mumtaz et al., 2007; Tham et al., 2013). Median age of 65 
(Tham et al., 2013) or mean age of 58 (Auer et al., 2010) were reported in these studies, very 
similar to the results reported in Figures 3.1 and 3.2. Greater prevalence of ESBL-producing 
organisms in patients aged over 60 y has been reported, with age being identified as a risk 
factor for susceptibility to ESBL infection (Mumtaz et al., 2007).   
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Figure 3.1: Age group distribution by gender, 2010 and 2012. 
Results indicate that there is increased numbers of patients aged over 60 years and that the gender distribution 
changes over the age of 80 y. 
(A) 
(B) 
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Figure 3.2: Percentage resistance by AmpC & ESBL disk diffusion detection within each decade of the patient 
age in 2010 and 2012. 
Results indicate that there is increased risk of multi resistant infection (ESBL in present or absence of AmpC by 
AmpC & ESBL disk diffusion detection) with increasing age in both 2010 and 2012. 
 
3.2.3 Body site distribution 2010 and 2012  
The majority of ESBL isolates collected in both 2010 and 2012 were from UTIs (77.6% in 2010 
and 82.7% in 2012), followed by systemic infections detected by blood cultures (7.7% in 2010 
and 9.9% in 2012) (Figure 3.3). While 11 isolates were collected from skin infections in 2010 
(6%), there were no isolates from skin infections in 2012 (Figure 3.3). Distribution of other 
infection sites was similar between the two time periods, i.e. abdominal (1.6% in 2010 and 
2% in 2012), respiratory tract infections (sputum samples) (4.4% in 2010 and 2% in 2012), and 
wounds (3.0% in 2010 (four isolates: leg, arm, foot, and thigh cultures) and 1.6% in 2012 (four 
isolates: 2x foot, 1x back, 1x arm cultures). There was one catheter tip isolate in 2010 (0.6%) 
and one each of stool, eye and nasal samples in 2012 (0.5% each) (Figure 3.3). 
The increased risk of females for ESBL infection (Table 3.1, Figure 3.1) is consistent with the 
majority of samples coming from UTIs (Figure 3.3). Females have a shorter urethra and the 
urethra is proximal to the anus, increasing the risk of UTIs. Estimates suggest that 
approximately half of the female population will experience a UTI within their lifetime 
(Foxman, 2003). In 2010, 87.1% of ESBL isolates taken from females in our study were from 
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UTIs, whereas only 57.6% of ESBL isolates from males were from UTIs (Figure 3.4A). Similarly, 
in 2012, while 91.7% of ESBL-samples from females were from UTIs, the figure was only 65.2% 
for males (Figure 3.4B). For the other more frequently encountered infection sites, males 
outnumbered females, with the exception of abdominal infections in 2010 (3 females, 0 
males) and 2012 (3 females, 1male) (Figure 3.4A and B). In particular, for systemic infections 
detected by blood culture (BLC), the second most common type of sample in each time 
period, 15.3% and 18.8% of samples gathered from males in 2010 and 2012 were BLC, 
compared to 4% and 5.3 % for females (Figure 3.4A and B). When the distribution of the top 
five infection sites in each year was assessed by Chi square analysis to compare distributions 
for females versus males (UC, BLC, RESP, SKIN, WOUND, 179/183 samples in 2010; UC, BLC, 
ABD, RESP, WOUND, 199/202 samples in 2012), the distributions were found to be 
significantly different in both time periods (2010: Chi square statistic=25.7241; p=0.000036; 
2012: Chi-square statistic= 28.0662; p= 0.000012). It can be concluded that although female 
patients are at an increased risk of UTIs, ESBL-positive infections can affect either gender in 
our study population and that males may be at higher risk than females of ESBL-systemic and 
other types of infections, including skin, respiratory and wound infections. This trend was 
consistent from 2010 to 2012. 
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Figure 3.3: Body site distribution 2010 and 2012 
ABD: abdominal culture; BLC: blood culture; CATH TIP: catheter tip; EYE: eye swab; NASAL: nasal swab; RESP: 
respiratory culture (upper and lower: expectorated sputum and trachial aspirate); SKIN: skin culture swab; 
STOOL: culture swab; UC: urinary culture; WOUND: wound culture swab. 
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Figure 3.4: Body site distribution by gender 2010 and 2012 
ABD: abdominal culture; BLC: blood culture; CATH TIP: catheter tip; EYE: eye swab; NASAL: nasal swab; RESP: 
respiratory culture (upper and lower: expectorated sputum and trachial aspirate); SKIN: skin culture swab; 
STOOL: culture swab; UC: urinary culture; WOUND: wound culture swab. 
 
Results indicate that the majority of ESBL-positive UTI samples (UC) are from females while the majority of 
samples from systemic infections (BLC) are from males in both time periods 
3.2.4 Location: In-patient v out-patient status 2010 and 2012 
The patient demographic information for both 2010 and 2012 showed that the majority of 
isolates were collected within an out-patient setting (114/183 (62.3%) for 2010 and 142/202 
(70.3%) for 2012). In the out-patient setting, the locations were divided between the clinic 
(2010: 50/114 (43.9%); 2012: 70/142 (49.3%) of out-patients) and the ER (2010: 64/114 
(A) 
(B) 
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(56.1%); 2012: 70/142 (49.3%) of out-patients) (Figure 3.5). In the in-patient setting, the most 
common location was overwhelmingly the ward (2010: 68/69 (98.6%); 2012: 60/60 (100%) of 
in-patients) (Figure 3.5). One in-patient in 2010 was located in the ICU. These results 
demonstrate the prevalence of ESBLs in both community and nosocomial environments, and 
that this remained a stable factor between the 2010 and 2012 time periods (Figure 3.5). 
 
 
Figure 3.5: Distribution of in-patients and out-patients in 2010 and 2012 
The results show that the distribution remained stable between the two time periods; in each period the majority 
of in-patients were located in the ward and out-patients were divided between the clinic and the ER. 
3.3 Bacterial species identification 
3.3.1 Overall species prevalence 
The VITEK® 2 (bioMerieux, Inc., USA) automated system was used for identification of 
bacterial species (Chapter 2, Section 2.3.1). Enterobacteriaceae dominated the species 
isolated (Figure 3.6). The predominant overall species in both 2010 and 2012 was E. coli, at 
138/183 (75.4%) and 147/202 (72.8%) respectively (Figure 3.6). This result was consistent 
with the fact that E.coli is the most common cause of UTIs and is also responsible for many 
systemic infections (Foxman, 2010).  
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The second most common organism in each year was K. pneumoniae at 25/183 (13.7%) and 
41/202 (20.3%) respectively (Figure 3.6). E. cloacae was the third most common in 2010 at 
15/183 (8.2%), but had fallen to fourth most common in 2012 at 3/202 (1.4%), behind E. 
aerogenes (4/202; 2%), of which there were three isolates in 2010 (1.6%, fourth most 
common) (Figure 3.6). Other less common species identified were Citrobacter freundii (one 
case in 2010, two cases in 2012), S. marcescens (one isolate in each time period), and M. 
morganii and P. mirabilis (two isolates each in 2012). Strains of K. pneumoniae, E. cloacae, E. 
aerogenes, P. mirabilis and M. morganii are components of the gut microbiota, while strains 
of C. freundii can cause opportunistic infections (Mariat et al., 2009). 
K. pneumoniae became relatively more common in 2012 compared to 2010 and E. cloacae 
became relatively less common (Figure 3.6). When Chi squared analysis was carried out to 
compare the distributions of the four most common species, E. coli, K. pneumoniae, E. cloacae 
and E. aerogenes, which together make up 181/183 (98.9%) and 195/202 (96.5%) of isolates 
for 2010 and 2012 respectively, the distributions were found to be significantly different (Chi-
square statistic = 11.8009; p-value= 0.008097). This was attributable to the changes in 
prevalence of K. pneumoniae and E. cloacae between 2010 and 2012 (Table 3.3).  
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Figure 3.6: Bacterial species distribution 2010 and 2012 
Table 3.3: Chi square comparison of bacterial species distribution 2010 v 2012 
Time period 
EC 
Observed N (expected 
N) 
KPN 
Observed N 
(expected N) 
ECL 
Observed N 
(expected N) 
EAER 
Observed N 
(expected N) 
Row Totals 
2010 138 (137.19) 25 (31.77) 15 (8.66) 3 (3.37) 181 
2012 147 (147.81) 41 (34.23) 3 (9.34) 4 (3.63) 195 
Column 
Totals 
285 66 18 7 
376 (Grand 
Total) 
 
EC: Escherichia .coli; KPN: Klebsiella pneumoniae; ECL: Enterobacter cloacae; EAER: Enterobacter aerogenes. 
3.3.2 Bacterial species distribution by gender 2010 and 2012 
Given the significant overall change in bacterial species distribution between 2010 and 2012, 
and the differences in infection sites for females versus males, the impact of gender on the 
bacterial species distribution was considered (Figure 3.7). The species distribution for females 
remained relatively stable between 2010 and 2012, except for a drop in E. cloacae species 
from 8/124 isolates from females (6.5%) to 1/133 (0.75%). The difference in distribution for 
E. coli, K. pneumoniae, E. cloacae and E. aerogenes in females was not significant when 
compared by Chi squared analysis for 2010 versus 2012 (Chi-square statistic= 6.42; p= 0. 
092872). However, the distribution for males changed substantially, with E. coli falling from 
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72.9% (43/59 males in 2010) to 58% (40/69 males in 2012), K. pneumoniae increasing from 
10.2% (6/59 males in 2010) to 30.4% (21/69 in 2012), and E. cloacae falling from 11.9% (7/59 
males in 2010) to 2.9% (2/69 males in 2012). When Chi squared analysis was carried out to 
compare the distribution of bacterial species in males between 2010 and 2013, a significant 
difference was observed, particularly due to the changes in prevalence of K. pneumoniae and 
E. cloacae (Chi-square statistic= 11.6232; p= 0. 008792) (Table 3.4).
 
Figure 3.7: Distribution of bacterial species by gender 2010 versus 2012 
EC: Escherichia .coli; KPN: Klebsiella pneumoniae; ECL: Enterobacter cloacae; EAER: Enterobacter aerogenes; 
CITF: Citrobacter freundii; MOMO: Morganella morganii; SERMAR: Serratia marcescens; PRMI: Proteus mirabilis. 
The results show that the distribution for males but not females altered significantly between 2010 and 2012. 
 
Table 3.4: Chi square comparison of bacterial species distribution in males 2010 v 2012 
Time period 
EC 
Observed N (expected 
N) 
KPN 
Observed N 
(expected N) 
ECL 
Observed N 
(expected N) 
EAER 
Observed N 
(expected N) 
Row Totals 
2010 43 (38.46) 6 (12.51) 7 (4.17) 1 (1.85) 57 
2012 40 (44.54) 21 (14.49) 2 (4.83) 3 (2.15) 66 
Column 
Totals 
83 27 9 4 
123 (Grand 
Total) 
EC: Escherichia .coli; KPN: Klebsiella pneumoniae; ECL: Enterobacter cloacae; EAER: Enterobacter aerogenes. 
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3.4 ESBL and AmpC detection 
3.4.1 Overview 
Isolates recovered from the 385 hospital and community infections in 2010 and 2012 were 
suspected to be ESBL-positive; however AmpC, dual resistance (both AmpC and ESBL) or 
negative were other possible phenotypes. To distinguish between these possibilities, a two-
step approach, if an ESBL producing organism was suspected, was adopted, as recommended 
by the HPA (HPA, 2012) (Sections 1.10.2, 2.3). Detection of resistant or intermediate MIC 
results for third generation cephalosporins was carried out according to the CLSI guidelines 
by VITEK® 2 , using Gram Negative Identification (GNI) and Gram Negative Susceptibility (AST-
GN30),  including the confirmatory ESBL test. To distinguish between ESBL and AmpC, the 
AmpC & ESBL disk diffusion detection test was also employed (Mast Group, 2016). 
3.4.2 VITEK® 2 AST detection 
The susceptibility patterns of the suspected ESBL-producing isolates were interpreted against 
cefoxitin, ampicillin-sulbactam, imipenem, meropenem, ertapenem, amikacin, gentamicin, 
tigecycline ciprofloxacin, niturofrantoin, colistin, and trimethoprim-sulphamethoxazol 
according to 2009 CLSI M100-S19 breakpoints standards. Interpretation was based on the 
comparison between the reductions in growth caused by one of the cephalosporins (Chapter 
2, Section 2.3.1). The test outcome was read as either ESBL positive or ESBL negative. AmpC, 
or carbapenemase were suggestive results figured out by AES (Advanced Expert System). In 
2010, 160/183 (87.4%) isolates were positive for ESBL and 23/183 (12.6%) were negative, 
compared to in 2012 when the proportion positive for ESBL had risen to 195/202 (96.5%) and 
the negative proportion had fallen to 7/202 (3.5%) (Figure 3.8). Using the Z score test for 
comparing the proportions of POS/NEG in 2010 compared to 2012 indicated that there is a 
significant difference between the two time periods (Z-Score = -3.3277, p =0.00086), 
suggesting that the proportion of isolates positive for ESBL according to VITEK® 2 was 
significantly increased in 2012 compared to 2010 (Figure 3.8). Resistance/sensitivity to 
individual antibiotics are considered in Section 3.5. 
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Figure 3.8: Distribution of ESBL-positive versus negative by VITEK® 2 in 2010 and 2012 
The results indicate that the proportion of ESBL-positive samples rose significantly between 2010 and 2012. 
 
3.4.3 Mast AmpC & ESBL disk diffusion detection 
Proportion of ESBL, AmpC and dual resistance within the Saudi Aramco Dhahran Health 
Center in 2010 compared to 2012 was compared using the AmpC & ESBL disk diffusion 
detection test (Mast Group, 2016) (Section 2.3.2). Figure 3.9 shows an example of the results 
obtained by disk diffusion for ESBL, ESBL/AmpC, AmpC and Negative.  
 
 
Figure 3.9: Examples of AmpC & ESBL disk diffusion detection test 
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In both time periods, ESBL-only was the predominant phenotype (Figure 3.10). Similarly to 
VITEK® 2, the proportion of ESBL-positive (only) isolates rose from 139/183 (75.9%) in 2010 
to 194/202 (96.0%) in 2012. By contrast, the proportion of AmpC-positive (only) isolates fell 
from 15/183 (8.2%) in 2010 to 7/202 (3.5%) in 2012, the proportion of ESBL/AmpC-double 
positive isolates fell from 6/183 (3.3%) in 2010 to 1/202 (0.5%) in 2012 and the number of 
negative isolates fell from 23/183 (12.6%) in 2010 to zero in 2012 (Figure 3.10). As for VITEK® 
2, using the Z score test for comparing the proportions of ESBL positive in 2010 compared to 
2012 indicated that there is a significant difference between the two time periods (Z-Score =-
5.7576, p= 0), suggesting that the proportion of isolates positive for ESBL according to disk 
diffusion was significantly increased in 2012 compared to 2010 (Figure 3.10). The proportion 
of AmpC-positive samples, by contrast, fell significantly (Z-Score=1.9974, p=0.0455), as did 
the proportion of double-positive ESBL/AmpC isolates (Z-Score=2.0415, p=0.04136). 
Comparing the whole distribution of AmpC, ESBL/AmpC, ESBL and negative isolates for 2010 
versus 2012 by Chi squared analysis indicated that the distribution changed significantly 
between 2010 and 2012 (Chi-square statistic=37.7188, p < 0.00001) (Table 3.5). This was 
attributable to ESBL positive results being higher than expected and all other categories lower 
than expected in 2012 compared to 2010 (Table 3.5). 
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Figure 3.10: Distribution of ESBL and AmpC-proportions by Mast AmpC & ESBL disk diffusion detection test 
2010 and 2012 
The results indicate that the proportion of ESBL-positive samples rose significantly between 2010 and 2012. 
 
Table 3.5: Chi square comparison of disk diffusion phenotype distribution 2010 v 2012 
Time 
period 
AmpC 
Observed N (expected N) 
ESBL/AmpC 
Observed N 
(expected N) 
ESBL 
Observed N 
(expected N) 
NEG 
Observed N 
(expected N) 
Row totals 
2010 15 (10.46) 6 (3.33) 139 (158.28) 23 (10.93) 183 
2012 7 (11.54) 1 (3.67) 194 (174.72) 0 (12.07) 202 
Column 
Totals 
22 7 333 385 
123 (Grand 
Total) 
 
3.4.3 Comparison of VITEK® 2 and disk diffusion results 
The results of both VITEK® 2 and disk diffusion antibiotic susceptibility testing suggested that 
the risk of ESBL-positive infection rose between 2010 and 2012 in the Saudi Aramco Dhahran 
Health Center, while risk of AmpC-positive infection fell. However, there was some 
inconsistency between results obtained by the two methods, in particular in 2010. When data 
derived from VITEK® 2 (ESBL POS or NEG) was compared to Mast disk diffusion data, it was 
observed that in 2010, 83.1% of VITEK® 2 ESBL-positive (POS) results (133/183) were also ESBL 
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only-positive by disk diffusion, while by 2012 this had risen to 99.5% (194/195 ESBL-positive 
by both methods) (Figure 3.11). However, in 2010, 12.5% of VITEK® 2 ESBL-positive (POS) 
results (20/160) were scored negative by disk diffusion, while 1.9% (3/160) were scored AmpC 
and 4/160 (2.5%) were scored ESBL/AmpC (Figure 3.11). In 2010, 52.2% (12/23) isolates 
scored ESBL-NEG by VITEK® 2 were AmpC-positive by disk diffusion; this had risen to 100% by 
2012 (Figure 3.11). However, in 2010, 26.1% (6/23) of isolates scored ESBL-NEG by VITEK® 2 
were scored ESBL-positive by disk diffusion, while a further 8.7% were scored ESBL/AmpC, 
and the final 13.0% of isolates were also scored negative (Figure 3.11). These discrepancies, 
especially in the 2010 data, highlight the need to carry out a two-step approach to 
phenotyping if an ESBL producing organism is suspected, but also to adopt a genotyping 
approach in addition. Genotyping analysis is discussed in the next chapter. The identification 
in 2012 of all VITEK® 2 NEG results as AmpC-positive by disk diffusion also highlights the 
necessity to carry out a phenotyping test that can distinguish between ESBL and AmpC 
expression. 
 
 
 
 
 
 
 
 
 
Figure 3.11: Comparison of VITEK® 2 and Mast AmpC & ESBL disk diffusion results 2010 and 2012. 
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3.4.4 Gender and Resistance Type by disk diffusion 
When the resistance type and patient gender were considered, there was a marginally 
significant difference in the distribution of AmpC, ESBL/AmpC, ESBL and NEG for Mast AmpC 
& ESBL disk diffusion when females and males were compared for 2010 (Chi-square 
statistic=8.0965, p=0.044058), but there was no significant difference between the numbers 
of isolates with different resistance mechanisms compared to the patient gender for 2012. 
However, if resistance expression for each gender was compared between 2010 and 2012, 
there was a significant difference in the distributions for both females (Chi-square 
statistic=25.9266, p < 0.00001) and males (Chi-square statistic=13.7139, p=0.003322) (Table 
3.6), similarly to the groups as a whole. Thus, while being of male versus female gender did 
not appear to make an impact on resistance type, the distribution change observed for the 
whole group (Section 3.4.3), in which ESBL increased between 2010 and 2012 and NEG results 
decreased, was repeated for both females and males. More of each gender were ESBL in 2012 
than would be statistically expected.  
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Table 3.6: Chi square comparison of disk diffusion phenotype distribution for females and males 2010 v 2012 
time 
period 
AmpC 
Observed N (expected 
N) 
ESBL/AmpC 
Observed N 
(expected N) 
ESBL 
Observed N 
(expected N) 
NEG 
Observed N 
(expected N) 
Row totals 
2010 
females 
9 (5.31) 1 (0.48) 98 (110.49) 16 (7.72) 124 
2012 
females 
2 (5.69) 0 (0.52) 131 (118.51) 0 (8.28) 133 
Column 
Totals 
11 1 229 16 
257 (Grand 
Total) 
Time 
period 
AmpC 
Observed N (expected 
N) 
ESBL/AmpC 
Observed N 
(expected N) 
ESBL 
Observed N 
(expected N) 
NEG 
Observed N 
(expected N) 
Row totals 
2010 males 6 (5.07) 5 (2.77) 41 (47.94) 7 (3.23) 59 
2012 males 5 (5.93) 1 (3.23) 63 (56.06) 0 (3.77) 69 
Column 
Totals 
11 6 104 7 
128 (Grand 
Total) 
3.4.5 Patient Age and Resistance Type by disk diffusion 
The patient cohorts for 2010 and 2012 were divided into age groups to compare the 
resistance mechanisms expressed by the infection causing isolates as assessed by disk 
diffusion. Risk of ESBL and/or AmpC –positive infection increased with age in both 2010 and 
2012, with a similar age distribution in both 2010 and 2012 (Figure 3.2). When the prevalence 
of the different resistance phenotypes were considered for each age group, a significant 
difference was detected with age in the distribution of phenotypes within the 2010 age 
groups (Chi-square statistic=25.562, p=0.001248), mainly attributable to the higher than 
predicted AmpC prevalence and lower than predicted ESBL prevalence in the 0-19 age group 
(Figure 3.12). However, no significant difference could be determined between the patient 
age groups and resistance type in the 2012 cohort (Chi-square statistic=7.4502, p=0.488925). 
The percentage of each resistance type within each age group is shown in Figure 3.12. This 
graph reveals the similarities in the distribution between age groups 0-19, 20-39, 40-59, 60-
79 and >80 y in 2012, and by contrast the variation of the 0-19 y age group from the other 
age groups in 2010. The results obtained suggest that for 2010, all age groups except 0-19 y 
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were had a similar ESBL prevalence among the infections detected (Figure 3.12A). The 0-19 y 
age group had the highest prevalence of AmpC only (26.9%; 7/26 isolates) of any age group 
in either time period (Figure 3.12). There were no dual-resistance isolates in the 20-39 or 40-
59 y age groups and no AmpC only in the 20-39 or >80 y age groups (Figure 3.12A). By 2012, 
all age groups were at an approximately equally high risk of ESBL and an equally low risk of 
AmpC or ESBL/AmpC dual resistance (Figure 3.12B). There were no cases of ESBL/AmpC dual 
resistance for any age group in 2012 except those >80 y (one case) and no cases of AmpC only 
for the 20-39 y age group.  
Susceptibility of younger patients aged less than 1 y to AmpC resistance has been observed 
in other studies (Pitout et al., 2007). Within the Saudi Aramco Dhahran Health Center similar 
observations of increased AmpC resistance in younger patients were made in 2010, but not 
in 2012. Low overall levels of AmpC expression were observed in 2012, suggesting that within 
both the elderly and young population AmpC production was being detected and treated 
appropriately by 2012. When comparing 2010 to 2012, the most striking observation was the 
increased relative prevalence of ESBL-positive infections across the age groups between 2010 
and 2012. This suggests that numbers of ESBL infections are increasing across the population 
each year and that they are dominating in each age group, within the Saudi Aramco Dhahran 
Health Center. By contrast, a fall in both AmpC and ESBL/AmpC dual resistance numbers and 
relative prevalence for each age group was observed (Figure 3.12).  
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Figure 3.12: Distribution of ESBL, AmpC and ESBL/AmpC by age group in 2010 and 2012 
 (A) Phenotype distribution by disk diffusion for 2010; (B) Phenotype distribution by disk diffusion for 2012. Results 
show variability in phenotype distribution for the 0-19 y age group in 2010 but no significant variability in 
phenotype prevalence across age groups in 2012. 
3.5 Antibiotic Susceptibility of the Isolates 
3.5.1 Overall antibiotic sensitivity 
Antimicrobial susceptibility testing (AST) was carried out using VITEK® 2, with the Gram 
Negative Identification (GNI) and Gram Negative Susceptibility (AST-GN30) card (Chapter 2, 
Section 2.3.1). Figure 3.13 shows the distribution of antibiotic resistance (Figure 3.13A), 
(A) 
(B) 
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intermediate resistance/sensitivity (Figure 3.13B) and sensitivity (Figure 3.13C) in 2010 versus 
2012 for all patients for the antibiotics Amikacin (AK), Ampicillin/sulbactam (AMS; ESBL 
inhibitor), Ceftazidime (CAZ), Ciprofloxacin (CIP); Colistin (CO) Ceftriaxone (CRO), Cefazolin 
(CZ), Ertapenem (ERP), Nitrofurantoin (FD), Cefepime (FEP), Cefoxitin (FOX), Gentamicin (GM), 
Imipenem (IPM), Meropenem (MER), Trimethoprim/sulfamethoxazole (SXT) and Tigecycline 
(TGC). 
The overall resistance patterns were apparently similar in 2010 and 2012 (Figure 3.13A). 
However, when the patterns for intermediate resistance/sensitivity and sensitivity were 
considered, differences in the distributions became more apparent (Figure 3.13B and 3.13C). 
For -lactams, levels of resistance between 70-100% were observed in both 2010 and 2012 
for ampicillin/sulbactam and for the first generation cephalosporin, cefazolin and the third 
generation cephalosporin, ceftriaxone. This was not unexpected given the high levels of 
positivity for ESBL and AmpC revealed in the phenotyping described in Section 3.2. For the 
second generation cephalosporin cefoxitin, there was no significant difference between 2010 
and 2012, with 68.9% and 72.3% sensitivity respectively (Figure 3.13C). For the third-
generation cephalosporin, ceftazidime, the sensitivity percentage was already low in 2010 at 
35.5% and fell further to only 2.0% in 2012, while percentage intermediate rose from 35.0% 
to 80.2%. The distribution was significantly different between 2010 and 2012 (Chi-square 
statistic=99.3274, p < 0.00001). This reduction in CAZ resistance is consistent with other 
studies (Cantón et al., 2011; Kumar et al., 2014). For the fourth-generation cephalosporin 
cefepime, the percentage of isolates sensitive was 79.8% in 2010, but this fell to only 7.4% in 
2012, while percentage intermediate rose from 6.0% to 74.3%. The distribution was 
significantly different between 2010 and 2012 (Chi-square statistic=228.1349, p < 0.00001)  
No isolates in either 2010 or 2012 were resistant to the carbapenems, meropenem or 
ertapenem (Figure 3.13A); 100% of isolates in 2010 and 2012 were sensitive to ertapenem 
(Figure 3.13C), while 100% were sensitive to meropenem in 2010 and 99.5% in 2012, where 
one isolate was of intermediate resistance/sensitivity (Figure 3.13B and 3.13C). For the other 
carbapenem imipenem there was 97.8% sensitivity in 2010 and 98% sensitivity in 2012 (Figure 
3.13C). These results imply that there is still significant sensitivity to carbapenem antibiotics 
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in ESBL- and AmpC-positive infections in patients in the Saudi Aramco Dhahran Health Center, 
possibly because carbapenems remain more rarely used antibiotics, reserved for complicated 
infections.  
For non--lactam antibiotics, there was also 100% sensitivity to the polymyxin colistin and to 
the glycylcycline tigecycline (Figure 3.13C). Use of colistin in therapy for Gram-negative 
multidrug-resistant bacteria is becoming more common in contexts such as organ 
transplantation (Florescu et al., 2016) or in potentialization of β-lactams in combination 
therapy (Al Atya et al., 2016). A recent global surveillance study on 19,719 Enterobacteriaceae 
isolates collected during 2012 and 2013 showed 98.4% sensitivity to colistin, however there 
was a trend for lower susceptibility in the presence of carbapenemase-producing bacteria 
which could give future cause for concern (Bradford et al., 2016). Results from the Tigecycline 
Evaluation and Surveillance Trial (T.E.S.T.) (Tärnberg et al., 2016), and the SENTRY 
Antimicrobial Surveillance Program (2011–2014) (Sader et al., 2016) suggest that sensitivity 
of Gram-negative organisms including Enterobacteriaceae to tigecycline is still high, and the 
drug has been approved by the US Food and Drug Administration (FDA) for the treatment of 
various types of complicated infections, including skin and soft-tissue, and intra-abdominal, 
as well as for community-acquired bacterial respiratory infections (Pournaras et al., 2016). 
However, there are mechanisms whereby resistance to tigecycline can be acquired, for 
example via RND-type transporters, so prudent antibiotic stewardship remains important in 
optimising use of this drug. The results of this study are therefore consistent with 
international experience with colistin and tigecycline sensitivity. 
For the fluoroquinolone ciprofloxacin, there was low sensitivity of 25.7% and 29.2% in 2010 
and 2012 respectively, but there was no significant change between the two years. Likewise 
for the combination drug trimethoprim/sulfamethoxazole (SXT), there was low sensitivity of 
33.9% and 36.1% in 2010 and 2012 respectively, with no significant change between the two 
years. For the nitrofuran nitrofurantoin (FD), a higher percentage of isolates was sensitive in 
each year, i.e. 68.3% in 2010 and 58.4% in 2012. Again, there was no significant difference 
between the two years. 
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For the aminoglycoside antibiotic amikacin, 98.4% of isolates were sensitive in 2010; this had 
fallen to 69.3% in 2012, while the percentage intermediate rose from 1.1% to 29.2%. The 
distribution of AK sensitivity, resistance and intermediate sensitivity/resistance was 
confirmed to differ significantly between 2010 and 2012 when tested by Chi square analysis 
(Chi-square= 58.467, p < 0.00001). For the other aminoglycoside antibiotic gentamicin (GM), 
there was no significant difference between 2010 and 2012, with 51.4% and 55.4% sensitivity 
respectively (Figure 3.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
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Figure 3.13: Distribution of antibiotic resistance, sensitivity and intermediate resistance/sensitivity in 2010 
and 2012 
 (A) Resistance distribution; (B) Intermediate distribution; (C) Sensitivity distribution 
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline 
The results show significant changes in the sensitivity/intermediate patterns for AK, FEP, and CAZ 
3.5.2 Patient age group and antibiotic sensitivity  
To determine whether there was any significant variation with age in prevalence of sensitivity 
of infections to -lactam or non--lactam antibiotics, the percentage of isolates within each 
age group block (0-19, 20-39, 40-59, 60-79 and >80 y) which were sensitive to each individual 
antibiotic was calculated (Figure 3.14 and 3.15). Figure 3.14 shows the percentage of isolates 
within any given age group which were sensitive to -lactams in 2010 versus 2012 (Figure 
3.14A and B) and Figure 3.15 shows percentage of isolates within any given age group which 
were sensitive to non--lactams in 2010 versus 2012 (Figure 3.15A and B). For -lactams, 
while the overall drop in sensitivity to antibiotics including ampicillin/sulbactam (AMS), 
cefazolin (CZ), ceftriaxone (CRO), cefepime (FEP) and ceftazidime (CAZ) was evident across 
age groups between 2010 and 2012, percentage of isolates sensitive to each antibiotic was 
(C) 
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relatively constant across the age groups within both 2010 (Figure 3.15A) and 2012 (Figure 
3.15B). There was no change in sensitivity to cefoxitin or to the carbapenems. 
With respect to non--lactams, while the decrease in sensitivity to amikacin across all age 
groups from 2010 to 2012 was evident, there was no obvious difference in prevalence of 
sensitivity to any particular antibiotic with respect to age; percentage of isolates sensitive to 
each antibiotic was relatively constant across the age groups within both 2010 (Figure 3.15A) 
and 2012 (Figure 3.15B). The only exception was ciprofloxacin (CIP), for which prevalence of 
sensitivity compared to resistance/intermediate dropped with increasing age in 2010 (Chi-
square statistic=10.2947; p=0.035745), although there was no significant change in 2012. 
There was no change with age group in either year for GM, FD or SXT, and there was 100% 
sensitivity to colistin and tigecycline in both years across age groups.  
86 
 
 
 
 
 
Figure 3.14: Prevalence of-lactam antibiotic sensitivity in each age group in 2010 and 2012 
 (A) 2010; (B) 2012 
AMS: Ampicillin/sulbactam (ESBL inhibitor); CZ: Cefazolin; CRO: Ceftriaxone; CAZ: Ceftazidime; FEP: Cefepime; 
FOX: Cefoxitin; IPM: Imipenem; MER: Meropenem; ERP: Ertapenem;  
  
(A) 
(B) 
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Figure 3.15: Prevalence of non--lactam antibiotic sensitivity in each age group in 2010   and 2012 
 (A) 2010; (B) 2012 
AK: Amikacin; CIP: Ciprofloxacin; GM: Gentamicin; FD: Nitrofurantoin; SXT: Trimethoprim/sulfamethoxazole; 
TGC: Tigecycline; CO: Colistin; 
  
(A) 
(B) 
88 
 
 
 
 
3.5.3 Patient gender and antibiotic sensitivity 
To determine whether there was any significant variation with gender in prevalence of 
sensitivity of infections to -lactam or non--lactam antibiotics, the percentage of females 
with isolates sensitive to each individual antibiotic, and also the percentage was calculated 
for both 2010 and 2012 (Figure 3.16 and 3.17). As with age group, while the overall drop in 
sensitivity between 2010 and 2012 to drugs including the -lactams ampicillin/sulbactam 
(AMS), cefazolin (CZ), ceftriaxone (CRO), cefepime (FEP) and ceftazidime (CAZ) (Figure 3.16A 
and B), and the aminoglycoside amikacin (Figure 3.17A and B) and there was no apparent 
gender difference in sensitivity to any particular antibiotics, and no difference between years 
for any antibiotics.  
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Figure 3.16: Prevalence of -lactam antibiotic sensitivity by gender in 2010 and 2012 
 (A) 2010; (B) 2012 
AMS: Ampicillin/sulbactam (ESBL inhibitor); CZ: Cefazolin; CRO: Ceftriaxone; CAZ: Ceftazidime; FEP: Cefepime; 
FOX: Cefoxitin; IPM: Imipenem; MER: Meropenem; ERP: Ertapenem  
 
(A) 
(B) 
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Figure 3.17: Prevalence of non--lactam antibiotic sensitivity by gender in 2010 and 2012 
 (A) 2010; (B) 2012 
AK: Amikacin; CIP: Ciprofloxacin; GM: Gentamicin; FD: Nitrofurantoin; SXT: Trimethoprim/sulfamethoxazole; 
TGC: Tigecycline; CO: Colistin 
 
 
 
 
 
(A) 
(B) 
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3.5.4 Bacterial organism and antibiotic sensitivity  
To determine whether there was any significant variation in sensitivity of the different 
bacterial organisms detected in isolates from 2010 and 2012 to the -lactam or non--
lactam antibiotics tested, the percentage of the top four bacterial species in each year (E. 
coli, K. pneumoniae, E. cloacae and E. aerogenes) sensitive to each individual antibiotic was 
calculated for both 2010 and 2012 (Figure 3.18 and 3.19).  
For -lactam antibiotics, there was overall low sensitivity to ampicillin/sulbactam (AMS), 
cefazolin (CZ), ceftriaxone (CRO), and ceftazidime (CAZ) across all bacterial species, with a 
lower percentage of all species sensitive to these antibiotics in 2012 than in 2010 (Figure 
3.18B). The overall drop in percentage of isolates sensitive to cefepime (FEP) in 2012 was 
attributable to equivalent drops in sensitivity among E. coli (80.4% to 2 % sensitive) and K. 
pneumoniae (80% to 9.8%) (Figure 3.18A and B), with the majority of isolates of each species 
being classed as intermediate in 2012 (80.3% of E. coli and 65.9% of K. pneumoniae). 100% of 
both E. cloacae and E. aerogenes isolates in 2012 were, by contrast, sensitive to FEP, although 
again caution should be exercised given the low number of isolates of each. Our observations 
of increasing resistance to cefepime in E. coli and K. pneumoniae is consistent with studies 
from other parts of the world, while clinical Enterobacter spp. strains tend to be sensitive to 
this drug (Endimiani et al., 2008; Fritsche et al., 2008; Goossens et al., 2005). The results also 
revealed that while high percentages of both E. coli and K. pneumoniae were sensitive to 
cefoxitin (FOX) in both 2010 (76.1% and 80% of isolates respectively) and 2012 (72.8% and 
90.2% of isolates respectively), both E. cloacae and E. aerogenes isolates were uniformly 
resistant to this drug, with the exception of one E. cloacae isolate in 2010. These results are 
consistent with the recognised resistance of Enterobacter spp. to cephamycins such as 
cefoxitin (Paterson, 2006; Ritchie et al., 2009). All the carbapenems, meropenem, ertapenem 
and imipenem, had overall excellent activity across all bacterial species in both 2010 and 
2012. 
For non--lactam antibiotics, the results revealed that the overall lower sensitivity to amikacin 
observed in 2012 compared to 2010 was mainly due to a similar decreased sensitivity of E. 
coli isolates (Figure 3.19A). For K. pneumoniae, E. cloacae and E. aerogenes, overall high levels 
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of sensitivity to amikacin were retained in 2012 (85.4%, 100% and 100% respectively) but only 
63.3% of E. coli isolates were sensitive in 2012 compared to 97.8% in 2010. The status of E. 
coli as the most prevalent bacterial species meant this reduction had a large impact on the 
overall sensitivity figures, however these results suggest that amikacin could still be an 
effective choice of treatment for ESBL-positive K. pneumoniae, E. cloacae and E. aerogenes 
isolates in the Saudi Aramco Dhahran Health Center, but should probably be avoided for 
treatment of ESBL-positive E. coli. It should be noted that as there were only three E. cloacae 
and four E. aerogenes isolates in 2012, caution should be exercised in drawing firm 
conclusions on treatment of isolates expressing these species. Amikacin resistance in E. coli 
has been observed in other studies due to acquisition of MDR-plasmids by E. coli carrying 
genes such as the 16S rRNA methylase (rmtB) genes (Sun et al., 2012). Sensitivity to the other 
aminoglycoside gentamicin were variable among the bacterial species between 2010 and 
2012. It was uniformly low for E. coli and K. pneumoniae (52.9% and 32% of isolates in 2010 
and 55.1% and 48.8% of isolates in 2012 respectively). While 100% of E. cloacae and E. 
aerogenes isolates were sensitive in 2012, again the low numbers suggest caution should be 
exercised in drawing firm conclusions. The results from non--lactam antibiotics also suggest 
that ESBL-positive E. coli were relatively sensitive to nitrofurantoin (FD) (80.4% of isolates in 
2010 and 76.2% in 2012), but that the percentage of sensitive isolates was low for K. 
pneumoniae, E. cloacae and E. aerogenes (Figure 3.18A and B). This was consistent between 
2010 and 2012. Thus FD might be considered as a treatment for ESBL-positive E. coli in the 
Saudi Aramco Dhahran Health Center. This is consistent with results of other studies, for 
example in a study on treatment for ambulatory patients with UTIs associated with ESBL-
positive E. coli, there was 94% susceptibility to nitrofurantoin (Auer et al., 2010). Also of note 
was the apparently constant high sensitivity of E. aerogenes isolates to 
trimethoprim/sulfamethoxazole (SXT). However, again the low number of E. aerogenes 
isolates suggests that caution should be exercised in drawing firm conclusions. Sensitivity to 
ciprofloxacin was low for E. coli, K. pneumoniae and E. cloacae in both 2010 (21.7%, 20% and 
66.7% respectively) and 2012 (25.9%, 31.7% and 66.7% respectively). Sensitivity for E. 
aerogenes isolates went from 66.7% in 2010 to 100% in 2012, but again in 2012 this was 
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derived from only four isolates. Activity of tigecycline and colisitin was uniformly 100% for all 
bacterial strains in both 2010 and 2012.  
With respect to the remaining bacterial species, C. freundii, M. morganii, S. marcescens and 
P. mirabilis, there were too few isolates in each year to draw any firm conclusions regarding 
any changes in sensitivity/resistance. For example, there were no M. morganii or P. mirabilis 
isolates in 2010. The breakdown in sensitivity, resistance and intermediate for each antibiotic 
for these species is summarised in Table 3.7. It is noteworthy that only the carbapenem 
(meropenem, ertapenem and imipenem) and the non--lactams colistin and tigecycline 
appear to be consistently effective against P. mirabilis, as well as against the other four 
species. There are otherwise no interpretable trends.  
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Figure 3.18: Prevalence of-lactam antibiotic sensitivity for E. coli, K. pneumoniae, E. cloacae and E. 
aerogenes in 2010 and 2012 
 (A) 2010; (B) 2012 
AMS: Ampicillin/sulbactam (ESBL inhibitor); CZ: Cefazolin; CRO: Ceftriaxone; CAZ: Ceftazidime; FEP: Cefepime; 
FOX: Cefoxitin; IPM: Imipenem; MER: Meropenem; ERP: Ertapenem;  
 
(A) 
(B) 
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Figure 3.19: Prevalence of non-lactam antibiotic sensitivity for E. coli, K. pneumoniae, E. cloacae and E. 
aerogenes in 2010 and 2012 
 (A) 2010; (B) 2012 
AK: Amikacin; CIP: Ciprofloxacin; GM: Gentamicin; FD: Nitrofurantoin; SXT: Trimethoprim/sulfamethoxazole; 
TGC: Tigecycline; CO: Colistin 
  
(B) 
(A) 
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Table 3.7: Count of sensitive, intermediate and resistant isolates for C. freundii, M. morganii, S. marcescens 
and P. mirabilis 2010 and 2012 
Isolates C. freundii M. morganii S. marcescens P. mirabilis 
Time 
Period  
 
2010 
(N=1) 
2012 
(N=2) 
2010 
(N=0) 
2012 
(N=2) 
2010 
(N=1) 
2012 
(N=1) 
2010 
(N=0) 
2012 
(N=2) 
Antibiotic S I R S I R S I R S I R S I R S I R S I R S I R 
-lactams                         
AMS 0 0 1 0 0 2    0 0 2 0 0 1 0 0 1    0 0 2 
CZ 0 0 1 0 0 2    0 0 2 0 0 1 0 0 1    0 0 2 
CRO 0 0 1 0 1 1    0 1 1 1 0 0 0 0 1    0 2 0 
CAZ 0 0 1 0 1 1    0 1 1 1 0 0  0 1    0 0 2 
FEP 1 0 0 0 2 0    0 2 0 1 0 0 0 0 1    0 1 1 
FOX 0 0 1 0 0 2    0 1 1 0 1 0 0 0 1    0 0 2 
IPM 1 0 0 2 0 0    2 0 0 1 0 0 1 0 0    2 0 0 
MER 1 0 0 2 0 0    2 0 0 1 0 0 1 0 0    2 0 0 
ERP 1 0 0 2 0 0    2 0 0 1 0 0 1 0 0    2 0 0 
Non--
lactams 
                        
AK 1 0 0 2 0 0    2 0 0 1 0 0 1 0 0    0 2 0 
CIP 0 0 1 1 0 1    1 0 1 0 0 1 0 0 1    0 0 2 
GM 0 0 1 2 0 0    1 0 1 0 0 1 0 0 1    0 0 2 
FD 1 0 0 1 1 0    0 0 2 0 0 1 0 0 1    0 0 2 
SXT 0 0 1 1 0 1    1 0 1 0 0 1 1 0 0    0 0 2 
TGC 1 0 0 2 0 0    2 0 0 1 0 0 1 0 0    2 0 0 
CO 1 0 0 2 0 0    2 0 0 1 0 0 1 0 0    2 0 0 
 
AMS: Ampicillin/sulbactam (ESBL inhibitor); CZ: Cefazolin; CRO: Ceftriaxone; CAZ: Ceftazidime; FEP: Cefepime; 
FOX: Cefoxitin IPM: Imipenem; MER: Meropenem; ERP: Ertapenem AK: Amikacin; CIP: Ciprofloxacin; GM: 
Gentamicin; FD: Nitrofurantoin; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline; CO: Colistin 
 
3.6 Conclusions 
This section of the study highlighted that female gender and increasing age, particularly in 
males, were risk factors for ESBL infection. The majority of patients were from an out-patient 
setting, highlighting the prominence of ESBL infections in the community in the Eastern 
Province of Saudi Arabia. While UTIs are the most common type of infection overall, 
distribution of infection sites differs significantly with gender, with males predominating for 
systemic infections detected by blood cultures and females for UTIs. There were no 
discernible changes in trends between 2010 and 2012 in these distributions. E. coli was the 
predominant bacterial species in both 2010 and 2012, followed by K. pneumoniae. Prevalence 
97 
 
 
 
of K. pneumoniae increased significantly between 2010 and 2012 and prevalence of E. cloacae 
fell significantly. The proportion of ESBL-positive infections rose overall between 2010 and 
2012 as detected by both VITEK® 2 and disk diffusion, with no apparent difference in 
distribution by gender or age group.  
There was also a worrying trend for reduced sensitivity to a range of antibiotics of different 
classes for ESBL- and AmpC-positive infections in patients in the Saudi Aramco Dhahran Health 
Center. This could be due to a number of factors such as cross-species horizontal transfer of 
resistance determinants, previous antibiotic therapy leading to potential cross resistance and 
over-prescription of some antibiotics such as ampicillin/sulbactam, cefazolin and ceftriaxone., 
to which levels of resistance of between 70-100% were observed in both 2010 and 2012 and 
ceftazidime, for which prevalence of sensitivity fell by 2012. Sensitivity prevalence of E. coli 
and K. pneumoniae to cefepime also fell sharply between 2010 and 2012. Thus none of these 
antibiotics should be considered as blind treatments for cases where ESBL infections are 
suspected. With the possible exception of E. aerogenes isolates, neither gentamicin nor 
trimethoprim/sulfamethoxazole should be considered either, although the low number of E. 
aerogenes isolates makes it difficult to draw firm conclusions. 
Prevalence of sensitivity to cefoxitin remained relatively high between 2010 and 2012, 
however this was largely due to sensitivity of E. coli and K. pneumoniae while both E. cloacae 
and E. aerogenes isolates were uniformly resistant to this drug. Thus while cefoxitin might be 
considered as a treatment for E. coli and K. pneumoniae infections, it should be discounted 
for E. cloacae and E. aerogenes. Prevalence of E. coli sensitivity to amikacin fell between 2010 
and 2012, while sensitivity of K. pneumoniae, E. cloacae and E. aerogenes remained relatively 
high. Thus this non--lactam could be considered as a blind treatment for K. pneumoniae, E. 
cloacae and E. aerogenes but not E. coli. By contrast, for nitrofurantoin prevalence of E. coli 
sensitivity remained relatively high, while it fell for K. pneumoniae, E. cloacae and E. 
aerogenes, suggesting this antibiotic should only be considered for E. coli.  
The carbapenems, meropenem, ertapenem and imipenem, had overall excellent activity 
across all bacterial species in both 2010 and 2012, as was sensitivity to the polymyxin colistin 
and to the glycylcycline tigecycline. Thus while all of these antibiotics could be considered as 
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blind treatment options, strict antibiotic stewardship principles need to be applied. In this 
context, a recent survey of antimicrobial stewardship programs (ASP) in Gulf Cooperation 
Council (GCC) states confirmed that in hospitals where ASPs have been implemented there 
has been a significant reduction in use of broad spectrum antibiotic use, hospital-acquired 
infection, inappropriate prescribing and antimicrobial resistance (Enani, 2016). The National 
Antibiotic Stewardship Program established in Saudi Arabia in 2013 and rolled out to 
encompass over ten regions and forty hospitals should significantly reduce antibiotic 
consumption and MDR organisms in participating hospitals as it continues to be expanded to 
other regions and hospitals (Alomi, 2015).  
Clinicians and prescribing pharmacists within the the Saudi Aramco Dhahran Health Center 
should meanwhile receive further and on-going education on increasing resistance levels of 
ESBL infections and the patterns of resistance for different species, and should ensure 
consistent adherence to appropriate prescribing standards. Education of patients is also 
important to convey the concept of appropriate prescribing and to raise awareness that not 
all infections require antibiotics. Where it is necessary to prescribe antibiotics, patients need 
to be made aware of the importance of compliance in following instruction on their 
prescription and completing the entire course, to reduce potential for development of further 
resistance. 
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4. Genotyping results 
4.1 Overview 
In this chapter, results of genotypic characterization of ESBL-producing bacterial isolates 
collected between January 2010 and December 2013 in the Saudi Aramco Dhahran Health 
Center in the Eastern Province of Saudi Arabia are presented. They include results of 
genotypic analysis of ESBL TEM, SHV and CTX-M expression by multiplex PCR and by Check-
MDR CT102 DNA microarray (CheckPoints BV, Wageningen, Netherlands), bacterial 
fingerprinting by Enterobacterial Repetitive Intergenic Consensus (ERIC) PCR and 
macrorestriction pattern analysis genotyping by PFGE. There has been a lack of any recent 
genotypic analysis of microbial resistance patterns in this population. The most recent 
analysis was carried out Enterobacteriaceae isolates collected between April and December 
2006, when prospective multiplex PCR analysis of 84 E.coli and 16 K. pneumoniae samples 
showed that the CTX-M genotype was present in 71% of samples, either singly or in 
combination with TEM (Bindayna et al., 2010). The blaCTX-M gene was found mainly in urinary 
isolates (63/71; 88.7%).  
In this study, the same patient sample group is used as in the phenotypic analyses described 
in Chapter 3. Genotypic analysis by multiplex PCR is described for samples collected in 2010 
(n=183) and characteristics are compared to samples collected in 2012 (n=202), making up 
the total number of 385 patient samples. Check-MDR CT102 DNA microarray analysis is 
described for 159 samples collected from 2012-2013, as a pilot study. 
4.1 Genotype of bacterial isolates by multiplex PCR: whole patient group 
Genotyping of bacterial isolates was carried out using multiplex PCR with primer pairs specific 
to betaTEM, betaSHV, and betaCTX-M (Monstein et al., 2007) using conditions described in 
Chapter 2, Section 2.4.2. Table 4.1 shows the genotype profiles obtained distributed by 
bacterial species for the whole group of 385 samples over 2010 and 2012. 
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Table 4.1: Genotype distribution by bacterial species detected by multiplex PCR 
 
Multiplex 
PCR results 
Bacterial species 
 
Total 
(PCR 
results) 
EC KPN ECL EAER CITF MOMO SERMAR PRMI 
TEM 42 
(14.7%) 
13 
(19.7%) 
7 
(38.9%) 
0 0 1 (50%) 2 (100%) 2 
(100%) 
67 
(17.4%) 
CTX-M 141 
(49.5%) 
3 
(4.55%) 
1 
(5.55%) 
2 
(28.6%) 
0 1 (50%) 0 0 148 
(38.4%) 
SHV 3 
(1.05%) 
3 
(4.55%) 
0 0 0 0 0 0 6 (1.55%) 
TEM, CTX-M 65 
(22.8%) 
10 
(15.2%) 
1 
(5.55%) 
0 2 
(66.7%) 
0 0 0 78 
(20.25%) 
TEM, SHV 1 (0.4%) 2 (3.0%) 0 0 0% 0 0 0 3 (0.8%) 
CTX-M, SHV 4 (1.4%) 8 
(12.1%) 
0 0 0% 0 0 0 12 (3.1%) 
TEM, CTX-M, 
SHV 
3 
(1.05%) 
20 
(30.3%) 
0 0 0% 0 0 0 23 (6.0%) 
NEG 26 
(9.1%) 
7 
(10.6%) 
9 (50%) 5 
(71.4%) 
1 
(33.3%) 
0 0 0 48 
(12.5%) 
Total (bacterial 
species) 
285 
(100%) 
66 
(100%) 
18 
(100%) 
7 (100%) 3 (100%) 2 (100%) 2    (100%) 2 
(100%) 
385 
(100%) 
EC: Escherichia .coli; KPN: Klebsiella pneumoniae; ECL: Enterobacter cloacae; EAER: Enterobacter aerogenes; 
CITF: Citrobacter freundii; MOMO: Morganella morganii; SERMAR: Serratia marcescens; PRMI: Proteus mirabilis 
 
CTX-M only was the most common genotype, occurring in 148/385 total isolates (38.4%). This 
was mainly due to its occurrence in 141/285 (49.5%) of E. coli isolates (Table 4.1). The next 
most common genotype overall was a combination of CTX-M and TEM (78/385; 20.25%), 
followed by TEM only (67/385; 17.4%) and negative (NEG) (48/385; 12.5%). CTX-M was 
detected alone or in combination with TEM and/or SHV in 67.8% (261/385), of total isolates, 
making it the dominant ESBL gene type detected (Table 4.1). This is consistent with previous 
observations on Enterobacteriaceae isolates collected in the Saudi Aramco Dhahran Health 
Center (Bindayna et al., 2010).  
Among E. coli isolates, the next most common genotype after CTX-M only was TEM + CTX-M 
(65/285; 22.8%), followed by TEM only (42/285; 14.7%). Among K. pneumoniae isolates, there 
was a wide distribution of genotypes, with the most common being a combination of CTX-M, 
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TEM and SHV (20/66; 30.3%) (Table 4.1). K. pneumoniae thus contributed 87% (20/23) of the 
CTX-M + TEM + SHV isolates (Table 4.1). The next most common K. pneumoniae genotype was 
TEM only (13/66; 19.7%), followed by TEM + CTX-M (10/66; 15.2%) (Table 4.1). Half of E. 
cloacae isolates gave a negative result, while the most common ESBL genotype for this 
bacterial species was TEM only (7/18; 38.9%) (Table 4.1). Both S. marcescens and both P. 
mirabilis isolates were also TEM only (Table 4.1). The majority of E. aerogenes isolates were 
negative (5/7; 71.4%), while the remaining two were CTX-M only (Table 4.1). The two C. 
freundii isolates to give a positive result were both CTX-M + TEM, while one M. morganii 
isolate was TEM only and the other was CTX-M only (Table 4.1). 
4.2 PCR results 2010 v 2012 
4.2.1 General comparison of PCR profiles for 2010 v 2012 
When the 2010 and 2012 results were considered separately, a number of differences 
emerged in the PCR profile distributions. Figure 4.1 shows an example of results obtained 
from multiplex PCR analysis and 1.2% agarose gel electrophoresis at 150 V/cm for 45 min in 
Tris-acetate-EDTA (TAE) 1x (40 mM Tris acetate, 1 mM EDTA) buffer (Section 2.4.3), allowing 
adequate separation of the different resistance genes. SHV expression is demonstrated by a 
747bp DNA fragment, CTX by a 593bp DNA fragment and TEM by a 445bp DNA fragment.  
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Figure 4.1: Agarose gel showing examples of multiplex PCR results for TEM, CTX and SHV 
Agarose gel shows blaTEM 445 bp, blaCTX-M 593 bp, and blaSHV 747 bp products after PCR amplification with primers 
in Table 2.2 and under conditions described in Section 2.4.2. Lane 1: 1 kb DNA Ladder; Lane (5, 13 and 16) blaTEM,; 
Lane (2, 3, 6, 8, 9, 10 and 11) blaCTX ; Lane (4, and 12) blaTEM + blaCTX-M ; Lane 7: blaSHV + blaTEM; Lane 20: blaSHV + 
blaCTX-M; Lane (18 and 19) blaSHV + blaTEM + blaCTX-M; Lane 14:water negative Q.C; Lane 17: blaSHV   positive Q.C K. 
pneumoniae ATCC700603, and Lane 15: blaTEM negative Q.C  E. coli ATCC25922. 
 
The distributions are shown in Figure 4.2. In both years, the CTX-M only genotype was 
dominant at 64/183 (35.0%) of isolates in 2010 and 84/202 (41.6%) of isolates in 2012. 
However, while the second most common genotype in 2010 was TEM only at 56/183 (30.6%) 
isolates, it accounted for only 11/202 (5.4%) of isolates in 2012 (Figure 4.1). The second most 
common pattern in 2012 was instead CTX-M +TEM at 56/202 (27.7%) of isolates, which was 
third most common in 2010 at 22/183 (12.0%) of isolates. The third most common in 2012 
was CTX-M + TEM + SHV at 21/202 (10.4%) of isolates, which was present in only 2 /183 
isolates (1.1%) in 2010. The CTX-M +SHV combination increased from 1.1% in 2010 to 5.0% in 
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2012. The remaining isolates for which a positive result was obtained were divided between 
less represented profiles, i.e. SHV only (1.6% (3/183) in 2010 and 1.5% (3/202) in 2012) and 
TEM + SHV (0.6% (1/183) in 2010 and 1.0% (2/202) in 2012) (Figure 4.1). In 2010 there was 
no amplification of any gene in 33/183 (18.0%) of isolates and for 2012 there was no 
amplification in 15/202 (7.4%) of isolates. Thus results are consistent with other studies in 
which the CTX-M ESBL types, in particular CTX-M-15, have become dominant over TEM and 
SHV worldwide (Sections 1.6.4 and 1.7) (Al-Agamy et al., 2014; Arnaud et al., 2015; Baraniak 
et al., 2013; Brolund et al., 2014; Burke et al., 2012; Cantón & Coque, 2006; Castanheira et 
al., 2013; Coque et al., 2008; Denisuik et al., 2013; Galas et al., 2008; Hansen et al., 2012; 
Horner et al., 2013, 2014; Huemer et al., 2011; Morris et al., 2009; Mshana et al., 2013a; 
Naseer et al., 2009; Ndugulile et al., 2005; Nicolas-Chanoine et al., 2012;  Nyberg et al., 2007; 
Rafaï et al., 2015; Ruppe et al., 2012; Seki et al., 2013; Valenza et al., 2014; Wickramasinghe 
et al., 2012; Woerther et al., 2013; Yano et al., 2013; Zamani et al., 2015; Zong et al., 2008; 
Zowawi et al., 2013). In addition, CTX-M in a combination with TEM and/or SHV increased 
significantly in 2012 compared to 2010. When Chi squared comparisons of all CTX-M-
containing combinations in 2010 versus 2012 were carried out, there was a significant 
difference in the distribution, mainly attributable to higher than predicted numbers of isolates 
expressing CTX-M in a combination with TEM and/or SHV in 2012 (Chi-square statistic = 
14.8439, p= 0.001955). 
While TEM was expressed alone or in combination with CTX-M and/or SHV in 44.3% of isolates 
in 2010 and 44.5% of isolates in 2012, the pattern of TEM expression changed from 
predominantly alone in 2010 (30.6% of isolates), followed by in combination with CTX-M 
(12.0%), to predominantly in combination with CTX-M (27.7%) or CTX-M plus SHV (10.4%) in 
2012. There was relatively low expression of SHV in both 2010 and 2012 at only 4.4% of 
isolates in 2010, either alone or in combination with CTX-M and/or TEM. There was a higher 
percentage of 17.9% in 2012, but the majority were found in combination with CTX-M + TEM 
(10.4%) or CTX-M (5.0%). This is in contrast to other studies from Saudi Arabia, in which SHV 
prevalence has been relatively high (Al-Agamy et al., 2009; Al-Qahtani et al., 2014; Tawfiq et 
al., 2011). However, it is consistent with the increasing predominance of CTX-M in Saudi 
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Arabia, including dominance of the CTX-M genotype, in 71% of samples, either singly or in 
combination with TEM, in a previous multiplex PCR study of f 100 Enterobacteriaceae isolates 
(E.coli, n=84 and K. pneumoniae, n=16) collected at the Saudi Aramco Dhahran Health Center 
(Bindayna et al., 2010). This trend towards increased expression of a combination of ESBL 
genes raises the prospect of greater antibiotic resistance among ESBL-positive infections in 
the Saudi Aramco Dhahran Health Center. The nature of this increased risk was assessed in 
relation to gender, age, in-patient/out-patient status and individual bacterial organisms for 
2010 versus 2012.  
 
Figure 4.2: Multiplex PCR profile distribution 2010 versus 2012 
4.2 PCR results 2010 and 2012 by gender and age group 
The isolates for both 2010 and 2012 were divided according to gender for each year to 
determine if there were any gender differences within years in the distribution of PCR ESBL 
multiplex profile results or if there was any significant difference between females in 2010 
versus 2012 or males in 2010 versus 2012 (Figure 4.3A and B). There was appreciable 
difference in the distribution for females versus males in either 2010 (Figure 4.3A) or 2012 
(Figure 4.3B). The pattern of change in distribution between 2010 and 2012 was similar for 
both females and males and reflected the overall increase in isolates positive for CTX-M in 
combination with SHV and/or TEM (13.7% and 15.3% for females and males respectively in 
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2010 versus 40.5% and 47.8% of isolates for females and males respectively in 2012) and 
sharp decrease in TEM alone (34.7% and 22% for females and males respectively in 2010 
versus 6.0% and 4.3% for females and males respectively in 2012).  
 
 
Figure 4.3: Multiplex PCR profile distributed by gender 2010 versus 2012 
Isolates for 2010 and 2012 were also divided with respect to age group (Figure 4.4A and B). 
In 2010, for those aged ≥ 80 y, the prevalence of CTX-M only exceeded that in other age 
groups (19/31 isolates, 61.3%) (Figure 4.4A). TEM only was the most prevalent PCR profile in 
the 20-39, 40-59 and 60-79 y age groups (30.8%, 37.5% and 38.4% respectively), while CTX-M 
only was the most prevalent in the youngest 0-19 y age group (26.9%) and the oldest >80 y 
(A) 
(B) 
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age group (61.3%). However, Chi squared analysis of the top five profiles (CTX-M, CTX-M+SHV, 
CTX-M+TEM, CTX-M+SHV+TEM and TEM only) did not indicate that there was any significant 
difference in distribution of multiplex PCR profiles according to age group in 2010 (Chi-square 
statistic =17.7905, p= 0.336304). Prevalence of CTX-M+SHV, CTX-M+SHV+TEM, SHV and 
TEM+SHV was uniformly low across all age groups in 2010 (Figure 4.3A). There were high 
levels of isolates in each age group for which there was no amplification of any gene (NEG), 
particularly for the 0-19 y age group for which this was the most common PCR result (10/19, 
38.5%). 
For 2012, there was likewise no evidence of significant variation of PCR profile distribution 
with age group (Chi-square statistic = 23.9531, p=0.090534) (Figure 4.4B). CTX-M only was the 
most prevalent profile for all age groups, followed by CTX-M + TEM (equal prevalence to CTX-
M in 20-39 y age group) (Figure 4.4B). CTX-M+SHV+TEM was the third most prevalent profile 
in all age groups, except for the 40-59 y group for which TEM only was more prevalent (14.0% 
TEM v 11.6% CTX-M+SHV+TEM). Overall, TEM only prevalence fell substantially across all age 
groups compared to 2010, while prevalence of CTX-M alone rose in all age groups except for 
the >80 y group (61.3% in 2010 v 40.4% in 2012) and prevalence of CTX-M in combination 
with TEM or with SHV and TEM rose in all age groups in 2012 versus 2010 (Figure 4.4A and B). 
This again highlights the growing problem of increased expression of a combination of ESBL 
genes which appears to be equally relevant among patients of all ages in the Saudi Aramco 
Dhahran Health Center. 
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Figure 4.4: Multiplex PCR profile distributed by age group 2010 versus 2012 
 
4.3 PCR results by in-patient/out-patient status 2010 and 2012 
To determine whether there was any variation in PCR profiles of isolates derived from the 
community as opposed to nosocomial isolates, groups were divided according to out-patient 
versus in-patient status for 2010 and 2012. There were no significant differences in 
distribution of PCR profile according to out-patient versus in-patient status for either year 
(A) 
(B) 
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(Figure 4.5A and B). This suggests that there is no major difference in the genes expressed in 
ESBL-positive infections in patients from the hospital or community and that the problem of 
increased expression of a combination of ESBL genes is equally relevant for both patient 
groups. 
 
 
Figure 4.5: Multiplex PCR profile distributed by in-patient v out-patient status 2010 versus 2012 
(A) 2010; (B) 2012  
 
 
(A) 
(B) 
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4.4 PCR results by organism 2010 and 2012 
Phenotyping analysis indicated that there was variation in sensitivity of the different bacterial 
organisms to some of the antibiotics tested between 2010 and 2012. To determine if this was 
reflected to differences in the PCR profiles of genes expressed in the different bacterial 
organisms between the two years, the PCR profile was determined for each bacterial species 
in both 2010 (Table 4.2) and 2012 (Table 4.3). The distribution of PCR profiles varied between 
bacterial species in both 2010 and 2012. In 2010, CTX-M only was the predominant profile for 
E. coli (61/138, 44.2%), followed by TEM only (35/138, 25.4%) and CTX-M + TEM (19/138, 
13.8%), whereas for K. pneumoniae TEM only was predominant (13/25, 52%), followed by 
CTX-M + TEM and CTX-M + TEM + SHV, both at only 2/25 isolates (8% each). The number of 
isolates of the other bacterial species from 2010 made it difficult to draw firm conclusions, 
but of the fifteen E. cloacae isolates, the seven that gave a positive result were all TEM only, 
while the other eight gave no amplification (NEG) (Table 3.2). Two out of three E. aerogenes 
isolates, on the other hand, were CTX-M only, while the one C. freundii isolate was CTX-M + 
TEM and the one S. marcescens isolate was TEM. Thus CTX-M and TEM dominated the ESBL 
genes expressed across species, but in different combinations according to the species. 
Comparing the distributions of CTX-M, CTX-M + TEM, CTX-M + TEM + SHV, TEM and CTX-M + 
SHV across the top three bacterial species, E. coli, K. pneumoniae and E. cloacae by Chi 
squared analysis confirmed the significant difference in distribution of these PCR profiles 
across the three species (Chi-square statistic =41.6541, p < 0.00001).  
The PCR profiles for both E. coli and K. pneumoniae changed significantly by 2012 (Table 4.3). 
Notably, the prevalence of TEM only among E. coli fell from 25.4% in 2010 to 4.8% in 2012, 
while it fell from the predominant profile in K. pneumoniae in 2010 (52%) to zero in 2012. 
While prevalence of CTX-M only did not change significantly for either species (80/147, 54.4% 
for E. coli and 2/41, 4.9% for K. pneumoniae), the combination of CTX-M + TEM rose from 
13.8% in 2010 to 31.3% in 2012 for E. coli and from 8% in 2010 to 19.5% in 2012 for K. 
pneumoniae (Table 4.2 and 4.3). In addition, CTX-M+TEM+SHV rose from 8% in 2010 for K. 
pneumoniae to 43.9% in 2012, and CTX-M + SHV rose from 4% to 17.1%. Thus while 
prevalence of CTX-M only expression remained low in K. pneumoniae, the phenomenon of 
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increased CTX-M in combination with TEM and/or SHV was particularly apparent for K. 
pneumoniae. Figure 4.6 shows the changes in PCR profile for both E. coli (Figure 4.6A) and K. 
pneumoniae (Figure 4.6B) in 2010 versus 2012 in graphical form. When the distribution of 
CTX-M, CTX-M + TEM, CTX-M + TEM + SHV, TEM and CTX-M + SHV was compared by Chi 
squared analysis for E. coli versus K. pneumoniae in 2012, there was a significant difference 
in the distribution between species (Chi-square statistic = 90.3756, p < 0.00001). When the 
distribution of these PCR profiles was compared for E. coli in 2010 versus 2012, this 
distribution was also significantly different, mainly attributable to the greater than expected 
CTX-M+TEM and lower than expected TEM in 2012 (Chi-square statistic = 34.6497, p < 
0.00001). Likewise, the distribution of these PCR profiles is also significantly different for K. 
pneumoniae comparing 2010 versus 2012 (Chi-square statistic = 32.331, p < 0.00001), mainly 
attributable to the higher than predicted CTX-M+TEM and CTX-M + TEM + SHV in 2012 and 
the loss of the TEM only profile (Figure 4.6B).  
The co-expression of CTX-M in combination with TEM and SHV in K. pneumoniae is consistent 
with observations in other studies (Manoharan et al., 2011). The alteration in gene expression 
to favour combinations of CTX-M with TEM and/or SHV in both E. coli and K. pneumoniae may 
also help explain the decreases in sensitivity to the cephalosporins cefazolin (CZ), ceftriaxone 
(CRO), and ceftazidime (CAZ) in 2012 than in 2010, and the drops in percentage of E. coli and 
K. pneumoniae isolates sensitive to cefepime (FEP) in 2012 (Section 3.5.4). The relationship of 
resistance determinants, indicated by PCR profile, and antibiotic susceptibility is considered 
in section 4.5 below. 
With respect to the other bacterial species, there were too few isolates of each in 2012 to 
make it possible to draw firm conclusions on any changes in PCR profile from 2010, and for 
M. morganii and P. mirabilis there were no isolates in 2010 for comparison. Of the four 2012 
E. aerogenes isolates, none gave an amplification product. The three E. cloacae isolates were 
divided between CTX-M, CTX-M+TEM and NEG (no product). The two C. freundii isolates were 
divided between CTX-M+TEM and NEG. The one S. marcescens isolate was TEM, just as in 
2010. The two M. morganii isolates were divided between CTX-M and TEM, while the two P. 
mirabilis isolates were both TEM (Table 4.3). 
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Table 4.2: PCR profile distribution by bacterial species 2010 
 Bacterial species 
PCR profile 2010 EC 
(N=138) 
KPN 
(N=25) 
ECL 
(N=15) 
EAER 
(N=3) 
CITF 
(N=1) 
SERMAR 
(N=1) 
TOTAL 
TEM 35 (25.4%) 13 (52.0%) 7 (46.7%) 0 0 1 (100%) 56 (30.6%) 
CTX-M 61 (44.2%) 1 (4.0%) 0 2 (66.7%) 0 0 64 (35.0%) 
SHV 2 (1.5%) 1 (4.0%) 0 0 0 0 3 (1.6%) 
TEM, CTX-M 19 (13.8%) 2 (8.0%) 0 0 1 (100%) 0 22 (12.0%) 
TEM, SHV 0 1 (4.0%) 0 0 0% 0 1 (0.6%) 
CTX-M, SHV 1 (0.7%) 1 (4.0%) 0 0 0% 0 2 (1.1%) 
TEM, CTX-M, SHV 0 2 (8.0%) 0 0 0% 0 2 (1.1%) 
NEG 20 (14.5%) 4 (16.0%) 8 (53.3%) 1 (33.3%) 0 0 33 (18.0%) 
Total (bacterial species) 138 (100%) 25 (100%) 15 (100%) 3 (100%) 1 (100%) 1 (100%) 183 (100%) 
 
Table 4.3: PCR profile distribution by bacterial species 2012 
 Bacterial species 
PCR profile 
2012 
EC 
(N=147) 
KPN 
(N=41) 
ECL 
(N=3) 
EAER 
(N=4) 
CITF 
(N=2) 
SERMAR 
(N=1) 
MOMO 
(N=2) 
PRMI 
(N=2) 
TOTAL 
TEM 7 (4.8%) 0 0 0 0 1 (100%) 1 (50%) 2 (100%) 11 (5.4%) 
CTX-M 80 (54.4%) 2 (4.9%) 1 (33.3) 0 0 0 1 (50%) 0 84 
(41.6%) 
SHV 1 (0.7%) 2 (4.9%) 0 0 0 0 0 0 3 (1.5%) 
TEM, CTX-M 46 (31.3%) 8 (19.5%) 1 (33.3) 0 1 (50%) 0 0 0 56 
(27.7%) 
TEM, SHV 1 (0.7%) 1 (2.4%) 0 0 0% 0 0 0 2 (1.0%) 
CTX-M, SHV 3 (2.0%) 7 (17.1%) 0 0 0% 0 0 0 10 (5.0%) 
TEM, CTX-M, 
SHV 
3 (2.0%) 18 
(43.9%) 
0 0 0% 0 0 0 21 
(10.4%) 
NEG 6 (4.1%) 3 (7.3%) 1 (33.3) 4 
(100%) 
1 (50%) 0 0 0 15 (7.4%) 
Total (bacterial 
species) 
147 (100%) 41 (100%) 3 (100%) 4 
(100%) 
2 
(100%) 
1 (100%) 2 (100%) 2 (100%) 202 
(100%) 
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Figure 4.6: Multiplex PCR profile for E. coli and K. pneumoniae 2010 versus 2012 
(A) E. coli; (B) K. pneumoniae 
The results show that the PCR profile for both E. coli and K. pneumoniae alter significantly between 2010 and 
2012. 
 
 
 
(B) 
(A) 
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4.5 PCR results and antibiotic resistance: resistance determinants and their 
isolate antibiotic susceptibility 
The relationship between antibiotic susceptibility of an isolate and the resistance determinant 
it carries, which can be detected by PCR, is important in indicating and identifying MDR 
organisms and can help suggest potential blind therapy options, if the resistance determinant 
could be identified efficiently and rapidly at point of care and matched to probable antibiotic 
susceptibility. Thus the susceptibility profile for nine -lactam and seven non--lactam 
antibiotics (Section 3.5) was determined for each isolate according to the resistance 
determinant it carried, detected by PCR. The profiles are shown for all resistance 
determinants identified in any of the isolates, i.e. the CTX-M only (Figure 4.7), TEM only 
(Figure 4.8), CTX-M+TEM (Figure 4.9), CTX-M+TEM+SHV (Figure 4.10), CTX-M+SHV (Figure 
4.11), SHV only (Figure 4.12) and TEM+SHV (Figure 4.13). It should be noted that the small 
number of isolates for SHV only (n=3 in each year) and TEM+SHV (n=1 in 2010 and n=2 in 
2012) make it difficult to draw firm conclusions for these resistance determinant profiles.  
In terms of -lactam antibiotics, the susceptibility data revealed that all resistance 
determinants resulted in high prevalence of resistance to ampicillin/sulbactam (AMS), 
suggesting that this is an inappropriate ESBL infection treatment choice in the Saudi Aramco 
Dhahran Health Center. There were also high levels of resistance regardless of resistance 
determinant for the cephalosporins ceftazidime (CAZ), ceftriaxone (CRO) and cefazolin (CZ), 
again suggesting that these would be inappropriate choices for blind treatment. For CTX-M 
only isolates, cefepimine (FEP) would also be an inappropriate choice (Figure 4.7A). However, 
levels of sensitivity to the second generation cephalosporin cefoxitin (FOX) were relatively 
high (prevalence 75% in 2010, 78.6% in 2012), making this a possible choice for CTX-M-only 
infections. All CTX-M-only isolates were sensitive to the three carbapenems imipenem (IPM) 
meropenem (MER) and ertapenem (ERP), thus these could all be considered as blind 
treatment options, with the caveat that rigorous antibiotic stewardship be applied to protect 
the status of carbapenems as antibiotics to which a wide range of infections are susceptible.  
For TEM only isolates, none of the cephalosporins CZ, CRO, CAZ, FEP or FOX would be 
appropriate choices of blind treatments (Figure 4.8A). While in 2010, there was relatively high 
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prevalence of sensitivity to FEP (82.1% of isolates) and FOX (62.5% of isolates), these had 
dropped to 18.2% and 36.4% respectively in 2012, with 63.6% of isolates having intermediate 
resistance/sensitivity to FEP and 18.2% being resistant, and 9.1% of isolates having 
intermediate resistance/sensitivity to FOX, with 54.5% being resistant. As with CTX-M only 
isolates, there was uniformly high prevalence of sensitivity to the three carbapenems IPM, 
MER and ERP (Figure 4.8A), thus these could all be considered as blind treatment options for 
TEM only isolates. For isolates expressing both TEM and CTX-M, again CZ, CRO, CAZ and FEP 
would be inappropriate choices (Figure 4.9A). For FEP, although 77.3% of CTX-M+TEM isolates 
were sensitive in 2010, this had dropped to 1.8% in 2012, with 71.4% intermediate and 26.8% 
resistant. In fact, this fall in prevalence of sensitivity to FEP appeared to occur across all 
resistance determinants, and did not depend on co-expression of more than one ESBL 
determinant (Figures 4.9-4.13). For FOX, 77.3% of isolates were sensitive in 2010 and 69.6% 
in 2012, thus this might be a possible antibiotic to consider for CTX-M+TEM isolates. There 
was also uniformly high prevalence of sensitivity to all three carbapenems IPM, MER and ERP, 
again suggesting that these could all be considered as blind treatment options for CTX-
M+TEM isolates (Figure 4.9A). Similarly for isolates expressing CTX-M+TEM+SHV, CZ, CRO, 
CAZ and FEP would be inappropriate choices (Figure 4.10A). Similarly to isolates expressing 
CTX-M+TEM, FOX would be a possible choice, with 100% of isolates sensitive in 2010 and 81% 
in 2012, although caution should be applied in interpreting these results as there were only 
two CTX-M+TEM+SHV isolates in 2010. As with all the other isolates, there were uniformly 
high levels of prevalence of sensitivity to all three carbapenems IPM, MER and ERP, again 
suggesting that these could all be considered as blind treatment options for CTX-M+TEM+SHV 
isolates (Figure 4.10A). Similarly to both CTX-M+TEM and CTX-M+TEM+SHV isolates, the 
cepahlosporins CZ, CRO, CAZ and FEP would be inappropriate choices for treatment of 
infections with CTX-M+SHV isolates, while FOX would be a possible choice as 90% of the ten 
positive CTX-M+SHV isolates in 2012 were sensitive to FOX (Figure 4.11A). As with all the other 
isolates, there were uniformly high levels of prevalence of sensitivity to all three carbapenems 
IPM, MER and ERP, again suggesting that these could all be considered as blind treatment 
options for CTX-M+SHV isolates (Figure 4.11A). Thus for all CTX-M expressing isolates, either 
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alone or in combination with TEM and/or SHV, the carbapenems were identified as effective 
antibiotic choices, consistent with other studies (Manoharan et al., 2011; Pitout et al., 2008). 
FOX also emerged as a potential blind treatment option for CTX-M expressing isolates, either 
alone or with TEM and/or SHV.  
There were only three SHV only isolates in 2010 and in 2012, making it difficult to draw firm 
conclusions on susceptibility. Based on the small number of isolates, the cepahlosporins CZ, 
CRO, CAZ and FEP would be inappropriate choices, whereas all isolates were sensitive to FOX, 
making this a possible blind treatment option for SHV only isolates (Figure 4.12A). All six 
isolates were also sensitive to all three carbapenems IPM, MER and ERP. As for the SHV+TEM 
isolates, there was only one in 2010 and two in 2012, again making it difficult to draw firm 
conclusions. From the available data only the three carbapenems IPM, MER and ERP could be 
confidently suggested as blind treatment options (Figure 4.13A). 
With respect to non--lactam antibiotics, all resistance determinants resulted in high 
prevalence of resistance to ciprofloxacin (CIP), suggesting that this is an inappropriate ESBL 
infection treatment choice in the Saudi Aramco Dhahran Health Center (Figures 4.7-4.13). For 
CTX-M only isolates, neither gentamicin (GM), nor trimethoprim/sulfamethoxazole (SXT) 
emerged as appropriate treatment options (Figure 4.7B), with sensitivity prevalence of 65.5% 
and 44.0% and resistance of 34.5% and 56.0% respectively in 2012. Although 98.4% of CTX-M 
only isolates were sensitive to amikacin (AK) in 2010, this had fallen to 59.5% in 2012, with 
39.3% of isolates having intermediate resistance/sensitivity, although only 1.2% were fully 
resistant (Figure 4.7B). Thus AK would be a possible but not the optimal choice of blind 
therapy for CTX-M only isolates. In 2010, 78.1% of isolates were sensitive to nitrofurantoin 
(FD), with 3.1% resistant, and in 2012 76.2% of CTX-M isolates were sensitive to FD, with 3.6% 
resistant. Thus FD might be a possible blind treatment option for CTX-M only isolates, 
although relatively high levels of intermediate resistance/sensitivity of 18.8% in 2010 and 
20.2% in 2012 should be taken into consideration (Figure 4.7B). All CTX-M isolates were 
sensitive to both the polymyxin colistin and to the glycylcycline tigecycline (Figure 4.7B). 
Indeed all isolates in general, regardless of resistance determinant, were sensitive to these 
two antibiotics (Figures 4.7-4.13). This is consistent with results in other studies worldwide 
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(Balkhed et al., 2013; Pitout et al., 2008). However, while colistin and tigecycline are potential 
blind treatment options for CTX-M infections, stringent antibiotic stewardship is required in 
use of these antibiotics as, for example, evidence of plasmid-mediated polymyxin resistance 
has emerged in Enterobacteriaceae in China and the United States (Liu et al., 2016; McGann 
et al., 2016), in some cases carried on the same plasmid as CTX-M genes (McGann et al., 
2016).  
For TEM only isolates, neither GM, FD nor SXT emerged as appropriate treatment choices, 
with 45.5%, 36.4% and 18.2% of isolates respectively being sensitive to these antibiotics 
(Figure 4.8B). 98.2% of TEM only isolates were sensitive to AK in 2010, with 72.7% (8/11) of 
the TEM only isolates of 2012 being sensitive to AK, with the remaining three of intermediate 
resistance/sensitivity. Thus AK is another possible blind treatment option for the TEM only 
isolates, which had become fewer by 2012 (n=11) compared to 2010 (n=56). For isolates 
expressing the CTX-M and TEM determinants together, AK remained as a possible choice, with 
95.5% of 2010 CTX-M+TEM isolates being sensitive and 71.4% of isolates collected in 2012 
being sensitive, with 28.6% of intermediate resistance/sensitivity and no fully resistant 
isolates (Figure 4.9B). Thus despite its apparently less than optimal action against CTX-M only 
isolates (Figure 4.7B), AK remains a possible blind treatment option for CTX-M+TEM isolates 
(Figure 4.9B).  
While 72.7% of CTX-M+TEM isolates were sensitive to FD in 2010, with 18.2% intermediate 
and 9.1% resistant, by 2012 the number of CTX-M+TEM isolates had risen (n=56 in 2012 v 
n=22 in 2010) and the prevalence of sensitivity to FD had fallen to 58.9%, with 23.2% 
intermediate and 17.9% now resistant (Figure 4.9B). Thus while FD might be a possible option 
for CTX-M only infections, it is less than optimal for CTX-M+TEM infections. Neither GM nor 
SXT emerged as appropriate treatment choices for CTX-M+TEM isolates. Similarly to CTX-
M+TEM isolates, GM, SXT and FD also did not emerge as appropriate treatment options for 
CTX-M+TEM+SHV isolates, with 47.6%, 4.8% and 9.5% of the 21 isolates collected in 2012 
respectively being sensitive to these antibiotics (Figure 4.10B). Both isolates from 2010 and 
17 of the 21 isolates in 2012 (81%) were sensitive to AK, with the remaining four 2012 isolates 
being of intermediate resistance/sensitivity and no fully resistant isolates (Figure 4.10B). Thus 
118 
 
 
 
as for CTX-M+TEM isolates, AK is a possible blind treatment option for CTX-M+TEM+SHV 
isolates. Similarly for CTX-M+ SHV isolates, both isolates from 2010 and all ten isolates from 
2012 were sensitive to AK, however FD would not be an appropriate antibiotic (Figure 4.11B). 
Thus AK emerged as a possible blind treatment option for isolates in which CTX-M was 
expressed in combination with TEM and/or SHV. Other studies have also shown susceptibility 
of CTX-M-positive ESBL-producing E. coli to AK, CO and TGC in the presence of co-resistance 
to GM, CIP and SXT, and replacement of, for example, GM by AK for severe infections has 
been suggested (Balkhed et al., 2013; Manoharan et al., 2011; Pitout et al., 2008). 
Paradoxically, the lowest prevalence of sensitivity to AK for isolates expressing CTX-M was for 
those expressing CTX-M alone, in the absence of PCR-detection of TEM or SHV, although in 
2012 only 1.2% of CTX-M only infections were fully resistant to AK (Figure 4.7B). 
There were only three SHV only isolates in 2010 and in 2012, making it difficult to draw firm 
conclusions on susceptibility. Based on the small number of isolates, only TGC and CO could 
be confidently confirmed as possible blind treatment options for SHV only isolates (Figure 
4.12B) with all six isolates being sensitive to both. As for the SHV+TEM isolates, there was only 
one in 2010 and two in 2012, again making it difficult to draw firm conclusions. From the 
available data AK, TGC and CO would be suggested as blind treatment options, as all three 
isolates were sensitive to all of these antibiotics (Figure 4.13B). 
  
119 
 
 
 
 
 
 
Figure 4.7: Percentage sensitivity, resistance and intermediate resistance/sensitivity to antibiotics of CTX-M-
expressing isolates 
 (A) -lactam antibiotics; (B) non--lactam antibiotics 
S: sensitive; I: intermediate; R: resistant; 2010: n=64 isolates; 2012: n=84 isolates 
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline. Results suggest FOX, 
IPM, MER, ERP, AK, FD, TGC, CO as possible blind treatment options. 
(A) 
(B) 
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Figure 4.8: Percentage sensitivity, resistance and intermediate resistance/sensitivity to antibiotics of TEM-
expressing isolates 
 (A) -lactam antibiotics; (B) non--lactam antibiotics 
S: sensitive; I: intermediate; R: resistant; 2010: n=56 isolates; 2012: n=11 isolates 
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline. Results suggest IPM, 
MER, ERP, AK, TGC, CO as possible blind treatment options. 
 
(A) 
(B) 
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Figure 4.9: Percentage sensitivity, resistance and intermediate resistance/sensitivity to antibiotics of CTX-
M+TEM-expressing isolates 
(A) -lactam antibiotics; (B) non--lactam antibiotics 
S: sensitive; I: intermediate; R: resistant; 2010: n=22 isolates; 2012: n=56 isolates 
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecyclin. Results suggest FOX, 
IPM, MER, ERP, AK, TGC, CO as possible blind treatment options. 
(A) 
(B) 
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Figure 4.10: Percentage sensitivity, resistance and intermediate resistance/sensitivity to antibiotics of CTX-
M+TEM+SHV-expressing isolates 
 (A) -lactam antibiotics; (B) non--lactam antibiotics 
S: sensitive; I: intermediate; R: resistant; 2010: n=2 isolates; 2012: n=21 isolates 
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline. Results suggest FOX, 
IPM, MER, ERP, AK, TGC, CO as possible blind treatment options. 
(A) 
(B) 
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Figure 4.11: Percentage sensitivity, resistance and intermediate resistance/sensitivity to antibiotics of CTX-
M +SHV-expressing isolates 
 (A) -lactam antibiotics; (B) non--lactam antibiotics 
S: sensitive; I: intermediate; R: resistant; 2010: n=2 isolates; 2012: n=10 isolates 
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline. Results suggest FOX, 
IPM, MER, ERP, AK, TGC, CO as possible blind treatment options. 
 
(A) 
(B) 
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Figure 4.12: Percentage sensitivity, resistance and intermediate resistance/sensitivity to antibiotics of SHV-
expressing isolates 
 (A) -lactam antibiotics; (B) non--lactam antibiotics 
S: sensitive; I: intermediate; R: resistant; 2010: n=3 isolates; 2012: n=3 isolates 
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline. Results suggest FOX, 
IPM, MER, ERP, AK, FD, TGC, CO as possible blind treatment options. 
 
(A) 
(B) 
125 
 
 
 
 
 
Figure 4.13: Percentage sensitivity, resistance and intermediate resistance/sensitivity to antibiotics of 
TEM+SHV-expressing isolates 
(A) -lactam antibiotics; (B) non--lactam antibiotics 
S: sensitive; I: intermediate; R: resistant; 2010: n=1 isolates; 2012: n=2 isolates 
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline. Results suggest IPM, 
MER, ERP, AK, TGC, CO as possible blind treatment options. 
 
 
 
 
 
(A) 
(B) 
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4.5 Correlation of PCR results with VITEK® 2/disk diffusion phenotyping  
To determine whether multiplex PCR-based genotyping results were generally consistent with 
the phenotyping results obtained by VITEK® 2 and disk diffusion (Sections 3.4.2 and 3.4.3), 
the different PCR profiles were matched to the corresponding VITEK® 2 POS/NEG results 
(Figure 4.14), or to the corresponding disk diffusion AmpC, ESBL/AmpC, ESBL and negative 
results (Figure 4.15). The percentage of isolates within each PCR category (CTX-M, CTX-
M+TEM, CTX-M+SHV, CTX-M+TEM+SHV, TEM, SHV, TEM+SHV, NEG) which were either 
VITEK® 2 positive (POS) or negative (NEG) was calculated for both 2010 and 2012 and are 
represented graphically in Figure 4.14. For 2010, for all isolates for which a positive PCR result 
was obtained, between 85.7% and 100% were also POS for VITEK® 2, while this rose to 
between 98.2% and 100% in 2012 (Figure 4.14), indicating that PCR and VITEK® 2 results were 
consistent. However, for isolates for which no PCR product was obtained (NEG), 63.6% in 2010 
and 66.7% in 2012 were scored POS by VITEK® 2 (Figure 4.14). This suggests that in these 
samples there may be ESBL genes beyond CTX-M, TEM or SHV expressed.  
 
 
Figure 4.14: Comparison of multiplex PCR profiles with VITEK® 2 identification 
Similarly, the percentage of isolates within each PCR category which were either disk diffusion 
AmpC, ESBL/AmpC, ESBL and negative were calculated for both 2010 and 2012 and are 
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represented graphically in Figure 4.15. For 2010, the predominant PCR profiles were CTX-M 
(n=64), TEM (n=56) and CTX-M+TEM (n=22). Isolates with these PCR profiles consistently were 
scored as either ESBL (92.2%, 82.1% and 86.4% respectively) or ESBL & AmpC (4.6%, 1.8% and 
4.5% respectively) by disk diffusion, although 8.9% of TEM only isolates were scored as AmpC 
(Figure 4.15). Results were less consistent for the other PCR profiles for which there were very 
few isolates in 2010, i.e. CTX-M+TEM+SHV (n=2), CTX-M+SHV (n=2), SHV (n=3) and TEM+SHV 
(n=1) (Figure 4.15). The low numbers of isolates in these cases make interpretation of any 
correlation difficult. In terms of isolates which gave no PCR amplification product, in 2010 
they were divided between AmpC (27.3%), ESBL (36.4%), ESBL & AmpC (3%) and NEG (33.3%). 
As with the VITEK® 2 comparison, this again suggests that in these samples there may be ESBL 
genes beyond CTX-M, TEM or SHV expressed. In 2012, between 98.2% and 100% of all isolates 
which gave a positive PCR result were scored as ESBL by disk diffusion, indicating excellent 
agreement (Figure 4.15). In terms of isolates which gave no PCR amplification product, in 2010 
they were divided between AmpC (33.3%), ESBL (60%), and ESBL & AmpC (6.7%). 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: Comparison of multiplex PCR profiles with disk diffusion identification 
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4.6 Genotyping by Check-MDR CT102 DNA microarray 
4.6.1 General characteristics of MDR patient sample and infection types 
The Check-MDR CT102 microarray (Check-Points, 2014) was used to detect which 
carbapenemase and/or ESBL types were present (Check-Points, 2014). While PCR detected 
CTX-M generally, the microarray could distinguish between types including CTX-M-1, CTX-M1-
type-15, CTX-M-2 and CTX-M-9. It also detected AmpC genes including blaDHA-1 and blaCMY-II 
and carbapenemase genes such as blaOXA-48. Microarray analysis was carried out only on 159 
patient samples collected between 2012 and 2013, as a pilot study.  
Figure 4.16 shows sample results from the MDR analysis.The age group and infection body 
site distributions for the MDR group according to gender are shown in Tables 4.4 and 4.5 
respectively. As in the patient group for which the 2010 v 2012 analysis was carried out 
(n=385) and the 2010 and 2012 sample groups, females outnumbered males (n=105 v 54) 
(Section 3.2.1 and 3.2.2). Also as before, the majority of patients were aged over 60 y (97/159, 
61%), with a relatively higher percentage of males aged 80 y or greater compared to females 
(35.2% of males v 16.2% of females) (Table 3.4) (Sections 3.2.1 and 3.2.2). However, when the 
age distribution for males versus females was compared by Chi squared analysis the 
difference was not quite significant, possibly due to the relatively small number of males in 
the sample (Chi-square statistic = 9.4084, p=0.051663).  
Also as before, the sample type was dominated by urinary cultures (UC) (130/159, 81.8%), 
followed by systemic infections detected by blood cultures (BLC) (17/159, 10.7%) (Table 3.5) 
(Section 3.2.3). Also as before, the distribution differed for females versus males, with UC 
representing 90.5% of infections in females versus 64.8% in males and BLC representing 5.7% 
of infections in females versus 20.4% in males (Table 4.5). The remaining samples from 
females were from abdominal (ABD) infections or stool samples (one each), neither of which 
were found in males. Three samples from males came from SPU infections which were not 
found in females, and the remainder were divided into one each of eye, nasal, wound back, 
wound foot and BF foot, none of which were found in females (Table 4.5). When the 
distribution of the top four infection sites (UC, BLC, ABD, STOOL) was compared between 
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females and males, it was found to differ significantly (Chi-square statistic =17.6758, 
p=0.000513), similarly to the result for the 2010 v 2012 comparison group. 
  
Figure 4.16: Samples of Check-MDR CT102 microarray (Check-Points) results. 
Table 4.4: Age group distribution by gender for MDR sample group 
Age group (y) Female (n=105) Male (n=54) Total (n=159) 
0-19 11 (10.5%) 4 (7.4%) 15 (9.4%) 
20-39 13 (12.4%) 2 (3.7%) 15 (9.4%) 
40-59 23 (21.9%) 9 (16.7%) 32 (20.1%) 
60-79 41 (39.0%) 20 (37.0%) 61 (38.4%) 
≥80 17 (16.2%) 19 (35.2%) 36 (22.6%) 
Total 105 (100%) 54 (100%) 159 (100%) 
 
Table 4.5: Infection site distribution by gender for MDR sample group 
Body site Female (n=105) Male (n=54) Total (n=159) 
UC 95 (90.5%) 35 (64.8%) 130 (81.8%) 
BLC 6 (5.7%) 11 (20.4%) 17 (10.7%) 
ABD 3 (2.9%) 0 3 (1.9%) 
SPU 0 3 (5.55%) 3 (1.9%) 
STOOL 1 (0.9%) 0 1 (0.6%) 
EYE 0 1 (1.85%) 1 (0.6%) 
NASAL 0 1 (1.85%) 1 (0.6%) 
WBACK 0 1 (1.85%) 1 (0.6%) 
WFOOT 0 1 (1.85%) 1 (0.6%) 
BFFOOT 0 1 (1.85%) 1 (0.6%) 
TOTAL 105 (100%) 54 (100%) 159 (100%) 
 
The distribution of the bacterial species detected in these 159 patients according to in-
patient/out-patient status is shown in Table 4.6. As with the patient group used for 
phenotyping and for PCR analysis over January 2010 and December 2013 (n=385; Section 
3.2.4), the majority of patients were out-patients (114/159; 71.7%) as compared to in-
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patients (45/159; 28.3%) (Table 4.6). E.coli was again the most prevalent organism (121/159; 
76.1%), followed again by K. pneumoniae (27/159; 17%) (Table 4.6), again similar to the whole 
group (Section 3.3.1). There were three E. aerogenes isolates, two each of E. cloacae, C. 
freundii and M. morganii, and one each of S. marcescens and P. mirabilis (Table 4.6). There 
was no significant difference in distribution of E.coli and K. pneumoniae between out-patients 
and in-patients (Chi-square statistic = 1.4367, p=0.230676). 
Thus the characteristics of the patients and isolates used for the MDR analysis were consistent 
with those used in the phenotyping and PCR analyses. 
Table 4.6: Bacterial species distribution in MDR sample group by in-patient versus out-patient status 
Location 
IN/OUT 
Distribution of bacterial isolates by in-patient versus out-patient (n=159) Total  
EC 
(n=121) 
KPN 
(n=27) 
ECL 
(n=2) 
EAER 
(n=3) 
CITF 
(n=2) 
MOMO 
(n=2) 
SERMAR 
(n=1) 
PRMI 
(n=1) 
 
IN 31 (25.6%) 10 (37%) 1 (50%) 
2 
(66.7%) 
0 0 1 (100%) 0% 45 (28.3%) 
OUT 90 (74.4%) 17 (63%) 1 (50%) 
1 
(33.3%) 
2 (100%) 2 (100%) 0 1 (100%) 
114 
(71.7%) 
Total 
121 
(100%) 
27 
(100%) 
2 
(100%) 
3 (100%) 2 (100%) 2 (100%) 1 (100%) 1 (100%) 
159 
(100%) 
EC: Escherichia .coli; KPN: Klebsiella pneumoniae; ECL: Enterobacter cloacae; EAER: 
Enterobacter aerogenes; CITF: Citrobacter freundii; MOMO: Morganella morganii; SERMAR: 
Serratia marcescens; PRMI: Proteus mirabilis 
4.6.2 MDR genotypes distribution by bacterial organism 
The genotypes detected by Check-MDR CT102 microarray among these 159 isolates are 
shown in Table 4.7. In total, twenty expression genotypes were detected, along with the 
negative (NEG) genotype (Table 4.7). The majority of isolates expressed CTX-M subtypes 
(119/159; 74.8%), alone or in combination with other genes, consistent with the Multiplex-
PCR data. In particular CTX-M-1, type-15-like was present in 98/159 (61.6%) of isolates (Table 
4.7). Overall, the most common genotype was CTX-M-1, type-15-like alone (56/159; 35.2%), 
followed by TEM + CTX-M-1, type-15 like (23/159; 14.5%), CTX-M-9 only (11/159; 6.9%) and 
TEM + SHV+ CTX-M-1, type-15 like (10/159; 6.3%) (Table 4.7).  
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The most common genotypes among E. coli isolates followed the same order, with CTX-M-1, 
type-15-like alone at 54/121 (44.6%), TEM + CTX-M-1, type-15 like (23/121; 19%), CTX-M-9 
only (11/121; 9.1%) and TEM + SHV+ CTX-M-1, type-15 like (4/121; 3.3%) (Table 4.7). In fact, 
all the CTX-M-9 only isolates were E. coli (Table 4.5). By contrast, among K. pneumoniae 
isolates, the most common genotype was SHV + CTX-M-1, type-15 like (7/27; 26%), followed 
by TEM+SHV+ CTX-M-1, type-15 like (6/27; 22.2%). CTX-M-1, type-15-like alone accounted for 
only two of the K. pneumoniae isolates (7.4%), the same as SHV only and SHV+CTX-M-1 (Table 
4.7). Comparing the top five genotypes (CTX-M-1, type-15-like alone, TEM + CTX-M-1, type-
15 like, CTX-M-9 only, TEM + SHV+ CTX-M-1, type-15 like, SHV+ CTX-M-1,type-15 like) 
between E. coli and K. pneumoniae by Chi squared analysis confirmed that the distribution 
was significantly different (Chi-square statistic = 71.0885, p< 0.00001). No E. aerogenes, E. 
cloacae, C. freundii or S. marcescens isolates gave a positive phenotype.  
CTX-M-1 was represented in seven isolates, in four of which it was present in combination 
with another resistance gene, two with TEM (one each E. coli and K. pneumoniae), and two 
with SHV (both K. pneumoniae). In general, CTX-M genes were frequently detected in 
combination with other ESBLs or with AmpC genes (in 48/159 (30.2%) of total isolates), 
consistent with observations with multiplex PCR. AmpC genes were represented in only four 
isolates, one each of AmpC-CMY-II or AmpC-DHA alone, both in E. coli, one CTX-M-1, type 15 
like+AmpC-DHA in M. morganii, and one TEM,AmpC+CMY-II in E. coli (Table 4.5). The OXA 
carbapenemase OXA-48 was present only in three E. coli isolates, once alone, once in 
combination with SHV+CTX-M-1,type-15 like and once in combination with CTX-M-9 (Table 
4.7). Thus carbapenemase genes appear to be present at only a low level in isolates infections 
in the Saudi Aramco Dhahran Health Center and to be confined to E. coli, consistent with the 
uniform susceptibility of the isolates to IPM, MER and ERP, but the situation requires careful 
on-going monitoring. 
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Table 4.7: Genotype distribution by bacterial species detected by Check-MDR CT102 DNA microarray 
 
MDR genotype 
Bacterial species (n=159) 
 
Total 
(MDR 
result
s) 
EC 
(n=12
1) 
KPN 
(n=27
) 
ECL 
(n=2) 
EAER 
(n=3) 
CITF 
(n=2) 
MOM
O 
(n=2) 
SERM
AR 
(n=1) 
PRMI 
(n=1) 
CTX-M-1, type 15 like 54 
(44.6
%) 
2 
(7.4%
) 
0 0 0 0 0 0 56 
(35.2
%) 
TEM,CTX-M-1,type-15 like 23 
(19%) 
0 0 0 0% 0 0 0 23 
(14.5
%) 
CTX-M-9 11 
(9.1%
) 
0 0 0 0 0 0 0 11 
(6.9%
) 
TEM,SHV, CTX-1,type-15 
like 
4 
(3.3%
) 
6 
(22.2
%) 
0 0 0 0 0 0 10 
(6.3%
) 
SHV,CTX-1,type-15 like 0 7 
(26%) 
0 0 0 0 0 0 7 
(4.4%
) 
CTX-M-1 3 
(2.5%
) 
0 0 0 0 0 0 0 3 
(1.9%
) 
TEM 2 
(1.65
%) 
0 0 0 0 0 0 1 
(100%
) 
3 
(1.9%
) 
SHV 1 
(0.83
%) 
2 
(7.4%
) 
0 0 0 0 0 0 3 
(1.9%
) 
TEM,CTX-M-1 1 
(0.83
%) 
1 
(3.7%
) 
0 0 0% 0 0 0 2 
(1.3%
) 
SHV-CTX-M-1 0 2 
(7.4%
) 
0 0 0 0 0 0 2 
(1.3%
) 
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TEM, AmpC-CMY-II 1 
(0.83
%) 
0 0 0 0 0 0 0 1 
(0.62
%) 
TEM,SHV 0 1 
(3.7%
) 
0 0 0 0 0 0 1 
(0.62
%) 
TEM,CTX-M-9 1 
(0.83
%) 
0 0 0 0% 0 0 0 1 
(0.62
%) 
SHV,CTX-M-1,type-15 
like,OXA-48 
1 
(0.83
%) 
0 0 0 0 0 0 0 1 
(0.62
%) 
CTX-M-1, type 15 like, 
AmpC-DHA 
0 0 0 0 0 1 
(50%) 
0 0 1 
(0.62
%) 
CTX-M-2 1 
(0.83
%) 
0 0 0 0 0 0 0 1 
(0.62
%) 
CTX-M-9,OXA-48 1 
(0.83
%) 
0 0 0 0 0 0 0 1 
(0.62
%) 
OXA-48 1 
(0.83
%) 
0 0 0 0 0 0 0 1 
(0.62
%) 
AmpC-CMY-II 1 
(0.83
%) 
0 0 0 0 0 0 0 1 
(0.62
%) 
AmpC-DHA 1 
(0.83
%) 
0 0 0 0 0 0 0 1 
(0.62
%) 
NEG 14 
(11.6
%) 
6 
(22.2
%) 
2 
(100
%) 
3 
(100%
) 
2 
(100%
) 
1 
(50%) 
1 
(100%
) 
0 29 
(18.2
%) 
Total (bacterial species) 121 
(100
%) 
27 
(100
%) 
2 
(100
%) 
3 
(100%
) 
2 
(100%
) 
2 
(100
%) 
1 
(100%
) 
1 
(100%
) 
159 
(100
%) 
EC: Escherichia .coli; KPN: Klebsiella pneumoniae; ECL: Enterobacter cloacae; EAER: 
Enterobacter aerogenes; CITF: Citrobacter freundii; MOMO: Morganella morganii; SERMAR: 
Serratia marcescens; PRMI: Proteus mirabilis 
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4.6.3 MDR genotype distribution by in-patient/out-patient status 
Table 4.8 shows the distribution of MDR- genotypes distributed according to in-patient versus 
out-patient status. CTX-M1-type-15-like alone was the most common genotype for both 
patient types (33.33% and 36.0% respectively), followed by TEM + CTX-M-1, type-15 like 
(11.11% and 15.8% respectively). However, the next most common for out-patients (as for 
the whole group) was CTX-M-9 (11/114; 9.6%), whereas there were no samples with CTX-M-
9 only genotype among the in-patient group (Table 4.8). The third most common genotype 
among in-patients was TEM + SHV+ CTX-M-1, type-15 like jointly with SHV+ CTX-M-1, type-15 
(both in 6.67% of in-patient samples, 3/45 each). TEM + SHV+ CTX-M-1, type-15 like was the 
fourth most common genotype in out-patient samples (7/114; 6.1%), while SHV+ CTX-M-1, 
type-15 was present in four samples (3.5%) (Table 4.8). 
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Table 4.8: Genotype distribution by in-patient versus out-patient status detected by Check-MDR CT102 DNA 
microarray 
MDR genotype In-patient (n=45) Out-patient (n=114) Total (n=159) 
CTX-M-1, type 15 like 15 (33.33%) 41 (36%) 56 (35.2%) 
TEM,CTX-M-1,type-15 
like 
5 (11.11%) 18 (15.8%) 23 (14.5%) 
CTX-M-9 0 11 (9.6%) 11 (6.9%) 
TEM,SHV, CTX-M-1,type-
15 like 
3 (6.67%) 7 (6.1%) 10 (6.3%) 
SHV,CTX-M-1,type-15 
like 
3 (6.67%) 4 (3.5%) 7 (4.4%) 
CTX-M-1 1 (2.22%) 2 (1.75%) 3 (1.9%) 
TEM 0 3 (2.6%) 3 (1.9%) 
SHV 2 (4.44%) 1 (0.9%) 3 (1.9%) 
TEM,CTX-M-1 2 (4.44%) 0 2 (1.3%) 
SHV-CTX-M-1 0 2 (1.75%) 2 (1.3%) 
TEM,AmpC-CMY-II 0 1 (0.9%) 1 (0.62%) 
TEM,SHV 1 (2.22%) 0 1 (0.62%) 
TEM,CTX-M-9 1 (2.22%) 0 1 (0.62%) 
SHV,CTX-M-1,type-15 
like,OXA-48 
1 (2.22%) 0 1 (0.62%) 
CTX-M-1, type 15 
like,AmpC-DHA 
0 1 (0.9%) 1 (0.62%) 
CTX-M-2 0 1 (0.9%) 1 (0.62%) 
CTX-M-9,OXA-48 1 (2.22%) 0 1 (0.62%) 
OXA-48 1 (2.22%) 0 1 (0.62%) 
AmpC-CMY-II 1 (2.22%) 0 1 (0.62%) 
AmpC-DHA 0 1 (0.9%) 1 (0.62%) 
NEG 8 (17.8%) 21 (18.4%) 29 (18.2%) 
Total (IN/OUT) 45 114 159 (100%) 
 
When Chi square analysis was carried out to compare the distribution between in-patients 
versus out-patients of the top five overall genotypes (CTX-M1-type-15-like alone; TEM + CTX-
1,type-15 like; CTX-M-9; TEM + SHV+ CTX-1,type-15 like; SHV+ CTX-1,type-15 like), no 
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significant difference was uncovered despite the absence of CTX-M-9 samples in the in-
patient group (Chi-square statistic =5.2883, p= 0.25897).  
4.6.4 Correlation of MDR with PCR results 
To determine if there was correlation between the genotypes generated by MDR microarray 
and the corresponding PCR results, Cohen’s kappa was calculated for each of the seven 
positive PCR profiles (CTX-M, CTX-M+TEM, CTX-M+TEM+SHV, CTX-M+SHV, TEM, SHV, 
TEM+SHV) compared to corresponding microarray results. Cohen’s kappa provides a metric 
of concordance to account for the fact that sometimes two methods can agree by chance 
alone (Kwiecien et al., 2011). It measures the normalised difference between the rate of 
agreement that is actually observed between the methods and the rate of agreement that 
one might expect purely by chance (Kwiecien et al., 2011).  
Table 4.9 shows the division of PCR profiles over the 159 samples and the corresponding MDR 
results generated for the isolates in each PCR profile. So for example, for the isolates with a 
CTX-M PCR profile (n=69), the equivalent microarray results were collected and any 
microarray result which gave any CTX-M subtype only, or a CTX-M subtype along with a gene 
that was not tested in PCR, (e.g. CTX-M-1, type-15-like+AmpC-DHA, n=1) was considered plus 
(+) for both PCR and MDR, and any other microarray result was considered minus (-) for MDR 
and + for PCR. Any MDR result which gave a CTX-M subtype only (or a CTX-M subtype along 
with a gene that was not tested in PCR), but did not fall within the isolates with the CTX-M 
PCR profile, was scored as plus (+) for MDR and minus (-) for PCR. All other results, for which 
neither MDR nor PCR gave a CTX-M result was scored as minus (-) for each. This procedure 
was carried out to give two-by-two tables denoting the number of cases identified as a 
particular type of ESBL by each method for each positive PCR profile. The Cohen’s kappa 
results which were calculated on this basis for each PCR profile versus MDR results are shown 
in Table 4.10. Cohen's kappa (κ) can range from -1 to +1. Based on the guidelines from Altman 
(1999), and adapted from Landis & Koch (1977), negative Cohen’s kappa means no agreement 
between methods, between 0 and 0.20 is slight, 0.21-0.40 is fair, 0.41-0.60 is moderate, 0.61-
0.80 is substantial, and 0.81-1 is almost perfect agreement. For all PCR profiles, the agreement 
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with results from MDR therefore varied between moderate for the profiles featuring CTX-M 
in combination with TEM and/or SHV and substantial for the singly expressed ESBL profiles 
and TEM+SHV (Table 4.10). 
Table 4.9: PCR profiles for MDR sample and equivalent MDR results 
PCR profile (n=159) MDR results 
CTX-M (n=69) CTX-M-1 (n=3) 
CTX-M-1 type 15-like (n=48) 
CTX-M-1 type 15-like + AmpC DHA (n=1) 
CTX-M-2 (n=1) 
CTX-M-9 (n=9) 
NEG (n=4) 
TEM + CTX-M-1 type 15-like (n=2) 
SHV+ CTX-M-1 type 15-like+OXA-48 (n=1) 
CTX-M+TEM (n=45) CTX-M-1 type 15-like+TEM (n=21) 
 CTX-M-1+TEM (n=1) 
 CTX-M-9+TEM (n=1) 
 CTX-M-1 type 15-like (n=7) 
 CTX-M-9 (n=2) 
 CTX-M-9+OXA-48 (n=1) 
 OXA-48 (n=1) 
 CTX-M-1 type 15-like+SHV (n=1) 
 CTX-M-1 type 15-like+SHV+TEM (n=3) 
 NEG (n=7) 
CTX-M+TEM+SHV (n=13) CTX-M-1 type 15-like+TEM+SHV (n=6) 
 CTX-M-1 type 15-like (n=1) 
 CTX-M-1 type 15-like+SHV (n=3) 
 CTX-M-1+SHV (n=1) 
 NEG (n=2) 
TEM (n=8) TEM (n=3) 
 TEM+Amp-CMY II (n=1) 
 Amp-CMY II (n=1) 
 NEG (n=3) 
CTX-M+SHV (n=7) SHV (n=1) 
 CTX-M-1 type 15-like+SHV (n=3) 
 CTX-M-1+SHV (n=1) 
 NEG (n=2) 
TEM+SHV (n=2) TEM+SHV (n=1) 
 CTX-M-1 type 15-like+TEM+SHV (n=1) 
SHV (n=2) SHV (n=2) 
NEG (n=13) NEG(n=11) 
 AMPC-DHA (n=1) 
 CTX-M-1+TEM (n=1) 
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Table 4.10: Cohen’s kappa for each PCR profile versus MDR 
PCR profile Cohen’s kappa (PCR v MDR) 
CTX-M 0.771 
CTX-M+SHV 0.442 
SHV 0.797 
TEM 0.655 
CTX-M+TEM+SHV 0.485 
TEM+SHV 0.664 
CTX-M+TEM 0.577 
 
4.6.5 MDR results and antibiotic sensitivity 
The relationship between antibiotic susceptibility of an isolate and the resistance determinant 
it carries is important in indicating and identifying MDR organisms and can help suggest 
potential blind therapy options, if the resistance determinant could be identified efficiently 
and rapidly at point of care and matched to probable antibiotic susceptibility. As with the PCR 
results, the susceptibility profile for nine -lactam and seven non--lactam antibiotics 
(Section 3.5) was determined for each isolate according to the resistance determinant(s) it 
carried according to MDR. The profiles are shown graphically for all resistance determinants 
which were identified in three or more isolates, i.e. the CTX-M-1 type 15-like only (n=56) 
(Figure 4.17), CTX-M-1 type 15-like+TEM (n=23) (Figure 4.18), CTX-M-9 (n=11) (Figure 4.19), 
CTX-M-1 type 15-like+TEM + SHV (n=10) (Figure 4.20), CTX-M-1 type 15-like +SHV (n=7) 
(Figure 4.21), CTX-M-1 only (n=3) (Figure 4.22), TEM only (Figure 4.23) and SHV only (n=3) 
(Figure 4.24) It should be noted that for other profiles, the small number of isolates (one or 
two each) made it difficult to draw firm conclusions for these resistance determinant profiles. 
The results for these profiles are summarised in Table 4.11. 
In terms of -lactam antibiotics, as with the PCR profiles the susceptibility data revealed that 
all MDR-detected resistance determinants resulted in high prevalence of resistance to 
ampicillin/sulbactam (AMS), where sensitivity/resistance could be determined, confirming 
that this is an inappropriate ESBL infection treatment choice in the Saudi Aramco Dhahran 
Health Center. Again as with PCR profiling, there were also high levels of resistance regardless 
of resistance determinant for the cephalosporins ceftazidime (CAZ), ceftriaxone (CRO), 
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cefazolin (CZ), and cefepimine (FEP), confirming that these would be inappropriate choices 
for blind treatment.  
For the isolates expressing CTX-M-1 type 15-like alone or in combination with TEM and/or 
SHV, and for isolates expressing CTX-M-9, levels of sensitivity to the second generation 
cephalosporin cefoxitin (FOX) were relatively high (Figures 4.17-4.21), making this a possible 
antibiotic for CTX-M-expressing infections. It was more difficult to draw clear conclusions for 
CTX-M-1 isolates, or TEM or SHV isolates, as there were only three of each. From the limited 
number of isolates, FOX could be considered for SHV only isolates as all three were sensitive 
(Figure 4.24), but no clear interpretation could be made for CTX-M-1 or TEM isolates (Figures 
4.22 and 4.23). 
As for PCR profiling, for all isolates no matter which MDR profile for which a determination 
could be made, none were resistant to the three carbapenems imipenem (IPM) meropenem 
(MER) and ertapenem (ERP), thus these could all be considered as blind treatment options for 
all isolates, again with the caveat that rigorous antibiotic stewardship be applied.  
For the other MDR profiles, there were only one or two isolates, making any conclusions on 
susceptibility difficult to draw. From the available data, the three carbapenems IPM, MER and 
ERP could be confidently suggested as blind treatment options in all cases (Table 4.11). It is 
worth noting that for the three isolates that expressed OXA-48 alone or in combination with 
SHV+ CTX-M-1 type 15-like or with CTX-M-9, all three isolates remained sensitive to the three 
carbapenems, where a determination could be made (Table 4.11). FOX may be suitable for 
CTX-M-1+SHV isolates as both were sensitive to this antibiotic. 
With respect to non--lactam antibiotics, there were generally high levels of resistance to 
ciprofloxacin (CIP), regardless of which MDR-detected resistant determinant(s) were present. 
Consistent with PCR profiling results, this suggests that this is an inappropriate ESBL infection 
treatment choice in the Saudi Aramco Dhahran Health Center (Figures 4.17-4.24).  
For CTX-M-1 type 15-like only isolates, neither gentamicin (GM), nor 
trimethoprim/sulfamethoxazole (SXT) emerged as appropriate treatment options (Figure 
4.17B), with sensitivity prevalence of 64.3% and 51.8% and resistance of 35.7% and 48.2% 
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respectively. Only 39.3% of CTX-M-1, type 15-like only isolates were sensitive to amikacin 
(AK), with 58.9% of isolates having intermediate resistance/sensitivity, although only 1.8% 
were fully resistant (Figure 4.17B). Thus AK would not be the optimal choice of blind therapy 
for CTX-M only isolates. This is reasonably consistent with results for isolates with CTX-M PCR 
profiles, although 59.5% of these isolates were sensitive in 2012. By contrast, 10/11 isolates 
with the MDR CTX-M-9 profile were sensitive to AK, as were two out the three CTX-M-1 
isolates and the single CTX-M-2 isolate (Figures 4.19, 4.22, Table 4.11). Thus the relative 
resistance to AK among isolates expressing CTX-M in the absence of another ESBL gene 
appears to relate chiefly to CTX-M-1 type 15-like isolates. Somewhat paradoxically, in the 
isolates in which CTX-M-1 type 15-like was expressed in combination with TEM and/or SHV, 
there was greater sensitivity to AK, i.e. 73.9% in CTX-M-1 type 15-like+TEM isolates, and 100% 
in both CTX-M-1, type 15-like+SHV and CTX-M-1, type 15-like+TEM+SHV isolates. 100% of the 
three SHV-only isolates were also sensitive to AK (Figure 4.24). However, only one of the three 
TEM isolates was sensitive, suggesting it may not be an appropriate antibiotic for blind 
treatment of infections featuring TEM-only isolates (Figure 4.23). This was not consistent with 
results from PCR analysis which showed that 72.7% of TEM-only isolates in 2012 were 
sensitive to AK. The small number of SHV and TEM isolates in the MDR sample group (only 
three of each) means that any results should be treated with caution.  
For nitrofurantoin (FD), 69.6% of both CTX-M-1 type 15-like only and of CTX-M-1 type 15-
like+TEM isolates were sensitive to this antibiotic, suggesting that it might cautiously be 
suggested as a possible blind treatment option these isolates. However, CTX-M-1 type 15-like 
only isolates had relatively high levels of intermediate resistance/sensitivity of 25%, and 
prevalence of resistance was 5.4%, while intermediate resistance prevalence for CTX-M-1 
type 15-like+TEM isolates was 13% and resistance prevalence was relatively high at 17.4%.; 
these figures should be taken into consideration when deciding on choosing FD as a potential 
treatment (Figures 4.17B, 4.18B). When SHV was added to the combination, FD sensitivity 
prevalence for CTX-M-1 type 15-like+TEM+SHV isolates was only 20% and for CTX-M-1 type 
15-like +SHV isolates it was zero, thus this is not an appropriate antibiotic for isolates with 
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these combinations of resistance determinants. This is relatively consistent with results for 
PCR.  
Prevalence of sensitivity to FD was 81.8% for CTX-M-9 isolates, while none of the 11 isolates 
had total resistance, suggesting that FD may be a suitable blind treatment option for 
infections featuring CTX-M-9 only (Figure 4.19). Two out of three CTX-M-1 isolates were 
sensitive (Figure 4.22B), as were two out of three SHV isolates (Figure 4.24B), but only one 
out of three TEM isolates (Figure 4.23), but again the small number of isolates prevents 
drawing of firm conclusions. For CTX-M-9 isolates, there was also 90.9% prevalence of 
sensitivity to GM, suggesting another alternative blind treatment option, although GM did 
not emerge as a suitable candidate for isolates with the other MDR profiles.  
SXT also did not appear to be an appropriate blind treatment candidate for isolates with any 
of the MDR profiles. However, all isolates regardless of MDR resistance determinant were 
sensitive to both colistin and to tigecycline (Figures 4.17-4.24, Table 4.11), consistent with the 
results from the isolates used in the phenotyping and PCR analyses. 
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Figure 4.17: Percentage sensitivity, resistance and intermediate resistance/sensitivity to antibiotics of CTX-
M-1, type 15-like expressing isolates 
(A) -lactam antibiotics; (B) non--lactam antibiotics 
S: sensitive; I: intermediate; R: resistant; ND: non-determined; n=56 isolates  
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline. Results suggest FOX, 
IPM, MER, ERP, FD, TGC, CO as possible blind treatment options. 
 
(A) 
(B) 
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Figure 4.18: Percentage sensitivity, resistance and intermediate resistance/sensitivity to antibiotics of CTX-
M-1, type 15-like+TEM-expressing isolates 
(A) -lactam antibiotics; (B) non--lactam antibiotics 
S: sensitive; I: intermediate; R: resistant; ND: non-determined; n=23 isolates  
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline. Results suggest FOX, 
IPM, MER, ERP, AK, FD, TGC, CO as possible blind treatment options. 
(A) 
(B) 
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Figure 4.19: Percentage sensitivity, resistance and intermediate resistance/sensitivity to antibiotics of CTX-
M-9-expressing isolates 
(A) -lactam antibiotics; (B) non--lactam antibiotics 
S: sensitive; I: intermediate; R: resistant; ND: non-determined; n=11 isolates  
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline. Results suggest FOX, 
IPM, MER, ERP, AK, FD, GM, TGC, CO as possible blind treatment options. 
 
(A) 
(B) 
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Figure 4.20: Percentage sensitivity, resistance and intermediate resistance/sensitivity to antibiotics of CTX-
M-1, type 15-like+TEM+SHV-expressing isolates 
(A) -lactam antibiotics; (B) non--lactam antibiotics 
S: sensitive; I: intermediate; R: resistant; ND: non-determined; n=10 isolates  
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline. Results suggest FOX, 
IPM, MER, ERP, AK, TGC, CO as possible blind treatment options. 
(A) 
(B) 
146 
 
 
 
 
 
Figure 4.21: Percentage sensitivity, resistance and intermediate resistance/sensitivity to antibiotics of CTX-
M-1, type 15-like+SHV-expressing isolates 
(A) -lactam antibiotics; (B) non--lactam antibiotics 
S: sensitive; I: intermediate; R: resistant; ND: non-determined; n=7 isolates  
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline. Results suggest FOX, 
IPM, MER, ERP, AK, TGC, CO as possible blind treatment options. 
 
 
(A
) 
(B) 
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Figure 4.22: Percentage sensitivity, resistance and intermediate resistance/sensitivity to antibiotics of CTX-
M-1-expressing isolates 
(A) -lactam antibiotics; (B) non--lactam antibiotics 
S: sensitive; I: intermediate; R: resistant; ND: non-determined; n=3 isolates  
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline. Results suggest FOX, 
IPM, MER, ERP, AK, FD, TGC, CO as possible blind treatment options 
 
(A) 
(B) 
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Figure 4.23: Percentage sensitivity, resistance and intermediate resistance/sensitivity to antibiotics of TEM-
expressing isolates 
(A) -lactam antibiotics; (B) non--lactam antibiotics 
S: sensitive; I: intermediate; R: resistant; ND: non-determined; n=3 isolates  
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline. Results suggest IPM, 
MER, ERP, TGC, CO as possible blind treatment options 
 
(A) 
(B) 
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Figure 4.24: Percentage sensitivity, resistance and intermediate resistance/sensitivity to antibiotics of SHV-
expressing isolates 
(A) -lactam antibiotics; (B) non--lactam antibiotics 
S: sensitive; I: intermediate; R: resistant; ND: non-determined; n=3 isolates  
AK: Amikacin; AMS: Ampicillin/sulbactam (ESBL inhibitor); CAZ: Ceftazidime; CIP: Ciprofloxacin; CO: Colistin; CRO: 
Ceftriaxone; CZ: Cefazolin; ERP: Ertapenem; FD: Nitrofurantoin; FEP: Cefepime; FOX: Cefoxitin; GM: Gentamicin; 
IPM: Imipenem; MER: Meropenem; SXT: Trimethoprim/sulfamethoxazole; TGC: Tigecycline. Results suggest FOX, 
IPM, MER, ERP, AK, GM, TGC, CO as possible blind treatment options 
 
 
(A) 
(B) 
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Table 4.11: Antibiotic resistances of less frequent MDR profile isolates 
 MDR PROFILE 
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 N=2 N=2 N=1 N=1 N=1 N=1 N=1 N=1 N=1 N=1 N=1 N=1 
lactams             
AMS 2R ND ND I R R ND ND R ND ND R 
CZ 2R ND ND R R R ND ND R ND ND R 
CRO 2R 2R R I R R R R R R R R 
CAZ 1R, 
1I 
2I R I I S I I I I R I 
FEP 1R, 
1I 
1R, 
1I 
I I I S I I R I S I 
FOX 1R, 
1S 
2S R S S S I S S S R S 
IPM 1I, 
1S 
2S S S S S S S S S S S 
MER 1I, 
1S 
ND ND S S S ND ND S ND ND S 
ERP 2S 2S S S S S S S S S S S 
             
Non-
lactams 
            
AK 1R, 
1S 
1I, 
1S 
S S I S S S S S S R 
CIP 2R 1R, 
1S 
R R S S R S S S R R 
GM 2R 1R, 
1S 
S R R R R R R R R S 
FD 1I, 
1S 
1R, 
1S 
I R S S R S S S S S 
SXT 1R, 
1S 
1R, 
1S 
R R R R R S R R R R 
TGC 2S 2S S S S S S S S S S S 
CO 2S 2S S S S S S S S S S S 
S: sensitive; I: intermediate; R: resistant; ND: non-determined 
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4.7 Genotyping of Escherichia coli isolates by PFGE and ERIC 
DNA was extracted from 285 E.coli isolates, recovered from patients mostly with urinary 
infections in 2010 and 2012, and PCR amplified using ERIC 1 and ERIC2 primers (Section 2.4.5). 
DNA fragments were separated by agarose gel electrophoresis, and banding profiles 
compared between isolates. Figure 4.25 shows an example of the banding patterns obtain in 
an ERIC gel.  
 
Figure 4.25: ERIC gel example 
The sizes of DNA fragments were recorded and assigned to bins to allow the different isolates 
to be compared. In total 13 bands were detected, ranging in size from (250 – 10,000) bp and 
identified as A to M in order of size. The number of bands for each isolate varied between 1 
and 6, with 19 isolates not having any bands. The presence of a band in an isolate was 
recorded as 1, whereas its absence was denoted by 0, and a binary matrix was constructed in 
Excel for further analysis using the phylogenetic analysis programme PAUP 4.0 (Swofford 
1998). The Nei and Li coefficient (Nei & Li 1979) was calculated from the matrix and used as 
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a genetic distance to construct a UPGMA dendrogram in PAUP 4.0 (Figure 4.26). 
      
Figure 4.26: UPGMA dendrogram of ERIC profiles for Escherichia coli isolates 
The 13 ERIC bands identified 18 main groups A to S at the 60% or above similarity level. Sub-
groups were present within the main groups. The bands that defined each of these sub-
groups are shown in Table 4.12. Variation within each sub-group existed where additional 
bands were observed. DNA from isolates that failed to amplify any bands were omitted from 
this analysis. Group O contained 29 isolates and group J had 25, but both of these groups had 
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considerable variation in banding profiles, generating 4 and 5 sub-groups respectively. The 
small number of bands generated meant that some sub-groups (B2, D2, G1, H2, J4, P1, Q3) 
and groups (C, S, T) were formed by the presence of a single band. This is not ideal. In order 
to confirm the presence of clonal groups, a CHEF-PFGE analysis of the isolates was performed. 
DNA plugs from 243 isolates were prepared and digested with Xha I restriction enzymes. The 
plugs were loaded into 1% w/v agarose gels and electrophoresed at 6V/cm. Figure 4.27 shows 
an example of banding patterns obtained by PFGE. The Xha I banding patterns observed 
generated 20 groups (A to U) (Figure 4.28). Groups A to C were formed at 55% similarity, while 
the rest were formed below this. Variation existed within each group and it is possible to form 
many more groups at greater levels of similarity. This is consistent with the CHEF-PFGE 
technique having greater discriminatory power. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27: PFGE gel example 
 
 
Lane Sample 
L Ladder 
1 MB1500951 
2 MB1500890 
3 MB1500888 
4 MB1500955 
5 MB1500949 
6 MB1500925 
L Ladder 
7 MB1500872 
8 MB1500918 
9 MB1500922 
10 MB1500947 
11 MB1500915 
12 MB1500819 
L Ladder 
L      1       2      3       4      5      6       L       7      8      9      10     11    12    L 
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Table 4.12: E.coli ERIC Groups with similar or identical banding profiles and their pre-dominant bands 
Isolates Group Bands Strains Groups Bands 
144, 157, 155, 145, 109, 169, 
56, 126, 173, 195, 156, 182 
A1 A 
(19) 
H, L 150, 151, 152, 45a, 165a, 123, 211, 
53, 214, 151a, 185a, 221, B23, B32 
 
L 
 
L 
(14) 
G, J 
57, 64, 160, 162, 159 A2 H, J, K 158, B4, 55 M 
 
M 
(3) 
D, J 
110, 189 A3 H, K, M C6, B5, 126a, 80, 31a, C3, 125, 177 
 
N 
 
N 
(9) 
H, I 
107, 188,     178, 178a, 84, 215, B34, 32a, B20, 
198a 
 
O1 O 
(29) 
C, D, F, G, H, 
I 
25    B36, B35, D9, 4, 184 
 
O2 D, F, G, H, I 
149, 166, 174, 191, 176, 198, 
132 
B1 B 
(9) 
G, K 33a, 195a, 21F, B17, 82 
 
O3
  
D, F, G, I 
129, 189 B2 K 37a, 188a, B8, 196a, B26, B27, 130, 
B30, C4, 7a, 122 
 
O4 D, I 
B13, 58, B22, 147, 104, 167, 
131a,  
C1 C 
(13) 
E D3, 37, 23, 49, 70, 58a, 48, 47, 44, 
46, 90, F8, 66, 128 
 
P1 P 
(22) 
D 
67, 134, 2, 131, 12, 38 C2 E 17, 21, 15, 10, 7, 18, 20, 11 
 
P2 D, E 
3a, 217, 24, 116, 115, 143, 
136  
D1 D 
(9) 
E, L B24, 11a, 13a, 119, 7F 
 
Q1 Q 
(13) 
D, H 
65, 124 D2 L 35, 4F, B12, B21 
 
Q2 D, H, I 
10a, 212, 189a, 67a, 175a, 73 E1 E 
(16) 
E, G, H, J, 
L 
27a, 148, 106, 187 
 
Q3 H 
92, D5, C2 E2 F, H, J 9a, 1, 94a, 83, 84a, 22, B33 
 
R1 R 
(10) 
D, E, F, I 
138, 66a, 104a, 135, 197 E3 H, J 5F, 222, 91 
 
R2 E, I 
94, 95 E4 F, J 121, 194, 19, 72, 176a 
 
S S 
(5) 
I 
139, 149a, B18, 74 F F 
(4) 
B, F 51, 33, 32, 39, 127, 154 
 
T T 
(6) 
M 
71, 90a, 8a, 36, B3, 68a, 59 G1 G 
(14) 
F     
78, 79, 6, B7, 173a, B9, 183a G2 F, G     
C5, 9, 219, 34a,  H1 H 
(7) 
A, F, H     
142, 144a, 152a H2 A     
137a, B28, 2F, 86a,   J1 J 
 
(25) 
A, C, G, H     
218, 143a, 82a J2 C, G, H     
D7, B6, 64a, D1, 206, B2 J3 C, H     
201, 81, 5, 201a, 80a, 197b, 
75, 107a 
J4 C     
D4, 182a, 96, 97 J5 C, I     
185, 183, 192, 196, 181, D8 K1 K 
(11) 
C, E, J, L     
62, 165, 61, 52, 63 K2 C, J     
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Figure 4.28: UPGMA Dendrogram of Xha I restriction pattern of E.coli isolates 
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4.8 Genotyping of Klebsiella pneumoniae isolates by ERIC and PFGE  
DNA was extracted from 64 K. pneumoniae isolates, and amplified using primers ERIC 1 and 
ERIC 2. The amplified products were separated in a 1% w/v agarose gel and the size of the 
fragments generated from each isolate noted. Amplified fragments were binned according to 
size generating 13 fragments, labelled A to M, that were used for comparison. A 0-1 binary 
data matrix was constructed in Excel and a UPGMA dendrogram plotted in PAUP 4.0 using the 
Nei-Li coefficient as the genetic distance (Figure 4.29). The UPGMA dendrogram (Figure 4.29) 
generated 7 main groups (A to G), with sub-groups determined for groups A, B, C, D and F. 
The pre-dominant bands defining each group and sub-group are given in Table 4.13. The 
number of bands defining each group and sub-group varied from 1 to 4. DNA from isolates of 
group E amplified no bands. It is, therefore, unclear whether these isolates share any 
relationship. Group F had 25 members, split into three sub-groups, while group A had ten 
members, split into three sub-groups. Over half of the isolates that generated a banding 
profile fell into these groups.  
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Figure 4.29: UPGMA Dendrogram showing groups for Klebsiella pneumoniae isolates based on ERIC profiles. 
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Table 4.13:K. pneumoniae ERIC groups with similar or identical banding profiles and their pre-dominant 
bands 
Strains Groups Bands 
186, 9F, 145, 163, 6F A1 A 
(10) 
F, G, K 
209, 12F A2 D, K, F 
20F, D2, 18F A3 E, F, G, K 
121, 13F B1 B 
(4) 
E, F 
150, 19F B2 E, I 
85, 216, 22F, 199, C1 C1 C 
(7) 
E, G 
146a, D6 C2 E, J 
B16, 22 D1 D 
(9) 
H 
101, 170 D2 H, I 
154, 29, 88 D3 F, H 
D10, 14, 125, 54, 158, 5, 179 E E 
(7) 
 
69, 142, 120, 123, 190, 6, 200, 105, 113, 194 F1 F 
(25) 
L 
146, 193, 114, 148, 118, 161 F2 K, L 
93, 100, 91, 50, 92, 203, 133, 99, 42 F3 K 
220, 10F, 36, 89 G G 
(4) 
J 
 
 
CHEF-PFGE plugs were prepared for 49 K.pneumoniae isolates and digested with Xha I, and 
the DNA fragments were separated by electrophoresis at 6V/cm for 19 hours in 1% w/v 
agarose gels.  The restriction profiles were compared and a UPGMA dendrogram produced 
using PAUP 4.0 software (Figure 4.30). The restriction profiles broadly recognised 8 groups, A 
to H, with some forming sub-groups. Isolates in group A clearly have identical, or similar, 
restriction profiles, especially those in sub-groups A1 and A2, indicative of a clonal group. All 
of these isolates belonged to ERIC group F, although matching these to sub-groups was 
inconsistent. This is perhaps unsurprising when it is considered that the ERIC groups are 
defined by the presence of a single band. 
Thus the ERIC and PFGE techniques identified groups with a potentially clonal origin, with the 
PFGE technique having the greater discriminatory power. 
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Figure 4.30: K. pneumoniae isolates Xha 1 restriction PFGE profiles and dendrogram 
4.9 Conclusions 
The results from PCR on isolates from ESBL infections in the Saudi Aramco Dhahran Health 
Center show that CTX-M was the most prevalent resistance determinant in both 2010 and 
2012, however there was a significant change in distribution over the period of the study. 
While CTX-M was present alone or in combination with TEM and/or SHV in 49.2% of isolates 
in 2010, this had risen to 84.7% in 2012. This is relatively consistent with results from a 
previous study on 84 E. coli and 16 K. pneumoniae isolates carried out at the Saudi Aramco 
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Dhahran Health Center which showed that CTX-M was the most prevalent ESBL resistance 
determinant, present in 71% of isolates (Bindayna et al., 2010). Distribution of resistance 
determinants in the current study did not appear to vary according to gender, age group or 
in-patient/out-patient status, unlike in the previous study where the blaCTX-M gene was 
present in a significantly higher proportion of out-patients compared to in-patients (Bindayna 
et al., 2010). Thus CTX-M was the dominant resistance determinant in both hospital and 
community settings in the Eastern Province of Saudi Arabia in the current study. This 
increasing prevalence of CTX-M, in particular the CTX-M-15 type, was also observed in recent 
studies from a tertiary hospital in Riyadh on both K. pneumoniae (Al-Qahtani et al., 2014) and 
E. coli (Al-Agamy et al., 2014). In the K. pneumoniae study, ESBL prevalence was 37.75% 
among 98 K. pneumoniae isolates (Al-Qahtani et al., 2014). Unlike the results of the current 
study, 91.9% of these were positive for blaSHV genes, however CTX-M genes prevalence was 
also high at 86.5%, with CTX-M-15 dominant (Al-Qahtani et al., 2014). In 152 E. coli isolates, 
ESBL overall prevalence was 20.39%, with 30 of 31 isolates positive for CTX-M-15 (Al-Agamy 
et al., 2014). The ERIC and PFGE techniques identified groups with a potentially clonal origin, 
with the PFGE being more discriminatory. 
The CTX-M-only genotype was the most prevalent in ESBL infections, at 35.0% of isolates in 
2010 and 41.6% of isolates in 2012. However, while the second most common genotype in 
2010 was TEM-only at 30.6% isolates, this had fallen to 5.4% in 2012. The second most 
common pattern in 2012 was instead CTX-M +TEM at 27.7% of isolates, up from 12% in 2010, 
then CTX-M + TEM + SHV at 10.4% of isolates, compared to 1.1% in 2010. The CTX-M +SHV 
combination increased from 1.1% in 2010 to 5.0% in 2012. Thus, CTX-M in a combination with 
TEM and/or SHV increased significantly in 2012 compared to 2010. Results of microarray MDR 
analysis revealed that the most prevalent CTX-M subtype, alone or in combination with other 
ESBL genes, was type 15 (61.6%), followed by CTX-M9 (8.2%).Thus results are consistent with 
other studies in which the CTX-M ESBL types, in particular CTX-M-15, have become dominant 
over TEM and SHV worldwide (Sections 1.6.4 and 1.7) (Al-Agamy et al., 2014; Arnaud et al., 
2015; Baraniak et al., 2013; Brolund et al., 2014; Burke et al., 2012; Cantón & Coque, 2006; 
Castanheira et al., 2013; Coque et al., 2008; Denisuik et al., 2013; Galas et al., 2008; Hansen 
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et al., 2012; Horner et al., 2013, 2014; Huemer et al., 2011; Morris et al., 2009; Mshana et al., 
2013a; Naseer et al., 2009; Ndugulile et al., 2005; Nicolas-Chanoine et al., 2012;  Nyberg et 
al., 2007; Rafaï et al., 2015; Ruppe et al., 2012; Seki et al., 2013; Valenza et al., 2014; 
Wickramasinghe et al., 2012; Woerther et al., 2013; Yano et al., 2013; Zamani et al., 2015; 
Zong et al., 2008; Zowawi et al., 2013).  
When considered in terms of different bacterial species, there were differences in particular 
between the two predominant species, E. coli and K. pneumoniae, and the profile for both 
species changed between 2010 and 2012. For K. pneumoniae TEM-only fell from the 
predominant profile at 52% in 2010 to zero in 2012, while for E. coli it fell from 25.4% in 2010 
to 4.8% in 2012. CTX-M only remained relatively stable in both species, and was present in 
only 4.9% of K. pneumoniae isolates compared to 54.4% for E. coli, but the expression of CTX-
M in combination with either TEM and/or SHV rose significantly for both species by 2012. 
Most notable was the increase in CTX-M+TEM+SHV from 8% in 2010 for K. pneumoniae to 
43.9% in 2012, making it the new dominant profile. Thus while prevalence of CTX-M only 
expression remained low in K. pneumoniae, the phenomenon of increased CTX-M in 
combination with TEM and/or SHV was particularly apparent for K. pneumoniae. This was 
slightly inconsistent with MDR results which showed that SHV + CTX-1,type-15 like was the 
most common profile for K. pneumoniae (26%), followed by TEM+SHV+ CTX-1,type-15 
(22.2%). However, these results still support an increase in CTX-M type 15 in K. pneumoniae 
in combination with TEM and/or SHV, while CTX-M1-type-15-like alone accounted for only 
two of the K. pneumoniae isolates (7.4%). 
Of carbapenemase determinants, OXA-48 was observed alone or in combination in three out 
of the 159 isolates subjected to MDR analysis, while there was no expression of KPC or NDM. 
The three OXA-48 isolates remained sensitive to the carbapenems in as far as resistance could 
be determined. In fact, there was uniformly high sensitivity to the carbapenems across all 
resistance determinants. There was also uniformly high sensitivity to the polymyxin colistin 
and to the glycylcycline tigecycline. As mentioned previously, this suggests that all of these 
antibiotics could be considered in blind treatment of ESBL infection, but with application of 
strict antibiotic stewardship principles (Alomi, 2015; Enani, 2016). For example, there is some 
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evidence that spread of CTX-M in E. coli may provide favourable conditions for spread of 
carbapenemase resistance (Lartigue et al., 2007). There is also recent evidence to suggest 
emergence of concerning levels of OXA-48 and NDM carbapenemase-producing K. 
pneumoniae in Jordan (Aqel et al., 2016). Also, plasmids carrying ESBL genes often also 
harbour resistance genes to other unrelated classes of antimicrobials (Livermore & 
Woodford, 2006; Paterson and Bonomo, 2005). A recent global surveillance study on 19,719 
Enterobacteriaceae isolates collected during 2012 and 2013 suggested a trend for lower 
susceptibility to colisitin in the presence of carbapenemase-producing bacteria (Bradford et 
al., 2016). Furthermore, while results from the Tigecycline Evaluation and Surveillance Trial 
(T.E.S.T.) (Tärnberg et al., 2016), and the SENTRY Antimicrobial Surveillance Program (2011–
2014) (Sader et al., 2016) suggest that sensitivity of Enterobacteriaceae to tigecycline remains 
high, resistance to tigecycline can be acquired, for example via RND-type transporters. Given 
the changing profiles of resistance determinants in this study, it is important to be vigilant as 
this suggests that there may be cross-species horizontal transfer of resistance determinants, 
with the potential for the mobile genetic elements to carry resistance determinants to other 
antibiotics along with the ESBL genes. 
The -lactams ampicillin/sulbactam (AMS), ceftazidime (CAZ), ceftriaxone (CRO, cefazolin (CZ) 
and cefepimine (FEP) would be inappropriate choices regardless of resistance determinant. 
Likewise trimethoprim/sulfamethoxazole (SXT) did not emerge as an appropriate choice for 
any resistance determinants. This is consistent with the fact that plasmids carrying ESBL genes 
often also carry resistance genes to aminoglycosides and to SXT (Livermore & Woodford, 
2006; Paterson and Bonomo, 2005). The fluoroquinolone ciprofloxacin (CIP) was similarly 
generally ineffective. This is consistent with the fact that, for example, some CTX-M β-
lactamases are associated with co-expression of different plasmid-mediated quinolone 
resistance (PMQR) determinants, such as the qnr genes for QnrA, QnrS and QnrB (Robicsek 
et al., 2006). Presence of these genes would render Enterobacteriaceae resistant to 
ciprofloxacin (Yang et al., 2014). In general, the increasing dominance of CTX-M ESBLs has 
probably been further fuelled by the phenomenon of co-resistance to other antibiotic types, 
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including aminoglycosides and fluoroquinolones, often found in CTX-M-expressing organisms 
(Cantón et al., 2012; Cantón & Ruiz-Garbajosa, 2011; Morosini et al., 2006).  
In terms of other antibiotic resistance, CTX-M-expressing isolates, including those expressing 
CTX-M type 15 with TEM and/or SHV or expressing CTX-M-9, had relatively high sensitivity to 
the second generation cephalosporin cefoxitin (FOX), making this a possible antibiotic for CTX-
M-expressing infections. It was more difficult to draw clear conclusions for CTX-M-1 or CTX-
M-2 isolates, as there were few isolates of each in the MDR sample group. FOX could also be 
considered for SHV only isolates, but the PCR data would suggest not for TEM isolates.  
Another antibiotic that could be considered for isolates expressing CTX-M type 15 in 
combination with TEM and/or SHV, and for CTX-M-9 isolates is amikacin, although somewhat 
paradoxically both PCR and MDR data indicate that it appears to be less effective for CTX-M 
–type 15 only isolates. While PCR data suggested that amikacin would also be effective against 
TEM-only isolates, the MDR data suggested otherwise, although there were only three TEM-
only isolates in the MDR sample group, making it difficult to draw firm conclusions. Amikacin 
also appears to be an effective choice for SHV-only isolates.  
Both PCR and MDR data suggested that nitrofurantoin (FD) could also be cautiously 
considered for isolates expressing CTX-M-1 type 15- only or CTX-M-9, and for CTX-M-1 type 
15 in combination with TEM isolates, but not with CTX-M –type 15+TEM+SHV isolates. It 
would also be likely to be effective for SHV-only but not TEM-only isolates. Thus overall FD 
would be considered sub-optimal, similarly to conclusions in the previous study from the 
Saudi Aramco Dhahran Health Center (Bindayna et al., 2010). For CTX-M-9 isolates, there was 
90.9% prevalence of sensitivity to GM, suggesting another alternative blind treatment option, 
although GM did not emerge as a suitable candidate for isolates with the other MDR profiles, 
consistent with the frequent co-expression of genes for aminoglycoside resistance on 
plasmids carrying ESBL genes, for example the novel aminoglycoside-modifying enzyme 
encoded by the aac(6′)-Ib-cr gene, which can also modify some fluoroquinolones (Livermore 
& Woodford, 2006; Paterson and Bonomo, 2005; Robicsek et al., 2006).  
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5.0 Discussion 
The rise of multi-drug resistant bacteria, including ESBL-expressing bacteria, is an on-going 
public health crisis, both in Saudi Arabia and the GCC region generally, and worldwide. There 
has been a lack of progress in bringing new antibiotic drugs to the market, with only two new 
antibiotic classes- active against Gram-positive bacteria- coming online in the last fifteen 
years, along with analogues of existing drugs (Coates et al., 2011). Thus there is still over-
reliance on empiric use of ‘broad spectrum’ antibiotics such as the cephalosporins, as well as 
non--lactam drugs such as gentamicin, in treatment of Gram-negative bacterial infections, 
for example with Enterobacteriaceae species, in spite of the ever-increasing expression of 
ESBL genes, often on mobile genetic elements such as plasmids that frequently carry 
resistance genes to other antibiotics including aminoglycosides, SXT or quinolones (Livermore 
& Woodford, 2006; Paterson and Bonomo, 2005; Robicsek et al., 2006; Yang et al., 2014). 
ESBL infections are associated with high morbidity and mortality compared to non-ESBL 
infections, particularly in more vulnerable patients such as neonates (de Kraker et al., 2011; 
Kayange et al., 2010; Melzer & Petersen, 2007). In fact, spread of ESBLs has a major negative 
impact on healthcare systems worldwide, being associated with poor patient outcomes, 
including longer hospital stays, more frequent readmissions, more severe illness and 
increased mortality, inadequate initial treatment and prolonged treatment, and additional 
nursing care needs (Esteve-Palau et al., 2015; Garner et al., 2015; Lee t al., 2006; MacVane et 
al., 2014b; Melzer & Petersen, 2007; Ndir et al., 2016; Tumbarello et al., 2010; WHO, 2011, 
2014). Analyses suggest that infection with cephalosporin-resistant Enterobacteriaceae 
species has a similar negative impact on patient outcomes such as hospital length of stay and 
mortality, as well as on associated healthcare costs as, for example, Methicillin-Resistant 
Staphylococcus aureus (MRSA) infection (Cosgrove, 2006). Early identification of bacterial 
species and antibiotic sensitivity patterns are essential in reduction of poor ESBL-associated 
patient outcomes and reduction of continuing emergence of MDR bacterial strains. In this 
study, the pattern of ESBL-positive bacterial strains emerging in the Saudi Aramco Dhahran 
Health Center in the Eastern Province of Saudi Arabia was compared for two patient cohorts 
between 2010 and 2012. 
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Findings generated from this study reveal that the prevalence of ESBL-producing bacteria has 
risen in the Saudi Aramco Dhahran Health Center over the two year cohorts that were studied. 
By contrast, a fall in both AmpC and ESBL/AmpC dual resistance numbers and relative 
prevalence for each age group was observed. Low levels of AmpC expression were observed 
in the 2012 cohort, suggesting that AmpC production was being detected and treated 
appropriately by 2012.  
Female gender and increasing age, particularly in males, were risk factors for ESBL infection. 
Increased susceptibility to ESBL infection with increasing age is consistent with observations 
in other studies (Auer et al., 2010; Mumtaz et al., 2007; Tham et al., 2013). Being over 60 
years of age has been associated with increased ESBL-positive infection prevalence, and 
increasing age has been identified as a risk factor for ESBL infection susceptibility (Mumtaz et 
al., 2007). Recent meta-analyses suggest that the prevalence of ESBL-positive UTIs is also 
increasing in the paediatric population (Flokas et al., 2016). The results of the study herein 
suggest that despite the increased risk with age, ESBL-positive infections occur in a wide 
patient age range. In our study, there was a significant difference in the distribution of ages 
between males and females, with a significantly higher proportion of males being over 80 
years old. This suggests that in the Eastern Province of Saudi Arabia, increasing age places 
males at particular risk of ESBL-positive infections.  
Female patients were at overall higher risk of ESBL-positive infections compared to males, 
consistent with results of other studies (Lee et al., 2010; Wani et al., 2009). This increased 
susceptibility of females was related to the preponderance of UTIs overall, which were the 
most common site of infection, and to which females are physiologically more susceptible. 
Approximately half of the female population can expect to experience a UTI within their 
lifetime (Foxman, 2003). By contrast, the majority of systemic infections detected by BLC, 
which was the second most common type of sample in both cohorts, occurred in males in 
both 2010 and 2012. Thus, although female patients are at an increased risk of UTIs, ESBL-
positive infections can affect either gender, and males may be at higher risk than females of 
ESBL-systemic infections. 
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Most infections were detected in patients from an out-patient setting, suggesting the 
significant risk of contracting ESBL infections in the community in the Eastern Province of 
Saudi Arabia. There was no discernible change in this trend between 2010 and 2012.  
E. coli was the predominant bacterial species in both 2010 and 2012, followed by K. 
pneumoniae. The dominance of E. coli is consistent with other studies both locally and 
internationally, and with the fact that E.coli is the most common cause of UTIs, as well as 
being responsible for many systemic infections (Bindayna et al., 2010; Briongos‐Figuero et al., 
2012; Foxman, 2010; Khanfar et al., 2009; Picozzi et al., 2014). E.coli forms a large proportion 
of normal human intestinal microbiota, thus individuals are at risk of carriage of ESBL 
producing E.coli as part of their normal flora. Prevalence of K. pneumoniae increased 
significantly between 2010 and 2012 and prevalence of E. cloacae fell significantly. This is 
consistent with increases in the prevalence of ESBL-positive K. pneumoniae elsewhere in 
Saudi Arabia (Ahmad et al., 2009; Al-Agamy et al., 2009; Al-Qahtani et al., 2014). The increase 
in K. pneumoniae was mainly attributable to increased prevalence in males, as the distribution 
of bacterial species did not change significantly for females between 2010 and 2012. By 
contrast, the distribution for males changed substantially, with E. coli and E. cloacae 
prevalence both falling significantly, although E. coli remained the dominant species at 58% 
in males, and K. pneumoniae increased signficantly from 10.2% to 30.4%. This increased 
susceptibility to K. pneumoniae infection for males versus females has also been observed in 
studies from some other countries, particularly among older males (Esmin-Akter et al., 2013; 
Janda & Abbott, 2006; Public Health Agency of Canada, 2011). Increased prevalence of ESBL-
positive K. pneumoniae is of particular concern in the context of the increased occurrence of 
carbapenemase-producing enzymes in K. pneumoniae, including in studies on outbreaks in 
Saudi Arabia (Shibl et al., 2013; uz Zaman et al., 2014).  
Of particular concern in this study was the reduced sensitivity to a range of cephalosporin 
antibiotics for ESBL-positive infections in patients in the Saudi Aramco Dhahran Health Center. 
Levels of resistance to the first generation cephalosporin cefazolin and the third-generation 
cephalosporin ceftriaxone was between 70 and 100% in both 2010 and 2012. Meanwhile, 
sensitivity to another third-generation cephalosporin, ceftazidime (CAZ), already low in 2010, 
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fell between 2010 and 2012. This reduction in CAZ resistance is consistent with other studies 
(Cantón et al., 2011; Kumar et al., 2014). Prevalence of sensitivity of E. coli and K. pneumoniae 
to the fourth-generation cephalosporin, cefepime also fell sharply between 2010 and 2012. 
Thus none of these cephalosporins should be considered as blind treatments for cases where 
ESBL infections are suspected. Prevalence of sensitivity to the second generation 
cephalosporin cefoxitin was relatively high between 2010 and 2012, mainly due to sensitivity 
of E. coli and K. pneumoniae. By contrast, both E. cloacae and E. aerogenes isolates were 
uniformly resistant to this drug. Thus cefoxitin might be cautiously considered as a treatment 
for E. coli and K. pneumoniae infections, but not for E. cloacae and E. aerogenes. For -lactams 
other than the cephalosporins, there was also overall low sensitivity to ampicillin/sulbactam 
(AMS). This low sensitivity to AMS and most of the cephalosporins could be attributable to a 
number of factors, such as cross-species horizontal transfer of resistance determinants, cross-
resistance due to previous antibiotic use and over-prescription of some antibiotics. 
By contrast to the cephalosporins and AMS, there was overall high sensitivity to the three 
carbapenemases tested, namely meropenem, ertapenem and imipenem. Indeed, 100% of all 
isolates were sensitive to ertapenem in both 2010 and 2012. These results imply that 
antibiotic stewardship is succeeding in maintaining significant sensitivity to carbapenem 
antibiotics in the Saudi Aramco Dhahran Health Center. This is important to maintain in the 
face of increasing levels of carbapenem-resistant infections attributable to, for example, OXA-
48, NDM and KPN expression in Enterobacteriaceae, and OXA-23 and OXA-51 in A. baumannii, 
both in Saudi Arabia and in other countries in the region (Alyamani et al., 2015; Aqel et al., 
2016; Balkhy et al., 2016; Shibl et al., 2013; uz Zaman et al., 2014). In this study, microarray 
analysis revealed the presence of OXA-48 expression, alone or in combination, in three 
isolates. However, these isolates were sensitive to the carbapenems. There was no NDM, or 
KPC detected in either the 2010 or 2012 cohorts. Nevertheless, the presence of OXA-48 in 
some isolates further highlights the necessity for vigilance in guarding against the rise of 
carabepenem resistance.  
In terms of the seven non--lactam antibiotics tested, there was variation in sensitivity of the 
different organisms depending on the antibiotic. There was overall 100% sensitivity to the 
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polymyxin colistin and to the glycylcycline tigecycline, consistent with experience both 
internationally and within Saudi Arabia (Al-Agamy et al., 2014; Al-Qahtani et al., 2014; Alomi, 
2015; Enani, 2016; Sader et al., 2016). It is important that while both of these antibiotics could 
be considered in treatment of ESBL-positive infections, this needs to be guided by the 
principles of antibiotic stewardship (Alomi, 2015; Enani, 2016). ESBL-carrying plasmids often 
carry resistance genes to other unrelated classes of antimicrobials (Livermore & Woodford, 
2006; Paterson and Bonomo, 2005). Results of a recent global surveillance study on 19,719 
Enterobacteriaceae isolates suggested that sensitivity to colisitin can be compromised in the 
presence of carbapenemase-producing bacteria (Bradford et al., 2016). Furthermore, while 
trial results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) (Tärnberg et al., 
2016), and the SENTRY Antimicrobial Surveillance Program (2011–2014) (Sader et al., 2016) 
have shown continuting high sensitivity of Enterobacteriaceae to tigecycline, resistance to this 
antibiotic can be acquired, for example via RND-type transporters. Tigecycline has been 
approved by the US Food and Drug Administration (FDA) for the treatment of complicated 
infections such as skin and soft-tissue and intra-abdominal infections, and for community-
acquired bacterial respiratory infections (Pournaras et al., 2016). The results of this study are 
therefore consistent with international experience with colistin and tigecycline sensitivity. 
For the other non--lactams tested, sensitivity to the aminoglycoside amikacin varied 
depending on bacterial species. E. coli sensitivity fell between 2010 and 2012, while sensitivity 
of K. pneumoniae, E. cloacae and E. aerogenes remained relatively high. Thus amikacin could 
be considered as a blind treatment for K. pneumoniae, E. cloacae and E. aerogenes but not E. 
coli. The other aminoglycoside, gentamicin (GM), did not emerge as an appropriate treatment 
choice for any of the bacterial species. By contrast, E. coli sensitivity to the nitrofuran, 
nitrofurantoin, remained relatively high, while it fell for K. pneumoniae, E. cloacae and E. 
aerogenes, suggesting this antibiotic should be cautiously considered for E. coli only. These 
results highlight the need to efficiently identify the bacterial species responsible for infections 
as early as possible in determining appropriate treatments. Neither the fluoroquinolone 
ciprofloxacin, nor the combination drug trimethoprim/sulfamethoxazole, (SXT), emerged as 
appropriate treatment choices. These results are consistent with carriage of resistance genes 
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to aminoglycosides, SXT or quinolones on plasmids carrying ESBL (Livermore & Woodford, 
2006; Paterson and Bonomo, 2005; Robicsek et al., 2006; Yang et al., 2014).  
Thus while the carbapenems meropenem, ertapenem and imipenem, tigecycline, colistin, and 
in more limited circumstances cefoxitin, amikacin or nitrofurantoin, could all be considered 
as effective treatment options for ESBL-positive bacteria, strict antibiotic stewardship 
principles are essential. Over-use of broad-spectrum antibiotics should be avoided and most 
cephalosporins are currently ineffective. Reduction in use of cepahlosporins and of non--
lactams to which there is currently low sensitivity among ESBL-positive organisms, such as 
ciprofloxacin, trimethoprim/sulfamethoxazole or gentamicin, may help reduce the 
prevalence of resistance to these drugs. A recent survey of antimicrobial stewardship 
programs (ASP) currently operative in GCC states showed a significant reduction in use of 
broad spectrum antibiotic use, hospital-acquired infection, inappropriate prescribing and 
antimicrobial resistance in hospitals where ASPs have been implemented (Enani, 2016).  
The GCC Antimicrobial Resistance (AMR) Strategic Plan centres around five key elements, 
namely: 1. Developing an understanding of the extent of the issue of AMR in the GCC 
countries in both humans and animals and in agriculture/environment; 2. Preservation of the 
available and limited effective antimicrobials for human use; 3. Developing the ability to 
quickly recognise and identify emerging MDR organisms; 4. Limiting the spread of resistant 
organisms via patients, animals and agriculture; and 5. Encouraging collaborative research 
efforts in the MDR field (Balkhy et al., 2016). These elements require input from stakeholders 
such as legislators, healthcare workers including prescribers, researchers and patients. This 
study should contribute in particular to elements 1 to 3. In 2013, the National Antibiotic 
Stewardship Program was established in Saudi Arabia and was rolled out to encompass over 
ten regions and forty hospitals. Expansion to further regions and hospitals should be a 
significant driver in reduction of antibiotic consumption and promotion of other principles of 
antibiotic stewardship in participating hospitals (Alomi, 2015). The results of the study herein 
suggest that in the Saudi Aramco Dhahran Health Center, benefit would be derived from 
applying- and frequently reviewing- prescribing policies which allow for rotation of 
antibiotics, and reduction of overprescribing. Effective infection prevention and control 
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measures, for example in the areas of surveillance and reporting standards, readiness and 
competence to implement policies and respond to outbreaks, staff training, hospital 
infrastructure and design, and hygiene standards would also be of benefit in limiting 
outbreaks and responding effectively in the event of an outbreak involving ESBL-positive 
organisms. 
Molecular analyses revealed that, consistent with international experience, CTX-M was the 
most prevalent resistance determinant in both 2010 and 2012, in the Saudi Aramco Dhahran 
Health Center. This dominance of CTX-M is consistent with results from a previous study at 
the Saudi Aramco Dhahran Health Center on E. coli and K. pneumoniae isolates (Bindayna et 
al., 2010). A significant shift in distribution occurred between 2010 and 2012, with CTX-M 
expression alone or in combination with TEM and/or SHV rising from 49.2% to 84.7%. 
Distribution of resistance determinants did not vary according to gender, age group or in-
patient/out-patient status, in contrast to the previous study, where the blaCTX-M gene was 
present in a significantly higher proportion of out-patients than in-patients (Bindayna et al., 
2010). Thus CTX-M was the dominant resistance determinant in both hospital and community 
settings in the Eastern Province of Saudi Arabia in the current study. Increased prevalence of 
CTX-M, in particular CTX-M-15, has also been observed in recent studies from other parts of 
Saudi Arabia, including in a tertiary hospital in Riyadh, in both K. pneumoniae (Al-Qahtani et 
al., 2014) and E. coli (Al-Agamy et al., 2014). A recent study in another Riyadh hospital also 
indicated that most ESBL-positive E. coli and K. pneumoniae isolates were CTX-M expressing, 
from the CTX-M-1, CTX-M-9 and CTX-M-25 clusters (Somily et al., 2015). However, there were 
some differences in the expression patterns revealed in the study herein compared to the 
Riyadh studies. For example, in K. pneumoniae in one Riyadh study, 91.9% of ESBL-positive 
isolates expressed blaSHV genes (Al-Qahtani et al., 2014). In our study there was relatively low 
overall expression of SHV, at only 4.4% of isolates in 2010, either alone or in combination with 
CTX-M and/or TEM, and 17.9% in 2012, with the majority in combination with CTX-M and/or 
TEM. In K. pneumoniae specifically, SHV was present alone or in combination in a higher 
proportion of isolates- 49.9% over the whole period of the study- but still substantially lower 
than in the Riyadh study. Expression levels of TEM changed significantly between 2010 and 
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2012, particularly in K. pneumoniae, where expression of TEM-only fell from the predominant 
profile in 2010 to zero in 2012. 
Microarray analysis performed as a pilot study on isolates from 159 patients shed further light 
on the CTX-M subtypes that dominated, and could be used to identify, for example, CTX-M-
1, CTX-M1-type-15, CTX-M-2 and CTX-M-9, as well as detecting AmpC genes including blaDHA-
1 and blaCMY-II and carbapenemase genes such as blaOXA-48. Consistent with international 
experience, the most prevalent CTX-M subtype, alone or in combination with other ESBL 
genes, was type 15-like (Al-Agamy et al., 2014; Arnaud et al., 2015; Baraniak et al., 2013; 
Brolund et al., 2014; Burke et al., 2012; Cantón & Coque, 2006; Castanheira et al., 2013; Coque 
et al., 2008; Denisuik et al., 2013; Galas et al., 2008; Hansen et al., 2012; Horner et al., 2013, 
2014; Huemer et al., 2011; Morris et al., 2009; Mshana et al., 2013a; Naseer et al., 2009; 
Ndugulile et al., 2005; Nicolas-Chanoine et al., 2012;  Nyberg et al., 2007; Rafaï et al., 2015; 
Ruppe et al., 2012; Seki et al., 2013; Valenza et al., 2014; Wickramasinghe et al., 2012; 
Woerther et al., 2013; Yano et al., 2013; Zamani et al., 2015; Zong et al., 2008; Zowawi et al., 
2013). CTX-M9 was the second most common CTX-M subtype, but this genotype was 
observed only in E. coli isolates. The prevalence of CTX-M-15 is consistent with results 
observed in studies in other parts of Saudi Arabia, for both E. coli and K. pneumoniae (Al-
Agamy et al., 2014; Al-Qahtani et al., 2014). However, the results obtained for K. pneumoniae 
were slightly inconsistent with PCR results. While the PCR results indicated that CTX-
M+TEM+SHV was the dominant K. pneumoniae profile by 2012, MDR results indicated that 
SHV + CTX-M-1,type-15 like was the most common, with TEM+SHV+ CTX-M-1,type-15 next. 
However, results from both methodologies suggested that while CTX-M-15 on its own was 
relatively rare in K. pneumoniae isolates from the Saudi Aramco Dhahran Health Center, there 
was a marked increase in prevalence of CTX-M in combination with TEM and/or SHV between 
2010 and 2012. Results between the two methodologies were more consistent for E. coli, with 
MDR analysis indicating that CTX-M-only, of either subtype 15, 9, 1 or 2, was present alone in 
57% of isolates, while CTX-M-only was similarly the dominant profile indicated by PCR for E. 
coli, present in 54.4% of isolates in 2012. 
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When antibiotic susceptibility was considered for different resistance determinants, subtle 
differences were evident. The -lactams ampicillin/sulbactam (AMS), ceftazidime (CAZ), 
ceftriaxone (CRO), cefazolin (CZ) and cefepimine (FEP) all emerged inappropriate choices 
regardless of resistance determinant, consistent with phenotyping data. Likewise 
trimethoprim/sulfamethoxazole (SXT) or ciprofloxacin did not emerge as an appropriate 
choice for any resistance determinants, consistent with the fact that plasmids carrying ESBL 
genes often also carry resistance genes to aminoglycosides, SXT and quinones (Livermore & 
Woodford, 2006; Paterson and Bonomo, 2005; Robicsek et al., 2006; Yang et al., 2014). In 
fact, evidence suggests that the increasing worldwide dominance of CTX-M ESBLs, also 
observed in the study herein, has probably been enhanced by co-resistance to other antibiotic 
types (Cantón et al., 2012; Cantón & Ruiz-Garbajosa, 2011; Morosini et al., 2006). For CTX-M-
9 isolates, gentamicin (GM) emerged as a possible blind treatment option, although not for 
isolates with the other MDR profiles. 
Cefoxitin emerged as a possible choice for CTX-M-expressing infections. Amikacin could also 
be considered for isolates expressing CTX-M type 15 in combination with TEM and/or SHV, 
and for CTX-M-9 isolates, but seemed less effective for CTX-M –type 15 only isolates. PCR and 
MDR data were conflicting on the effectiveness of amikacin for TEM-only isolates, but it was 
apparently an effective choice for SHV-only isolates. Both PCR and MDR data suggested that 
while nitrofurantoin (FD) could also be cautiously considered for some isolates, overall it 
would be considered sub-optimal, consistent with previous studies from the Saudi Aramco 
Dhahran Health Center (Bindayna et al., 2010). Regardless of resistance determinant, the 
three carbapenems imipenem (IPM) meropenem (MER) and ertapenem (ERP) were effective, 
as were colistin and tigecycline. These results demonstrate how the expression of dfferent 
resitance determinant combinations can impact significantly on effectiveness of antibiotics, 
and hence the importance of having appropriate methods available at point-of-care to 
analyse resistance determinant expression rapidly and accurately when deciding on an 
appropriate therapy. 
There were limitations in the phenotypic and genotypic methodologies used in this study, as 
highlighted when correlation between methods was performed. For phenotypic detection, 
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both of the methods used, i.e. VITEK® 2 and disk diffusion, have previously been shown to 
hav high specificity and sensitivity in identification of ESBL-producing Enterobacteriaceae 
(Poulou et al., 2014; Spanu et al., 2006). Both methods showed an increased prevalence of 
ESBL-positive infection between 2010 and 2012 in the Saudi Aramco Dhahran Health Center, 
while risk of AmpC-positive infection fell. However, the VITEK® 2 method was scored as ESBL 
positive or negative, with AmpC, or carbapenemase as suggestive results in ‘negative’ isolates, 
suggested by AES (Advanced Expert System). Thus, there was some inconsistency between 
results obtained by the two methods, particularly for isolates scored negative by VITEK® 2. In 
2010, over half of isolates scored ESBL-NEG by VITEK® 2 were scored AmpC-positive by disk 
diffusion, while the figure was 100% by 2012. There was more consistency for isolates scored 
positive by VITEK® 2, with 83.1% agreement in 2010 and 99.5% in 2012. However, in 2010, 
the remaining VITEK® 2 ESBL-positive (POS) isolates were scored NEG, AmpC or ESBL/AmpC 
by disk diffusion. This serves to highlight the usefulness of carrying out a two-step approach 
to phenotyping, for example as recommended by the HPA (HPA, 2012), and to also use a 
genotyping approach. The necessity to carry out a phenotyping test that can distinguish 
between ESBL and AmpC expression was also highlighted by these results. 
For the genotyping study, while the Multiplex PCR method used could distinguish between 
the most common ESBL genes, i.e. CTX-M, TEM and SHV, it gave no information on subtypes 
or on other genes such as the carbapenemase genes or AmpC genes. The potential 
disadvantages of this were highlighted when consistency of multiplex PCR-based genotyping 
results with phenotyping results obtained by VITEK® 2 or disk diffusion was considered. While 
there was generally consistency between positive PCR results and ESBL-positive phenotyping 
results, there was less consistency for PCR-negative results, suggesting that in a high 
proportion of the PCR-negative results there may be expression of ESBL genes other than CTX-
M, TEM or SHV, as well as possible AmpC gene expression.  
The use of MDRCT102 addressed the issue of examination of subtypes and of other types of 
resistance genes, however this was used as a pilot study herein and more analysis and testing 
is needed for this system in our laboratory, as well as further investigation to detect, for 
example, variants of TEM, and SHV. While there were some inconsistencies between the PCR 
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and MDR data, generally there was agreement ranging from moderate for isolates in which 
CTX-M was expressed in combination with TEM and/or SHV, to substantial for isolates in 
which there was a singly-expressed ESBL profile, and for isolates expressing TEM+SHV. 
The ERIC-PCR and CHEF-PFGE techniques identified groups that could have a clonal origin, 
with the CHEF-PFGE technique having the greater discriminatory power. This is unsurprising 
because the CHEF-PFGE technique generated a greater number of bands for comparison. It is 
important to be able to accurately identify clonal groups of bacteria causing infections, as 
they are the groups being currently actively spread. Routine screening of bacterial isolates for 
their genotypes allows identification of clonal groups. Arbitrary primed PCR techniques, such 
as random amplification of polymorphic DNA (RAPD) (Sabat et al., 2013) and ISSR (Abdel-
Mawgood, 2012), provide a relatively quick way to genotype bacterial strains, specially 
identifying clonal groups, however they can lead to inconsistencies and difficulties in 
reproducibility due to technical sensitivities such as choice of DNA polymerase or DNA 
template concentration. ERIC PCR gives greater consistency in banding profiles (Versalovic, 
Koeuth, & Lupski, 1991). Meanwhile, Clamped Homogenous Electric Field (CHEF)-PFGE, as 
used in this study, is the gold standard of bacterial genotyping. For this technique to identify 
clonal groups, it is important to extract the chromosomal DNA intact, so that its digest profile 
is representative of its restriction genotype. In order to facilitate this, bacterial cells are lysed 
within an agarose gel matrix, and DNA digested within this matrix. This makes the technique 
time consuming compared with PCR genotyping techniques. The measures of genetic 
diversity made by CHEF-PFGE and ERIC-PCR are not equivalent, with greater variation being 
detected using CHEF-PFGE (Casarez et al 2007; Kidd et al 2011). In this study, the ERIC-PCR 
technique generated relatively few bands for comparison, with little overlap between the 
groups. This made determining the relationship between the groups difficult using this 
technique. The E.coli and K.pneumoniae isolates represent a mixture of clonal groups and 
genetically unique strains. This is consistent with the concept that the hospital populations 
comprise strains responsible for infections obtained in the community that are genetically 
unique, and clonal strains that are being spread within the hospital. The genetic variation 
observed within some of the clonal groups may represent established lineages within 
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hospitals that have had time to diverge. The K.pneumoniae CHEF-PFGE group A is an example 
of such a group.  
The information gained from this study has the potential to help guide re-evaluation of 
prescribing and infection control policies in the Saudi Aramco Dhahran Health Center, guided 
by sound antibiotic stewardship principles, as laid down in the GCC Antimicrobial Resistance 
(AMR) Strategic Plan (Balkhy et al., 2016) and in the National Antibiotic Stewardship Program 
(Alomi, 2015). On-going evaluation of the effectiveness and accuracy of the two-step 
phenotypic methodology and of genotyping by multiplex PCR, as well as further study on the 
MDR system, will help in improving the early identification of bacterial species and antibiotic 
sensitivity patterns. This will help inform appropriate prescription choices and dosin. The 
study has also identified important epidemiological patterns, such as the increased risk in 
older men, the rise of ESBLs in an out-patient setting, and the changes in ESBL-positive K. 
pneumoniae prevalence and resistance determinant patterns. The importance of training of 
clinicians, pharmacists and other healthcare workers in the principles of antibiotic 
stewardship cannot be over-stated in the efforts to limit the rise antibiotic resistance 
observed in this hospital. In many cases internationally, there have been steps taken to team 
hospital infection control programs and antimicrobial stewardship programs to maximise the 
effectiveness of both and hence optimise impact on use of antibiotics (Sydnor & Perl, 2011). 
Thus the ASP in the hospital acts as a bridge between the microbiology laboratory, with its 
monitoring role, and clinicians, with their diagnosing and prescribing role. The establishment 
of effective screening programmes for both in-patients and out-patients, as well as for the 
healthcare workers themselves, would be of prime importance. Methods for raising public 
awareness on aspects of ESBL infections, for example the increased risk with age, female 
gender, or co-morbidities, the importance of basic hygiene procedures such as hand-washing 
in infection prevention and control, and the importance of rigorously following instructions 
when an antibiotic is prescribed, should be considered. Organizations such as the European 
Centre for Disease Prevention and Control (ECDC) and HPE produce factsheets for the general 
public (ECDC, 2016; PHE, 2014). Methods for disseminating information to the public via the 
print and screen media, as well as social media, should be considered. 
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In all, this study has shed light on the changing-face of ESBL-positive infection patterns in the 
Saudi Aramco Dhahran Health Center, and on differences in this hospital compared to 
hospitals in other parts of Saudi Arabia. The results should help progress the effective 
reduction and management of these infections in our hospital. 
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